<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Oxytocin receptor antagonists for inhibiting preterm labour - Flenady, V - 2014 | Cochrane Library</title> <meta content="Oxytocin receptor antagonists for inhibiting preterm labour - Flenady, V - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004452.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Oxytocin receptor antagonists for inhibiting preterm labour - Flenady, V - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004452.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD004452.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Oxytocin receptor antagonists for inhibiting preterm labour" name="citation_title"/> <meta content="Vicki Flenady" name="citation_author"/> <meta content="Mater Research Institute ‐ The University of Queensland (MRI‐UQ)" name="citation_author_institution"/> <meta content="vflenady@mmri.mater.org.au" name="citation_author_email"/> <meta content="Hanna E Reinebrant" name="citation_author"/> <meta content="Mater Research Institute ‐ The University of Queensland (MRI‐UQ)" name="citation_author_institution"/> <meta content="Helen G Liley" name="citation_author"/> <meta content="Mater Mothers’ Hospital, Mater Research, The University of Queensland" name="citation_author_institution"/> <meta content="Eashan G Tambimuttu" name="citation_author"/> <meta content="Royal Brisbane and Women's Hospital" name="citation_author_institution"/> <meta content="Dimitri NM Papatsonis" name="citation_author"/> <meta content="Amphia Hospital Breda" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD004452.pub3" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/06/06" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004452.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004452.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004452.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Albuterol [therapeutic use]; Infant, Extremely Low Birth Weight; Obstetric Labor, Premature [*drug therapy]; Oligopeptides [*therapeutic use]; Randomized Controlled Trials as Topic; Receptors, Oxytocin [*antagonists &amp; inhibitors]; Ritodrine [therapeutic use]; Terbutaline [therapeutic use]; Tocolytic Agents [*therapeutic use]; Vasotocin [*analogs &amp; derivatives, therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004452.pub3&amp;doi=10.1002/14651858.CD004452.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004452.pub3&amp;doi=10.1002/14651858.CD004452.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004452.pub3&amp;doi=10.1002/14651858.CD004452.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004452.pub3&amp;doi=10.1002/14651858.CD004452.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004452.pub3&amp;doi=10.1002/14651858.CD004452.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004452.pub3&amp;doi=10.1002/14651858.CD004452.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004452.pub3&amp;doi=10.1002/14651858.CD004452.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004452.pub3&amp;doi=10.1002/14651858.CD004452.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004452.pub3&amp;doi=10.1002/14651858.CD004452.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004452.pub3&amp;doi=10.1002/14651858.CD004452.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004452.pub3&amp;doi=10.1002/14651858.CD004452.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004452.pub3&amp;doi=10.1002/14651858.CD004452.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004452.pub3&amp;doi=10.1002/14651858.CD004452.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004452.pub3&amp;doi=10.1002/14651858.CD004452.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004452.pub3&amp;doi=10.1002/14651858.CD004452.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004452.pub3&amp;doi=10.1002/14651858.CD004452.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004452.pub3&amp;doi=10.1002/14651858.CD004452.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004452.pub3&amp;doi=10.1002/14651858.CD004452.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004452.pub3&amp;doi=10.1002/14651858.CD004452.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004452.pub3&amp;doi=10.1002/14651858.CD004452.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004452.pub3&amp;doi=10.1002/14651858.CD004452.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004452.pub3&amp;doi=10.1002/14651858.CD004452.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004452.pub3&amp;doi=10.1002/14651858.CD004452.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="ZDBB8PHY";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD004452\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD004452\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004452\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004452\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD004452.pub3",title:"Oxytocin receptor antagonists for inhibiting preterm labour",firstPublishedDate:"Jun 6, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pregnancy and Childbirth Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ZDBB8PHY&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004452.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004452.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD004452.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD004452.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004452.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD004452.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD004452.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD004452.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD004452.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD004452.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4402 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD004452.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004452.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004452.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004452.pub3/full#CD004452-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004452.pub3/full#CD004452-sec-0106"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004452.pub3/full#CD004452-sec-0022"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004452.pub3/full#CD004452-sec-0027"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004452.pub3/full#CD004452-sec-0030"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004452.pub3/full#CD004452-sec-0074"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004452.pub3/full#CD004452-sec-0100"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004452.pub3/appendices#CD004452-sec-0111"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/table_n/CD004452StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/table_n/CD004452StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004452.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004452.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004452.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004452.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004452.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD004452.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Oxytocin receptor antagonists for inhibiting preterm labour</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004452.pub3/information#CD004452-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Vicki Flenady</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004452.pub3/information#CD004452-cr-0003">Hanna E Reinebrant</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004452.pub3/information#CD004452-cr-0004">Helen G Liley</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004452.pub3/information#CD004452-cr-0005">Eashan G Tambimuttu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004452.pub3/information#CD004452-cr-0006">Dimitri NM Papatsonis</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/information/en#CD004452-sec-0153">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 06 June 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD004452.pub3">https://doi.org/10.1002/14651858.CD004452.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD004452-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004452-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004452-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004452-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004452-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD004452-abs-0001" lang="en"> <section id="CD004452-sec-0001"> <h3 class="title" id="CD004452-sec-0001">Background</h3> <p>Preterm birth, defined as birth between 20 and 36 completed weeks, is a major contributor to perinatal morbidity and mortality globally. Oxytocin receptor antagonists (ORA), such as atosiban, have been specially developed for the treatment of preterm labour. ORA have been proposed as effective tocolytic agents for women in preterm labour to prolong pregnancy with fewer side effects than other tocolytic agents. </p> </section> <section id="CD004452-sec-0002"> <h3 class="title" id="CD004452-sec-0002">Objectives</h3> <p>To assess the effects on maternal, fetal and neonatal outcomes of tocolysis with ORA for women with preterm labour compared with placebo or any other tocolytic agent. </p> </section> <section id="CD004452-sec-0003"> <h3 class="title" id="CD004452-sec-0003">Search methods</h3> <p>We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (1 December 2013). </p> </section> <section id="CD004452-sec-0004"> <h3 class="title" id="CD004452-sec-0004">Selection criteria</h3> <p>We included all randomised controlled trials (published and unpublished) of ORA for tocolysis of labour between 20 and 36 completed weeks' gestation. </p> </section> <section id="CD004452-sec-0005"> <h3 class="title" id="CD004452-sec-0005">Data collection and analysis</h3> <p>Two review authors independently evaluated methodological quality and extracted trial data. When required, we sought additional data from trial authors. Results are presented as risk ratio (RR) for categorical and mean difference (MD) for continuous data with the 95% confidence intervals (CI). Where appropriate, the number needed to treat for benefit (NNTB) and the number needed to treat for harm (NNTH) were calculated. </p> </section> <section id="CD004452-sec-0006"> <h3 class="title" id="CD004452-sec-0006">Main results</h3> <p>This review update includes eight additional studies (790 women), giving a total of 14 studies involving 2485 women. </p> <p>Four studies (854 women) compared ORA (three used atosiban and one barusiban) with placebo. Three studies were considered at low risk of bias in general (blinded allocation to treatment and intervention), the fourth study did not adequately blind the intervention. No difference was shown in birth less than 48 hours after trial entry (average RR 1.05, 95% CI 0.15 to 7.43; random‐effects, (two studies, 152 women), perinatal mortality (RR 2.25, 95% CI 0.79 to 6.38; two studies, 729 infants), or major neonatal morbidity. ORA (atosiban) resulted in a small reduction in birthweight (MD ‐138.86 g, 95% CI ‐250.53 to ‐27.18; two studies with 676 infants). In one study, atosiban resulted in an increase in extremely preterm birth (before 28 weeks' gestation) (RR 3.11, 95% CI 1.02 to 9.51; NNTH 31, 95% CI 8 to 3188) and infant deaths (up to 12 months) (RR 6.13, 95% CI 1.38 to 27.13; NNTH 28, 95% CI 6 to 377). However, this finding may be confounded due to randomisation of more women with pregnancy less than 26 weeks' gestation to atosiban. ORA also resulted in an increase in maternal adverse drug reactions requiring cessation of treatment in comparison with placebo (RR 4.02, 95% CI 2.05 to 7.85; NNTH 12, 95% CI 5 to 33). No differences were shown in preterm birth less than 37 weeks' gestation or any other adverse neonatal outcomes. No differences were evident by type of ORA, although data were limited. </p> <p>Eight studies (1402 women) compared ORA (atosiban only) with betamimetics; four were considered of low risk of bias (blinded allocation to treatment and to intervention). No statistically significant difference was shown in birth less than 48 hours after trial entry (RR 0.89, 95% CI 0.66 to 1.22; eight studies with 1389 women), very preterm birth (RR 1.70, 95% CI 0.89 to 3.23; one study with 145 women), extremely preterm birth (RR 0.84, 95% CI 0.37 to 1.92; one study with 244 women) or perinatal mortality (RR 0.55, 95% CI 0.21 to 1.48; three studies with 816 infants). One study (80 women), of unclear methodological quality, showed an increase in the interval between trial entry and birth (MD 22.90 days, 95% CI 18.03 to 27.77). No difference was shown in any reported measures of major neonatal morbidity (although numbers were small). ORA (atosiban) resulted in less maternal adverse effects requiring cessation of treatment (RR 0.05, 95% CI 0.02 to 0.11; NNTB 6, 95% CI 6 to 6; five studies with 1161 women). </p> <p>Two studies including (225 women) compared ORA (atosiban) with calcium channel blockers (CCB) (nifedipine only). The studies were considered as having high risk of bias as neither study blinded the intervention and in one study it was not known if allocation was blinded. No difference was shown in birth less than 48 hours after trial entry (average RR 1.09, 95% CI 0.44 to 2.73, random‐effects; two studies, 225 women) and extremely preterm birth (RR 2.14, 95% CI 0.20 to 23.11; one study, 145 women). No data were available for the outcome of perinatal mortality. One small trial (145 women), which did not employ blinding of the intervention, showed an increase in the number of preterm births (before 37 weeks' gestation) (RR 1.56, 95% CI 1.13 to 2.14; NNTH 5, 95% CI 3 to 19), a lower gestational age at birth (MD ‐1.20 weeks, 95% CI ‐2.15 to ‐0.25) and an increase in admission to neonatal intensive care unit (RR 1.70, 95% CI 1.17 to 2.47; NNTH 5, 95% CI 3 to 20). ORA (atosiban) resulted in less maternal adverse effects (RR 0.38, 95% CI 0.21 to 0.68; NNTB 6, 95% CI 5 to 12; two studies, 225 women) but not maternal adverse effects requiring cessation of treatment (RR 0.36, 95% CI 0.01 to 8.62; one study, 145 women). No longer‐term outcome data were included. </p> </section> <section id="CD004452-sec-0007"> <h3 class="title" id="CD004452-sec-0007">Authors' conclusions</h3> <p>This review did not demonstrate superiority of ORA (largely atosiban) as a tocolytic agent compared with placebo, betamimetics or CCB (largely nifedipine) in terms of pregnancy prolongation or neonatal outcomes, although ORA was associated with less maternal adverse effects than treatment with the CCB or betamimetics. The finding of an increase in infant deaths and more births before completion of 28 weeks of gestation in one placebo‐controlled study warrants caution. However, the number of women enrolled at very low gestations was small. Due to limitations of small numbers studied and methodological quality, further well‐designed randomised controlled trials are needed. Further comparisons of ORA versus CCB (which has a better side‐effect profile than betamimetics) are needed. Consideration of further placebo‐controlled studies seems warranted. Future studies of tocolytic agents should measure all important short‐ and long‐term outcomes for women and infants, and costs. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD004452-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004452-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004452-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004452-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004452-abs-0004">Français</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD004452-abs-0003" lang="en"> <h3>Oxytocin receptor antagonists for inhibiting preterm labour</h3> <p>Tocolytic drugs suppress preterm labour and have the potential to postpone preterm birth long enough to, hopefully, improve infant outcome. This may be by allowing normal growth and maturation of the baby, or by allowing time for administration of magnesium sulphate to reduce risk of cerebral palsy and corticosteroids to help the baby's lungs and other organs to mature. They may also provide the opportunity, if necessary, for the mother to be transferred to a hospital that has facilities to provide neonatal intensive care. However, prolonging pregnancy may instead have adverse outcomes for the baby and so it is important to assess infant outcomes alongside duration of pregnancy. Oxytocin receptor antagonists (ORAs) are a group of tocolytic drugs, and we undertook this review to see if ORAs prolonged pregnancy and improved outcomes for infants compared with no treatment or with other tocolytic drugs. </p> <p>The tocolytic drugs, atosiban and barusiban, were the only ORAs we found that had been studied in trials; some trials compared with no treatment and others compared atosiban with betamimetics (another group of tocolytic drugs). We identified 14 studies, involving 2485 women. We found that, although atosiban resulted in fewer maternal side effects than other tocolytic drugs (especially betamimetics), atosiban was not effective in delaying or preventing preterm birth or improving neonatal outcome, and may possibly contribute to poorer infant outcomes. Further well‐designed studies would be helpful, especially in women with threatened preterm at low gestations where preterm birth puts babies at particularly high risk of death or disability. </p> <p>Atosiban is no better than placebo or other drugs in delaying or preventing preterm birth but it has fewer maternal side effects compared to other tocolytics. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD004452-sec-0106" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD004452-sec-0106"></div> <h3 class="title" id="CD004452-sec-0107">Implications for practice</h3> <section id="CD004452-sec-0107"> <p>This review did not demonstrate superiority of oxytocin receptor antagonists (ORA) (largely atosiban) as a tocolytic agent compared with placebo, betamimetics or calcium channel blockers (CCB) (largely nifedipine) in terms of pregnancy prolongation or neonatal outcomes, although ORA was associated with fewer maternal adverse effects than treatment with the CCB or betamimetics. The finding of an increase in infant deaths and more births before completion of 28 weeks of gestation in one placebo‐controlled study warrants caution. However, due to limitations of the small numbers studied and methodological quality, there is currently insufficient evidence on the role of ORA in the management of women in preterm labour to inform clinical practice. </p> </section> <h3 class="title" id="CD004452-sec-0108">Implications for research</h3> <section id="CD004452-sec-0108"> <p>Further well‐designed randomised controlled studies of tocolytic therapy are needed, in particular comparisons of ORA versus CCB (which have a better side‐effect profile than betamimetics), and further placebo‐controlled studies may also be warranted. All future studies with use of tocolytic agents should measure all important short‐ and long‐term outcomes for women and infants, and costs. Future studies should address the possibility that different tocolytic strategies are needed at different gestational ages in order to optimise safety and efficacy. At the time of writing this review, a randomised controlled trial comparing atosiban versus nifedipine in the management of preterm labour is ongoing in The Netherlands, (<a href="./references#CD004452-bbs2-0029" title="HeidaK . Nifedipine versus Atosiban in the treatment of threatened preterm labour: APOSTEL III. http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=2947 (accessed 6 January 2014). ">APOSTEL III</a>) NTR2947 and may help to fill this gap in knowledge. </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD004452-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD004452-sec-0022"></div> <section id="CD004452-sec-0023"> <h3 class="title" id="CD004452-sec-0023">Description of the condition</h3> <p>Preterm birth, defined as birth occurring between 20 and 36 completed weeks, is a major contributor to perinatal mortality and morbidity (<a href="./references#CD004452-bbs2-0059" title="LiuL , JohnsonHL , CousensS , PerinJ , ScottS , LawnJE , et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet2012;379(9832):2151‐61. ">Liu 2012</a>; <a href="./references#CD004452-bbs2-0073" title="HowsonCP , KinneyMV , Lawn JE(editors) . Born Too Soon: The Global Action Report on Preterm Birth. Geneva: World Health Organization, 2012. ">WHO 2012</a>). Worldwide, it is estimated that more than one in 10 births is preterm, affecting 15 million babies annually (<a href="./references#CD004452-bbs2-0032" title="BlencoweH , CousensS , OestergaardMZ , ChouD , MollerAB , NarwalR , et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet 2012 Jun 9;379(9832):2162‐72. ">Blencowe 2012</a>; <a href="./references#CD004452-bbs2-0073" title="HowsonCP , KinneyMV , Lawn JE(editors) . Born Too Soon: The Global Action Report on Preterm Birth. Geneva: World Health Organization, 2012. ">WHO 2012</a>). The incidence of preterm birth is 8.6% of births in high‐resource countries, and between 7.4% to 13.3% in low‐resource countries, and rose in both at least until the middle of the last decade (<a href="./references#CD004452-bbs2-0034" title="ChangHH , LarsonJ , BlencoweH , SpongCY , HowsonCP , Cairns‐SmithS , et al. Preventing preterm births: analysis of trends and potential reductions with interventions in 39 countries with very high human development index. Lancet2013;381(9862):223‐34. ">Chang 2013</a>; <a href="./references#CD004452-bbs2-0073" title="HowsonCP , KinneyMV , Lawn JE(editors) . Born Too Soon: The Global Action Report on Preterm Birth. Geneva: World Health Organization, 2012. ">WHO 2012</a>). </p> <p>In high‐income countries, very preterm birth (i.e. birth before 32 weeks' gestation) has an incidence of 1% to 2% (<a href="./references#CD004452-bbs2-0071" title="TuckerJ , McGuireW . Epidemiology of preterm birth. BMJ.2004;329(7467):675‐8. ">Tucker 2004</a>) but despite the availability of perinatal and neonatal care, it is responsible for approximately one third to one half of all perinatal deaths (<a href="./references#CD004452-bbs2-0038" title="DorlingJS , FieldDJ . Value and validity of neonatal disease severity scoring systems. Archives of Disease in Childhood. Fetal and Neonatal Edition2008;93(2):F80‐F82. ">Dorling 2008</a>; <a href="./references#CD004452-bbs2-0075" title="ZeitlinJ , DraperES , KolléeL , MilliganD , BoerchK , AgostinoR , et al. for the MOSAIC research group. Differences in rates and short‐term outcome of live births before 32 weeks of gestation in Europe in 2003: results from the MOSAIC cohort. Pediatrics2008;121(4):e936‐e944. ">Zeitlin 2008</a>). In high‐income countries, almost 95% of neonates born between 28 and 32 weeks' gestation will survive, with more than 90% surviving without impairment. In contrast, in many low‐income countries, only 30% of neonates born between 28 and 32 weeks will survive (<a href="./references#CD004452-bbs2-0073" title="HowsonCP , KinneyMV , Lawn JE(editors) . Born Too Soon: The Global Action Report on Preterm Birth. Geneva: World Health Organization, 2012. ">WHO 2012</a>). </p> <p>Preterm birth is associated not only with high immediate costs attributable to neonatal intensive care, but also with substantial long‐term costs, including costs for special education (<a href="./references#CD004452-bbs2-0063" title="PetrouS , EddamaO , ManghamL . A structured review of the recent literature on the economic consequences of preterm birth. Archives of Disease in Childhood. Fetal and Neonatal Edition2011;96(3):F225‐F232. ">Petrou 2011</a>), and other services for infants and children with intellectual and physical disability (<a href="./references#CD004452-bbs2-0063" title="PetrouS , EddamaO , ManghamL . A structured review of the recent literature on the economic consequences of preterm birth. Archives of Disease in Childhood. Fetal and Neonatal Edition2011;96(3):F225‐F232. ">Petrou 2011</a>). In addition to the lengthy neonatal intensive care treatment required for many preterm infants, preterm birth often places stress on parents, which is greater with decreasing gestational age (<a href="./references#CD004452-bbs2-0067" title="SchappinR , WijnroksL , Uniken VenemaMMAT , JongmansMJ . Rethinking stress in parents of preterm infants: a meta‐analysis. PLoS ONE2013;8(2):e54992. ">Schappin 2013</a>). </p> <p>Approximately 65% to 70% are spontaneous preterm births either following spontaneous preterm labour (40% to 45%) and those following preterm rupture of membranes (25% to 30%) (<a href="./references#CD004452-bbs2-0045" title="GoldenbergRL , CulhaneJF , IamsJD , RomeroR . Epidemiology and causes of preterm birth. Lancet2008;371(9606):75‐84.. ">Goldenberg 2008</a>). While the cause of spontaneous preterm birth is often unclear, some risk factors have been identified including: maternal age (adolescence and advanced age); history of preterm birth; race; multiple pregnancy, short inter‐pregnancy interval; infections; medical conditions; poor nutrition; psychological factors and genetic predisposition (<a href="./references#CD004452-bbs2-0045" title="GoldenbergRL , CulhaneJF , IamsJD , RomeroR . Epidemiology and causes of preterm birth. Lancet2008;371(9606):75‐84.. ">Goldenberg 2008</a>; <a href="./references#CD004452-bbs2-0064" title="PlunkettJ , MugliaLJ . Genetic contributions to preterm birth: implications from epidemiological and genetic association studies. Annals of Medicine2008;40:167‐95. ">Plunkett 2008</a>). </p> <p>There has been little progress in reducing the incidence of preterm birth, even in high‐income countries despite intensive antenatal care programs aimed at high‐risk groups, the widespread use of pharmacological agents to inhibit preterm birth (tocolytics) and other preventive and therapeutic interventions. Nevertheless, short‐term prolongation of pregnancy has the potential to allow other interventions to improve outcomes, including maternal corticosteroid administration to accelerate maturation of fetal lungs (<a href="./references#CD004452-bbs2-0066" title="RobertsD , DalzielSR . Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD004454.pub2] ">Roberts 2006</a>) and other organs (<a href="./references#CD004452-bbs2-0036" title="CrowleyP . Prophylactic corticosteroids for preterm birth. Cochrane Database of Systematic Reviews1996, Issue 2. [DOI: 10.1002/14651858.CD000065.pub2] ">Crowley 1996</a>), magnesium sulphate administration to reduce risk of cerebral palsy (<a href="./references#CD004452-bbs2-0039" title="DoyleLW , CrowtherCA , MiddletonP , MarretS , RouseD . Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD004661.pub3] ">Doyle 2009</a>) and maternal transfer before birth to a centre that can provide appropriate neonatal special or intensive care (<a href="./references#CD004452-bbs2-0058" title="LasswellSM , BarfieldWD , RochatRW , BlackmonL . Perinatal regionalization for very low‐birth‐weight and very preterm infants: a meta‐analysis. JAMA2013;304(9):992‐1000. ">Lasswell 2010</a>). For these reasons, short‐term tocolytic therapy is commonly used to inhibit preterm labour and postpone preterm birth. </p> </section> <section id="CD004452-sec-0024"> <h3 class="title" id="CD004452-sec-0024">Description of the intervention</h3> <p>A range of tocolytic agents that have been used to inhibit preterm labour are the topics of Cochrane systematic reviews including: nitric oxide donors (glyceryl trinitrate) (<a href="./references#CD004452-bbs2-0040" title="DuckittK , ThorntonS . Nitric oxide donors for the treatment of preterm labour. Cochrane Database of Systematic Reviews2002, Issue 3. [DOI: 10.1002/14651858.CD002860] ">Duckitt 2002</a>), calcium channel blockers (CCB) (commonly nifedipine) (update of <a href="./references#CD004452-bbs2-0055" title="KingJF , FlenadyVJ , PapatsonisDNM , DekkerGA , CarbonneB . Calcium channel blockers for inhibiting preterm labour. Cochrane Database of Systematic Reviews2003, Issue 1. [DOI: 10.1002/14651858.CD002255] ">King 2003</a> in progress), betamimetics (<a href="./references#CD004452-bbs2-0031" title="AnotayanonthS , SubhedarNV , NeilsonJP , HarigopalS . Betamimetics for inhibiting preterm labour. Cochrane Database of Systematic Reviews2006, Issue 4. [DOI: 10.1002/14651858.CD004352.pub2] ">Anotayanonth 2006</a>), magnesium sulphate (<a href="./references#CD004452-bbs2-0037" title="CrowtherCA , HillerJE , DoyleLW . Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database of Systematic Reviews2002, Issue 4. [DOI: 10.1002/14651858.CD001060] ">Crowther 2002</a>), cyclo‐oxygenase (COX) inhibitors (<a href="./references#CD004452-bbs2-0053" title="KhanprakobT , LaopaiboonM , LumbiganonP , SangkomkamhangUS . Cyclo‐oxygenase (COX) inhibitors for preventing preterm labour. Cochrane Database of Systematic Reviews2012, Issue 10. [DOI: 10.1002/14651858.CD007748.pub2] ">Khanprakob 2012</a>) and progesterone (<a href="./references#CD004452-bbs2-0069" title="SuLL , SamuelM , ChongYS . Progestational agents for treating threatened or established preterm labour. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD006770.pub2] ">Su 2010</a>). The betamimetics (ritodrine, salbutamol and terbutaline) have been shown to be effective in delaying delivery by seven days and longer, although no impact has yet been shown on perinatal mortality (<a href="./references#CD004452-bbs2-0031" title="AnotayanonthS , SubhedarNV , NeilsonJP , HarigopalS . Betamimetics for inhibiting preterm labour. Cochrane Database of Systematic Reviews2006, Issue 4. [DOI: 10.1002/14651858.CD004352.pub2] ">Anotayanonth 2006</a>; <a href="./references#CD004452-bbs2-0049" title="GyetvaiK , HannahM , HodnettE , OhlssonA . Tocolysis for preterm labor: a systematic review. Obstetrics &amp; Gynecology1999;94(5):869‐77. ">Gyetvai 1999</a>; <a href="./references#CD004452-bbs2-0054" title="KingJF , GrantA , KeirseMJNC , ChalmersI . Beta‐mimetics in preterm labour: an overview of the randomized controlled trials. British Journal of Obstetrics and Gynaecology1988;95:211‐22. ">King 1988</a>). Furthermore, betamimetics have a high frequency of unpleasant, sometimes severe maternal side effects including tachycardia, hypotension, tremor and a range of biochemical disturbances, and they have been associated with life‐threatening cardiovascular and respiratory events and deaths (<a href="./references#CD004452-bbs2-0043" title="U.S.Food , DrugAdministration . Drug Safety Communication: New warnings against use of terbutaline to treat preterm labor. http://www.fda.gov/Drugs/DrugSafety/ucm243539.htm. ">FDA 2011</a>). Compared with other tocolytic agents (mostly betamimetics), CCB prolonged pregnancy and improved short‐term neonatal outcomes, with fewer maternal adverse effects (update of <a href="./references#CD004452-bbs2-0055" title="KingJF , FlenadyVJ , PapatsonisDNM , DekkerGA , CarbonneB . Calcium channel blockers for inhibiting preterm labour. Cochrane Database of Systematic Reviews2003, Issue 1. [DOI: 10.1002/14651858.CD002255] ">King 2003</a> in progress). However, a fifth of women still delivered within 48 hours of CCB treatment, and nearly a third within seven days, so there is still a need for other safe, effective tocolytic agents, particularly at very early gestations. </p> <p>A number of oxytocin receptor antagonists have been developed, and of these, three, atosiban, barusiban and retosiban have been investigated in humans as tocolytic agents. To date, only atosiban is in use outside of clinical trials. Atosiban is an oxytocin receptor antagonist which was specifically developed for the treatment of preterm labour (<a href="./references#CD004452-bbs2-0060" title="MelinP . Development of an oxytocin antagonist atosiban. Research Clinical Forums1994;16:155‐68. ">Melin 1994</a>). Early reports of the use of atosiban for tocolysis showed promise both in vitro and in animal studies, and preliminary studies in pregnant and non‐pregnant humans suggested a very low incidence of maternal side effects (<a href="./references#CD004452-bbs2-0046" title="GoodwinTM , ValenzuelaG , SilverH , HayashiR , CreasyGW , LaneR . Treatment of preterm labor with the oxytocin antagonist atosiban. American Journal of Perinatology1996;13(3):143‐6. ">Goodwin 1996b</a>; <a href="./references#CD004452-bbs2-0048" title="GoodwinTM , ZograbyanA . Oxytocin receptor antagonists. Update. Clinics in Perinatology1998;25(4):859‐71. ">Goodwin 1998b</a>). Potential maternal side effects include adverse injection site reaction, nausea, vomiting, headache, chest pain and hypotension (<a href="./references#CD004452-bbs2-0008" title="MoutquinJ , RabinoviciJ . Comparison of atosiban versus ritodrine in the treatment of pre‐term labour. Acta Obstetrica et Gynecologica Scandinavica1997;76(167):33. MoutquinJM , ShermanD , CohenH , MohidePT , Hochner‐CelnikierD , FejginM , et al. Double‐blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study. American Journal of Obstetrics and Gynecology2000;182(5):1191‐9. ">Moutquin 2000</a>; <a href="./references#CD004452-bbs2-0070" title="TsatsarisV , CarbonneB , CabrolD . Atosiban for preterm labour. Drugs2004;64:375‐82. ">Tsatsaris 2004</a>). </p> </section> <section id="CD004452-sec-0025"> <h3 class="title" id="CD004452-sec-0025">How the intervention might work</h3> <p>Oxytocin is a peptide hormone produced in the pituitary, uterus, placenta and amnion. It has a variety of functions, which include stimulating myometrial activity (uterine contractions) as part of the pathway to normal and preterm labour. It binds receptors on myometrial cells, activating several intracellular pathways, which include protein kinase C phosphorylation of various proteins and a rise in intracellular calcium ions, both from intracellular stores via a GTP/phospholipase/inositol phosphate pathway and by activating voltage gated membrane channels allowing entry of extracellular calcium ions. Calcium ion binding to calmodulin then activates myosin light chain kinase, causing myometrial muscle contraction (<a href="./references#CD004452-bbs2-0072" title="VrachnisN , MalamasFM , SifakisS , DeligeorogluoE , IliodromitiZ . The oxytocin‐oxytocin receptor system and its antagonists as tocolytic agents. International Journal of Endocrinology2011;2011:350546. [DOI: 10.1155/2011/350546] ">Vrachnis 2011</a>). </p> <p>The oxytocin receptor antagonist, atosiban, is a peptide analogue of oxytocin that binds oxytocin receptors in the myometrial cell membrane, preventing the oxytocin‐induced rise in intracellular calcium and leading to relaxation of the myometrium (<a href="./references#CD004452-bbs2-0060" title="MelinP . Development of an oxytocin antagonist atosiban. Research Clinical Forums1994;16:155‐68. ">Melin 1994</a>). Atosiban is an antagonist with high affinity to both the vasopressin receptor (V<sub>1a</sub>) and oxytocin receptor (<a href="./references#CD004452-bbs2-0030" title="AkerlundM , BossmarT , BrouardR , KostrzewskaA , LaudanskiT , LemancewiczA , et al. Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women. British Journal of Obstetrics and Gynaecology1999;106(10):1047‐53. ">Akerlund 1999</a>). </p> <p><a href="./references#CD004452-bbs2-0004" title="GoodwinTM , PaulR , SilverH , SpellacyW , ParsonsM , ChezR , et al. The effect of the oxytocin antagonist atosiban on preterm uterine activity in the human. American Journal of Obstetrics and Gynecology1994;170:474‐8. GoodwinTM , PaulRH , SilverH , ParsonsM , ChezR , SpellacyW , et al. Safety and efficacy of the oxytocin antagonist atosiban in threatened preterm labor: initial US trial. American Journal of Obstetrics and Gynecology1992;166:359. ">Goodwin 1994</a> first described in 1994 the use of atosiban in humans for tocolysis. A previous review suggested that oxytocin antagonists could be effective and safe in preterm labour (<a href="./references#CD004452-bbs2-0035" title="CoomarasamyA , KnoxEM , GeeH , SongF , KhanKS . Effectiveness of nifedipine versus atosiban for tocolysis in preterm labour: a meta‐analysis with an indirect comparison of randomised trials. BJOG: an international journal of obstetrics and gynaecology2003;110:1045‐9. ">Coomarasamy 2003</a>). It has not been established whether the tocolytic effects of atosiban is due to its oxytocin or vasopressin receptor antagonist properties. </p> <p>Barusiban is a selective oxytocin receptor antagonist with its effect on the vasopressin receptor (<a href="./references#CD004452-bbs2-0061" title="NilssonL , ReinheimerT , SteinwallM , AkerlundM . FE 200 440: a selective oxytocin antagonist on the term‐pregnant human uterus. BJOG2003;110(11):1025‐8. ">Nilsson 2003</a>). Both atosiban and barusiban have a molecular structure very similar to the oxytocin molecule (a nonapeptide) (<a href="./references#CD004452-bbs2-0072" title="VrachnisN , MalamasFM , SifakisS , DeligeorogluoE , IliodromitiZ . The oxytocin‐oxytocin receptor system and its antagonists as tocolytic agents. International Journal of Endocrinology2011;2011:350546. [DOI: 10.1155/2011/350546] ">Vrachnis 2011</a>). However, as peptide antagonists lack oral bioavailability, development of novel non‐peptide compounds with high oxytocin receptor selectivity is currently ongoing. Non‐peptides such as retosiban are small molecules, structurally not related to oxytocin (<a href="./references#CD004452-bbs2-0033" title="BorthwickAD , LiddleJ . Retosiban and epelsiban: potent and selective orally available oxytocin antagonists. In: DömlingA editor(s). Protein‐Protein Interactions in Drug Discovery. KGaA, Weinheim, Germany: Wiley‐VCH Verlag GmbH &amp; Co, 2013:225‐56. ">Borthwick 2013</a>). It is currently not established how the molecular structure affects signalling pathways. It is plausible that the tocolytic effects of nonapeptides may differ from non‐peptide compounds based on their different binding affinity and selectivity to oxytocin receptors and also other receptors (<a href="./references#CD004452-bbs2-0033" title="BorthwickAD , LiddleJ . Retosiban and epelsiban: potent and selective orally available oxytocin antagonists. In: DömlingA editor(s). Protein‐Protein Interactions in Drug Discovery. KGaA, Weinheim, Germany: Wiley‐VCH Verlag GmbH &amp; Co, 2013:225‐56. ">Borthwick 2013</a>; <a href="./references#CD004452-bbs2-0072" title="VrachnisN , MalamasFM , SifakisS , DeligeorogluoE , IliodromitiZ . The oxytocin‐oxytocin receptor system and its antagonists as tocolytic agents. International Journal of Endocrinology2011;2011:350546. [DOI: 10.1155/2011/350546] ">Vrachnis 2011</a>). </p> </section> <section id="CD004452-sec-0026"> <h3 class="title" id="CD004452-sec-0026">Why it is important to do this review</h3> <p>Preterm labour is often insidious in onset and difficult to anticipate, and the causes are likely to be multifactorial, so prevention by treating the underlying causes has proved elusive. Therefore, effective tocolysis in suspected or established preterm labour is likely to remain critical to reducing infant morbidity and mortality associated with preterm birth, and to mitigating the long‐term consequences of prematurity on developmental and health outcomes. Since oxytocin receptor antagonists have undergone clinical trials and are available in some countries for the management of women in preterm labour, this updated review is important to assist clinicians and women in informed decision making about which tocolytic to use. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD004452-sec-0027" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD004452-sec-0027"></div> <section id="CD004452-sec-0028"> <h3 class="title" id="CD004452-sec-0028">Primary objectives of the review</h3> <p> <ol id="CD004452-list-0001"> <li> <p>To assess the effects on maternal, fetal and neonatal outcomes of any oxytocin receptor antagonist administered as a tocolytic agent to women in preterm labour when compared with placebo. </p> </li> <li> <p>To assess the effects on maternal, fetal and neonatal outcomes of any oxytocin receptor antagonist administered as a tocolytic agent to women in preterm labour when compared with other classes of tocolytic agents. </p> </li> </ol> </p> </section> <section id="CD004452-sec-0029"> <h3 class="title" id="CD004452-sec-0029">Secondary objective</h3> <p>A secondary objective of the review is to determine whether the effects of oxytocin receptor antagonists, when compared with placebo or any other tocolytic agent, are influenced by different population characteristics and duration of tocolytic therapy as follows:<br/> (i) women randomised before 28 weeks' gestation versus those randomised at 28 weeks or after;<br/> (ii) women with ruptured membranes at randomisation versus women with intact membranes;<br/> (iii) women with a singleton pregnancy versus women with a multiple pregnancy;<br/> (iv) women who received maintenance therapy* versus women who did not; and also by type of tocolytic agent as follows:<br/> (v) type of other tocolytic; betamimetics versus calcium channel blockers (CCB);<br/> (vi) type of oxytocin receptor antagonists (ORA); atosiban versus other ORA. </p> <p>(*Use of continued tocolytic agents after successful suppression of threatened preterm labour.) </p> </section> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD004452-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD004452-sec-0030"></div> <section id="CD004452-sec-0031"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD004452-sec-0032"> <h4 class="title">Types of studies</h4> <p>All published and unpublished randomised and cluster‐randomised studies in which oxytocin receptor antagonists were used for tocolysis in the management of preterm labour. Studies using quasi‐random methods of allocation and cross‐over studies were excluded. </p> </section> <section id="CD004452-sec-0033"> <h4 class="title">Types of participants</h4> <p>Women assessed as being in preterm labour (between 20 and 36 completed weeks' gestation) and considered suitable for tocolysis. </p> </section> <section id="CD004452-sec-0034"> <h4 class="title">Types of interventions</h4> <p> <ol id="CD004452-list-0002"> <li> <p>Oxytocin receptor antagonists administered as a tocolytic by any route compared with placebo. </p> </li> <li> <p>Oxytocin receptor antagonists administered as a tocolytic by any route compared with other classes of tocolytic agents. </p> </li> </ol> </p> </section> <section id="CD004452-sec-0035"> <h4 class="title">Types of outcome measures</h4> <p>This review aimed to assess the effects of oxytocin receptor antagonists on clinically relevant outcome measures relating to perinatal and infant short‐term and long‐term outcome as well as prolongation of pregnancy. Furthermore, maternal side effects and outcomes were also examined. </p> <p>Clinically relevant outcomes for trials of tocolysis for inhibiting preterm labour have been prespecified following consultation with the editors and authors of the individual reviews. </p> <p>Consensus was reached on a set of six ‘core’ outcomes, which are highlighted below. These will be included in all tocolysis reviews. In addition to these core outcomes, individual teams may include other outcomes as necessary. </p> <section id="CD004452-sec-0036"> <h5 class="title">Primary outcomes</h5> <p>Short‐term and long‐term serious infant outcome determined by the presence of any of the following. </p> <p> <ol id="CD004452-list-0003"> <li> <p><b>Serious maternal outcome</b> (defined as death, cardiac arrest, respiratory arrest, admission to intensive care unit). </p> </li> <li> <p><b>Birth less than 48 hours after trial entry.</b> </p> </li> <li> <p><b>Serious infant outcome</b> (defined as death or chronic lung disease [need for supplemental oxygen at 28 days of life or later], grade three or four intraventricular haemorrhage or periventricular leukomalacia, major neurosensory disability (defined as any of legal blindness, sensorineural deafness requiring hearing aids, moderate or severe cerebral palsy, or developmental delay/intellectual impairment [defined as developmental quotient (DQ) or intelligence quotient (IQ) less than 2 standard deviations below mean])). </p> </li> <li> <p><b>Perinatal mortality</b> (stillbirth defines as a birth not showing signs of life defined by any gestational age and birthweight in the trials and neonatal death up to 28 days). </p> </li> <li> <p><b>Very preterm birth</b> (before completion of 34 weeks of gestation). </p> </li> </ol> </p> </section> <section id="CD004452-sec-0037"> <h5 class="title">Secondary outcomes</h5> <p>These include other measures of effectiveness, complications and health service use.</p> <section id="CD004452-sec-0038"> <h6 class="title">Maternal</h6> <p> <ol id="CD004452-list-0004"> <li> <p><b>Maternal adverse effects.</b> </p> </li> <li> <p>Maternal adverse effects requiring cessation of therapy.</p> </li> <li> <p>Caesarean section.</p> </li> <li> <p>Antepartum haemorrhage.</p> </li> <li> <p>Postpartum haemorrhage.</p> </li> <li> <p>Satisfaction with care.</p> </li> <li> <p>Quality of life after the birth (measured by validated instruments).</p> </li> </ol> </p> </section> <section id="CD004452-sec-0039"> <h6 class="title">Infant/child</h6> <p> <ol id="CD004452-list-0005"> <li> <p>Extremely preterm birth (before completion of 28 weeks of gestation).</p> </li> <li> <p>Preterm birth (before completion of 37 weeks of gestation).</p> </li> <li> <p>Preterm neonate delivered with full course of antenatal steroids.</p> </li> <li> <p>Interval between trial entry and birth.</p> </li> <li> <p>Gestational age at birth.</p> </li> <li> <p>Birthweight.</p> </li> <li> <p>Apgar score less than seven at five minutes.</p> </li> <li> <p>Respiratory distress syndrome.</p> </li> <li> <p>Use of mechanical ventilation.</p> </li> <li> <p>Duration of mechanical ventilation.</p> </li> <li> <p>Persistent pulmonary hypertension of the neonate.</p> </li> <li> <p>Intraventricular haemorrhage.</p> </li> <li> <p>Necrotising enterocolitis.</p> </li> <li> <p>Retinopathy of prematurity.</p> </li> <li> <p>Neonatal jaundice.</p> </li> <li> <p>Neonatal sepsis.</p> </li> <li> <p>Infant death.</p> </li> <li> <p>Quality of life in childhood (measured by validated instruments).</p> </li> </ol> </p> </section> <section id="CD004452-sec-0040"> <h6 class="title">Health service use</h6> <p> <ol id="CD004452-list-0006"> <li> <p>Admission to neonatal intensive care unit.</p> </li> <li> <p>Neonatal length of hospital stay.</p> </li> <li> <p>Maternal length of hospital stay.</p> </li> </ol> </p> <p>In this update, primary and secondary outcomes measures were revised to enhance consistency across Cochrane tocolytic reviews and to better reflect important outcome measures. </p> </section> </section> </section> </section> <section id="CD004452-sec-0041"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD004452-sec-0042"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register by contacting the Trials Search Co‐ordinator (1 December 2013). </p> <p>The Cochrane Pregnancy and Childbirth Group’s Trials Register is maintained by the Trials Search Co‐ordinator and contains trials identified from: </p> <p> <ol id="CD004452-list-0007"> <li> <p>monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</p> </li> <li> <p>weekly searches of MEDLINE;</p> </li> <li> <p>weekly searches of Embase;</p> </li> <li> <p>handsearches of 30 journals and the proceedings of major conferences;</p> </li> <li> <p>weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts. </p> </li> </ol> </p> <p>Details of the search strategies for CENTRAL, MEDLINE and Embase, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the ‘Specialized Register’ section within the editorial information about the <a href="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PREG/frame.html" target="_blank">Cochrane Pregnancy and Childbirth Group</a>. </p> <p>Studies identified through the searching activities described above are each assigned to a review topic (or topics). The Trials Search Co‐ordinator searches the register for each review using the topic list rather than keywords. </p> <p>We did not apply any language restrictions.</p> </section> </section> <section id="CD004452-sec-0043"> <h3 class="title" id="CD004452-sec-0043">Data collection and analysis</h3> <p>For the methods used when assessing the studies identified in the previous version of this review, see <a href="./appendices#CD004452-sec-0112">Appendix 1</a>. </p> <p>For this update, we used the following methods when assessing all new and previously included studies. </p> <section id="CD004452-sec-0044"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently assessed all potential studies identified from the search strategy for inclusion in this review. Any disagreement was resolved through discussion, or via consultation of a third author if required. </p> </section> <section id="CD004452-sec-0045"> <h4 class="title">Data extraction and management</h4> <p>The authors used the standard methods of The Cochrane Collaboration and considered all potential studies for inclusion. At least two authors (D Papatsonis, V Flenady, H Reinebrant and E Tambimuttu) evaluated the methodological quality of studies and independently performed data extraction, as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions (</i><a href="./references#CD004452-bbs2-0052" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org, Version 5.1.0 [updated March 2011].. ">Higgins 2011</a>). </p> <p>Any discrepancies were resolved through discussion, or via consultation of a third author. We entered data into Review Manager software (<a href="./references#CD004452-bbs2-0065" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">RevMan 2012</a>) and checked for accuracy. </p> <p>When information was unclear, we attempted to contact authors of the original reports to provide further details. </p> </section> <section id="CD004452-sec-0046"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed risk of bias for each study using the criteria outlined in the<i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD004452-bbs2-0052" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org, Version 5.1.0 [updated March 2011].. ">Higgins 2011</a>)<i>.</i> We resolved any disagreement by discussion or by involving a third assessor<i>.</i> </p> <section id="CD004452-sec-0047"> <h5 class="title">(1) Random sequence generation (checking for possible selection bias)</h5> <p>We described for each included study the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups. </p> <p>We assessed the method as:</p> <p> <ul id="CD004452-list-0008"> <li> <p>low risk of bias (any truly random process, e.g. random number table; computer random number generator); </p> </li> <li> <p>high risk of bias (any non‐random process, e.g. odd or even date of birth; hospital or clinic record number); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD004452-sec-0048"> <h5 class="title">(2) Allocation concealment (checking for possible selection bias)</h5> <p>We described for each included study the method used to conceal allocation to interventions prior to assignment and assessed whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment. </p> <p>We assessed the method as:</p> <p> <ul id="CD004452-list-0009"> <li> <p>low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes); </p> </li> <li> <p>high risk of bias (open random allocation; unsealed or non‐opaque envelopes, alternation; date of birth); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD004452-sec-0049"> <h5 class="title">(3.1) Blinding of participants and personnel (checking for possible performance bias)</h5> <p>We described for each included study the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. We considered that studies were at low risk of bias if they were blinded, or if we judge that the lack of blinding would be unlikely to affect results. We assessed blinding separately for different outcomes or classes of outcomes. </p> <p>We assessed the method as:</p> <p> <ul id="CD004452-list-0010"> <li> <p>low, high or unclear risk of bias for participants;</p> </li> <li> <p>low, high or unclear risk of bias for personnel.</p> </li> </ul> </p> </section> <section id="CD004452-sec-0050"> <h5 class="title">(3.2) Blinding of outcome assessment (checking for possible detection bias)</h5> <p>We described for each included study the methods used, if any, to blind outcome assessors from knowledge of which intervention a participant received. We assessed blinding separately for different outcomes or classes of outcomes. </p> <p>We assessed methods used to blind outcome assessment as:</p> <p> <ul id="CD004452-list-0011"> <li> <p>low, high or unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD004452-sec-0051"> <h5 class="title">(4) Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data) </h5> <p>We described for each included study, and for each outcome or class of outcomes, the completeness of data including attrition and exclusions from the analysis. We stated whether attrition and exclusions were reported and the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. Where sufficient information was reported, or was supplied by the trial authors, we re‐included missing data in the analyses that we undertook. </p> <p>We assessed the method as:</p> <p> <ul id="CD004452-list-0012"> <li> <p>low risk of bias (e.g. no missing outcome data; missing outcome data balanced across groups); </p> </li> <li> <p>high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; ‘as treated’ analysis done with substantial departure of intervention received from that assigned at randomisation); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD004452-sec-0052"> <h5 class="title">(5) Selective reporting (checking for reporting bias)</h5> <p>We described for each included study how we investigated the possibility of selective outcome reporting bias and what we found. </p> <p>We assessed the method as:</p> <p> <ul id="CD004452-list-0013"> <li> <p>low risk of bias (where it is clear that all of the study’s pre‐specified outcomes and all expected outcomes of interest to the review have been reported); </p> </li> <li> <p>high risk of bias (where not all the study’s pre‐specified outcomes have been reported; one or more reported primary outcomes were not pre‐specified; outcomes of interest are reported incompletely and so cannot be used; study fails to include results of a key outcome that would have been expected to have been reported); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD004452-sec-0053"> <h5 class="title">(6) Other bias (checking for bias due to problems not covered by (1) to (5) above)</h5> <p>We described for each included study any important concerns we had about other possible sources of bias. </p> <p>We assessed whether each study was free of other problems that could put it at risk of bias: </p> <p> <ul id="CD004452-list-0014"> <li> <p>low risk of other bias;</p> </li> <li> <p>high risk of other bias;</p> </li> <li> <p>unclear whether there is risk of other bias.</p> </li> </ul> </p> </section> <section id="CD004452-sec-0054"> <h5 class="title">(7) Overall risk of bias</h5> <p>We made explicit judgements about whether studies are at high risk of bias, according to the criteria given in the <i>Handbook</i> (<a href="./references#CD004452-bbs2-0052" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org, Version 5.1.0 [updated March 2011].. ">Higgins 2011</a>). With reference to (1) to (6) above, we assessed the likely magnitude and direction of the bias and whether we consider it is likely to impact on the findings. We planned to explore the impact of the level of bias through undertaking sensitivity analyses ‐ <i>see</i><a href="#CD004452-sec-0073">Sensitivity analysis</a>. </p> </section> </section> <section id="CD004452-sec-0055"> <h4 class="title">Measures of treatment effect</h4> <section id="CD004452-sec-0056"> <h5 class="title">Dichotomous data</h5> <p>For dichotomous data, results are presented as summary risk ratio with 95% confidence intervals (CI). Where appropriate, calculations for number needed to treat for benefit (NNTB) and number needed to treat for harm (NNTH) were performed. </p> </section> <section id="CD004452-sec-0057"> <h5 class="title">Continuous data</h5> <p>For continuous data, the mean difference was used if outcome measures were comparable between studies. The standardised mean difference was intended for use to combine studies measuring comparable outcomes but using different methodology. </p> </section> </section> <section id="CD004452-sec-0058"> <h4 class="title">Unit of analysis issues</h4> <section id="CD004452-sec-0059"> <h5 class="title">Cross‐over trials</h5> <p>Cross‐over trials were excluded from this review.</p> </section> <section id="CD004452-sec-0060"> <h5 class="title">Cluster‐randomised trials</h5> <p>We did not identify any cluster‐randomised trials for inclusion in this review, but trials of this type may be identified and included in future updates. </p> <p>If cluster‐randomised trials are included in future updates, they will be included in the analyses along with individually‐randomised trials. Their sample sizes will be adjusted using the methods described in the <i>Handbook</i> (<a href="./references#CD004452-bbs2-0052" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org, Version 5.1.0 [updated March 2011].. ">Higgins 2011</a>) using an estimate of the intra cluster correlation co‐efficient (ICC) derived from the trial (if possible), or from another source. If ICCs from other sources are used, this will be reported and sensitivity analyses will be conducted to investigate the effect of variation in the ICC. If both cluster‐randomised trials and individually‐randomised trials are identified, the relevant information will be synthesised. The authors consider it reasonable to combine the results from both if there is little heterogeneity between the study designs and the interaction between the effect of intervention and the choice of randomisation unit is considered to be unlikely. Heterogeneity in the randomisation unit will also be acknowledged and a sensitivity analysis will be performed to investigate the effects of the randomisation units. </p> </section> <section id="CD004452-sec-0061"> <h5 class="title">Multi‐arm studies</h5> <p>For the subgroup comparisons undertaken, to avoid double counting, we planned to divide out data from the shared group approximately evenly among the comparisons as described in the <i>Handbook</i> 16.5.4 (<a href="./references#CD004452-bbs2-0052" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org, Version 5.1.0 [updated March 2011].. ">Higgins 2011</a>). </p> <p>One study (<a href="./references#CD004452-bbs2-0014" title="ArceJC . A proof of concept study assessing the effect of four different stage bolus intravenous doses of FE200440 and placebo on stopping preterm labor (ongoing trial). ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 21 March 2006). ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of a selective oxytocin antagonist (barusiban) in threatened preterm labour: a randomized, double‐blind, placebo‐controlled trial. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA. 2008:Abstract no: 129. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban on plasma concentrations and uterine contractility in threatened preterm labour: a randomised, double‐blind, placebo‐controlled trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2008;93(Suppl 1):Fa11‐Fa12. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2009;200(6):627.e1‐627.e10. ">Thornton 2009</a>) compared four different dosage regimens of barusiban (0.3, 1, 3 or 10 mg) with placebo. For the analyses undertaken in this review, we have combined all doses for comparison with placebo. </p> </section> <section id="CD004452-sec-0062"> <h5 class="title">Multiple pregnancy</h5> <p>Where multiple pregnancies are included, wherever possible, analyses should be adjusted for clustering to take into account the non‐independence of neonates from the same pregnancy (<a href="./references#CD004452-bbs2-0044" title="GatesS , BrocklehurstP . How should randomised trials including multiple pregnancies be analysed?. BJOG2004;111(3):213‐9. ">Gates 2004</a>). Treating neonates from multiple pregnancies as if they are independent, when they are more likely to have similar outcomes than neonates from different pregnancies, will overestimate the sample size and give CIs that are too narrow. Each woman can be considered a cluster in a multiple pregnancy, with the number of individuals in the cluster being equal to the number of fetuses in her pregnancy. Analysis using cluster trial methods allows calculation of relative risk and adjustment of CIs. Usually this will mean that the confidence intervals get wider. Although this may make little difference to the conclusion of a study, it avoids misleading results in those studies where the difference may be substantial. </p> <p>Seven studies reported outcomes for twin pregnancies (<a href="./references#CD004452-bbs2-0002" title="The European Atosiban Study Group. The oxytocin antagonist atosiban versus the ß‐agonist terbutaline in the treatment of preterm labor: a randomized, double‐blind, controlled study. Acta Obstetricia et Gynecologica Scandinavica2001;80:413‐22. The Worldwide Atosiban versus Beta‐antagonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. BJOG2001;108:133‐42. ">European 2001</a>; <a href="./references#CD004452-bbs2-0003" title="French/Australian Atosiban Investigators Group. Treatment of preterm labor with the oxytocin antagonist atosiban: a double‐blind, randomized, controlled comparison with salbutamol. European Journal Obstetrics, Gynecology and Reproductive Biology2001;98:177‐85. The Worldwide Atosiban versus Beta‐antagonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. BJOG2001;108:133‐42. ">French/Australian 2001</a>; <a href="./references#CD004452-bbs2-0004" title="GoodwinTM , PaulR , SilverH , SpellacyW , ParsonsM , ChezR , et al. The effect of the oxytocin antagonist atosiban on preterm uterine activity in the human. American Journal of Obstetrics and Gynecology1994;170:474‐8. GoodwinTM , PaulRH , SilverH , ParsonsM , ChezR , SpellacyW , et al. Safety and efficacy of the oxytocin antagonist atosiban in threatened preterm labor: initial US trial. American Journal of Obstetrics and Gynecology1992;166:359. ">Goodwin 1994</a>; <a href="./references#CD004452-bbs2-0008" title="MoutquinJ , RabinoviciJ . Comparison of atosiban versus ritodrine in the treatment of pre‐term labour. Acta Obstetrica et Gynecologica Scandinavica1997;76(167):33. MoutquinJM , ShermanD , CohenH , MohidePT , Hochner‐CelnikierD , FejginM , et al. Double‐blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study. American Journal of Obstetrics and Gynecology2000;182(5):1191‐9. ">Moutquin 2000</a>; <a href="./references#CD004452-bbs2-0009" title="NonnenmacherA , HoppH , DudenhausenJ . Effectiveness and safety of atosiban vs. pulsatile administration of fenoterol in the treatment of preterm labour. Zeitschrift fur Geburtshilfe und Neonatologie2009;213(5):201‐6. ">Nonnenmacher 2009</a>; <a href="./references#CD004452-bbs2-0011" title="GoodwinTM . 1st International preterm labour congress. Strategies to prevent the morbidity and mortality associated with prematurity; 2002 June 27‐30. Le Montreux Palace, Montreux Switzerland. 2002. GoodwinTM . Long‐term safety with oxytocin antagonists. 4th World Congress on Controversies in Obstetrics, Gynecology and Infertility; 2003 April 24‐27; Berlin, Germany. 2003:291. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes at 6 and 12 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes up to 24 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. RomeroR , SibaiBM , Sanchez‐RamosL , ValenzuelaGJ , VeilleJC , TaborB , et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double‐blind, placebo‐controlled trial with tocolytic rescue. American Journal of Obstetrics and Gynecology2000;182(5):1173‐83. SibaiB , RomeroR , Sanchex‐RamosL , ValenzuelaG , VeilleJ , TaborB , et al. A double‐blind placebo‐controlled trial of an oxytocin‐receptor antagonist (antocin) in the treatment of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S2. SilverH , ValenzuelaG , Sanchez‐RamosL , RomeroR , SibaiB , GoodwinT , et al. Maternal side effects and safety of the oxytocin receptor antagonist antocin. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S45. ">Romero 2000</a>; <a href="./references#CD004452-bbs2-0012" title="GarmiG . Nifedipine compared to atosiban for treating preterm labor [ClinicalTrials.gov (http://clinicaltrials.gov/)]. accessed 9 April 2008. SalimR , GarmiG , NachumZ , ZafranN , BaramS , ShalevE . Nifedipine compared with atosiban for treating preterm labor: A randomized controlled trial. Obstetrics and Gynecology2012;120(6):1323‐31. ">Salim 2012</a>). Two of these studies (<a href="./references#CD004452-bbs2-0004" title="GoodwinTM , PaulR , SilverH , SpellacyW , ParsonsM , ChezR , et al. The effect of the oxytocin antagonist atosiban on preterm uterine activity in the human. American Journal of Obstetrics and Gynecology1994;170:474‐8. GoodwinTM , PaulRH , SilverH , ParsonsM , ChezR , SpellacyW , et al. Safety and efficacy of the oxytocin antagonist atosiban in threatened preterm labor: initial US trial. American Journal of Obstetrics and Gynecology1992;166:359. ">Goodwin 1994</a>; <a href="./references#CD004452-bbs2-0011" title="GoodwinTM . 1st International preterm labour congress. Strategies to prevent the morbidity and mortality associated with prematurity; 2002 June 27‐30. Le Montreux Palace, Montreux Switzerland. 2002. GoodwinTM . Long‐term safety with oxytocin antagonists. 4th World Congress on Controversies in Obstetrics, Gynecology and Infertility; 2003 April 24‐27; Berlin, Germany. 2003:291. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes at 6 and 12 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes up to 24 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. RomeroR , SibaiBM , Sanchez‐RamosL , ValenzuelaGJ , VeilleJC , TaborB , et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double‐blind, placebo‐controlled trial with tocolytic rescue. American Journal of Obstetrics and Gynecology2000;182(5):1173‐83. SibaiB , RomeroR , Sanchex‐RamosL , ValenzuelaG , VeilleJ , TaborB , et al. A double‐blind placebo‐controlled trial of an oxytocin‐receptor antagonist (antocin) in the treatment of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S2. SilverH , ValenzuelaG , Sanchez‐RamosL , RomeroR , SibaiB , GoodwinT , et al. Maternal side effects and safety of the oxytocin receptor antagonist antocin. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S45. ">Romero 2000</a>) compared ORA (atosiban) versus placebo, one study (<a href="./references#CD004452-bbs2-0012" title="GarmiG . Nifedipine compared to atosiban for treating preterm labor [ClinicalTrials.gov (http://clinicaltrials.gov/)]. accessed 9 April 2008. SalimR , GarmiG , NachumZ , ZafranN , BaramS , ShalevE . Nifedipine compared with atosiban for treating preterm labor: A randomized controlled trial. Obstetrics and Gynecology2012;120(6):1323‐31. ">Salim 2012</a>) compared ORA versus CCB, and four studies compared ORA (atosiban) versus betamimetics (<a href="./references#CD004452-bbs2-0002" title="The European Atosiban Study Group. The oxytocin antagonist atosiban versus the ß‐agonist terbutaline in the treatment of preterm labor: a randomized, double‐blind, controlled study. Acta Obstetricia et Gynecologica Scandinavica2001;80:413‐22. The Worldwide Atosiban versus Beta‐antagonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. BJOG2001;108:133‐42. ">European 2001</a>; <a href="./references#CD004452-bbs2-0003" title="French/Australian Atosiban Investigators Group. Treatment of preterm labor with the oxytocin antagonist atosiban: a double‐blind, randomized, controlled comparison with salbutamol. European Journal Obstetrics, Gynecology and Reproductive Biology2001;98:177‐85. The Worldwide Atosiban versus Beta‐antagonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. BJOG2001;108:133‐42. ">French/Australian 2001</a>; <a href="./references#CD004452-bbs2-0008" title="MoutquinJ , RabinoviciJ . Comparison of atosiban versus ritodrine in the treatment of pre‐term labour. Acta Obstetrica et Gynecologica Scandinavica1997;76(167):33. MoutquinJM , ShermanD , CohenH , MohidePT , Hochner‐CelnikierD , FejginM , et al. Double‐blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study. American Journal of Obstetrics and Gynecology2000;182(5):1191‐9. ">Moutquin 2000</a>; <a href="./references#CD004452-bbs2-0009" title="NonnenmacherA , HoppH , DudenhausenJ . Effectiveness and safety of atosiban vs. pulsatile administration of fenoterol in the treatment of preterm labour. Zeitschrift fur Geburtshilfe und Neonatologie2009;213(5):201‐6. ">Nonnenmacher 2009</a>). </p> <p>For the studies with twin pregnancies, the sample sizes for reported newborn outcomes were adjusted using the methods described in the <i>Handbook</i> (<a href="./references#CD004452-bbs2-0052" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org, Version 5.1.0 [updated March 2011].. ">Higgins 2011</a>) using an estimate of the intra‐class correlation coefficient (ICC) of 0.2 as described by Yelland <i>et al</i> (<a href="./references#CD004452-bbs2-0074" title="YellandL , SalterA , RyanP , MakridesM . Analysis of binary outcomes from randomised trials including multiple births: when should clustering be taken into account?. Paediatric and Perinatal Epidemiology2011;25(3):283‐97. ">Yelland 2011</a>). </p> </section> </section> <section id="CD004452-sec-0063"> <h4 class="title">Dealing with missing data</h4> <p>For included studies, levels of attrition in the 'Risk of bias' table were noted. The authors planned to explore the impact of including studies with high levels of missing data in the overall assessment of treatment effect by using sensitivity analysis. Analyses were, as far as possible, performed on an intention‐to‐treat basis for all outcomes. Attempts were made to include all participants randomised to each group in the analyses, and all participants were analysed in the group to which they were allocated, regardless of whether or not they received the allocated intervention. The denominator for each outcome in each study was the number randomised minus any participants whose outcomes are known to be missing. </p> </section> <section id="CD004452-sec-0064"> <h4 class="title">Assessment of heterogeneity</h4> <p>Statistical heterogeneity was assessed in each meta‐analysis using the Tau², I² and Chi² statistics. Heterogeneity was regarded as substantial if the Tau² was greater than zero and either the I² was greater than 30% or there was a low P value (less than 0.10) in the Chi² test for heterogeneity. </p> </section> <section id="CD004452-sec-0065"> <h4 class="title">Assessment of reporting biases</h4> <p>If 10 or more studies had contributed data to meta‐analysis for any particular outcome, we planned to assess reporting biases (such as publication bias) using funnel plots. Possible asymmetry would have been assessed visually, and if asymmetry was suggested, we planned exploratory analyses for investigation. In this version of the review, insufficient data were available to allow us to carry out this planned analysis. </p> </section> <section id="CD004452-sec-0066"> <h4 class="title">Data synthesis</h4> <p>Statistical analyses were performed using the Review Manager software (<a href="./references#CD004452-bbs2-0065" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">RevMan 2012</a>). Fixed‐effect meta‐analysis was used for combining data where it was reasonable to assume that studies were estimating the same underlying treatment effect; i.e. where studies were examining the same intervention, and the studies’ populations and methods were judged sufficiently similar. If clinical heterogeneity was deemed sufficient to expect differences between studies in regards to the underlying treatment effects, or if substantial statistical heterogeneity was detected, random‐effects meta‐analysis was used to produce an overall summary. This was performed if an average treatment effect across studies was considered clinically meaningful. </p> <p>In one study (<a href="./references#CD004452-bbs2-0014" title="ArceJC . A proof of concept study assessing the effect of four different stage bolus intravenous doses of FE200440 and placebo on stopping preterm labor (ongoing trial). ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 21 March 2006). ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of a selective oxytocin antagonist (barusiban) in threatened preterm labour: a randomized, double‐blind, placebo‐controlled trial. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA. 2008:Abstract no: 129. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban on plasma concentrations and uterine contractility in threatened preterm labour: a randomised, double‐blind, placebo‐controlled trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2008;93(Suppl 1):Fa11‐Fa12. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2009;200(6):627.e1‐627.e10. ">Thornton 2009</a>), which compared four dosing regimens of barusiban with placebo and one study (<a href="./references#CD004452-bbs2-0005" title="GoodwinTM , ValenzuelaG , SilverH , HayashiR , CreasyGW , LaneR . Treatment of preterm labor with the oxytocin antagonist atosiban. American Journal of Perinatology1996;13(3):143‐6. GoodwinTM , ValenzuelaGJ , SilverH , CreasyG , Atosiban Study Group. Dose ranging study of the oxytocin antagonist atosiban in the treatment of preterm labor. Obstetrics &amp; Gynecology1996;88(3):331‐6. ">Goodwin 1996</a>) comparing four different dosing regimens of atosiban with betamimetics, outcomes from all four dosing regimens were combined in the analyses. </p> <p>The random‐effects summary was treated as the average range of possible treatment effects and the authors discussed the clinical implications of treatment effects differing between studies. If the average treatment effect was deemed to be not clinically meaningful studies were not combined. </p> <p>Where random‐effects analyses were used, the results are presented as the mean treatment effect with its 95% CI, and the estimates of Tau² and I². </p> </section> <section id="CD004452-sec-0067"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If we identified substantial heterogeneity, we performed investigations using subgroup analyses. Consideration was taken to whether an overall summary was meaningful, and if deemed relevant, we performed a random‐effects analysis. We assessed subgroup differences by interaction tests available within RevMan (<a href="./references#CD004452-bbs2-0065" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">RevMan 2012</a>). </p> <section id="CD004452-sec-0068"> <h5 class="title">A priori subgroup analyses</h5> <p>We planned the following subgroup analyses.</p> <section id="CD004452-sec-0069"> <h6 class="title">By population</h6> <p> <ul id="CD004452-list-0015"> <li> <p>Women randomised before 28 weeks' gestation versus those randomised at 28 weeks or after. </p> </li> <li> <p>Women with ruptured membranes at randomisation versus women with intact membranes.</p> </li> <li> <p>Women with a singleton pregnancy versus women with a multiple pregnancy.</p> </li> <li> <p>Women who received maintenance therapy* versus women who did not.</p> </li> </ul> </p> <p>(*Use of continued tocolytic agents after successful suppression of threatened preterm labour.) </p> </section> <section id="CD004452-sec-0070"> <h6 class="title">By intervention</h6> <p> <ul id="CD004452-list-0016"> <li> <p>Oxytocin receptor antagonists compared with placebo, further subgrouped by type of oxytocin receptor antagonist. </p> </li> <li> <p>Oxytocin receptor antagonists compared with other classes of tocolytic agents, further subgrouped by type of other tocolytic agent and type of oxytocin receptors antagonist. </p> </li> </ul> </p> <p>We will assess the following outcomes in subgroup analyses.</p> </section> <section id="CD004452-sec-0071"> <h6 class="title">Fetal/neonatal outcomes</h6> <p> <ul id="CD004452-list-0017"> <li> <p>Perinatal mortality (stillbirth and neonatal death up to 28 days).</p> </li> <li> <p>Infant death (up to 12 months).</p> </li> <li> <p>Major childhood sensorineural disability.</p> </li> <li> <p>Extremely preterm birth (before completion of 28 weeks of gestation).</p> </li> <li> <p>Very preterm birth (before completion of 34 weeks of gestation).</p> </li> <li> <p>Preterm birth (before completion of 37 weeks of gestation).</p> </li> <li> <p>Birth less than 48 hours after trial entry.</p> </li> <li> <p>Respiratory distress syndrome.</p> </li> <li> <p>Intraventricular haemorrhage.</p> </li> <li> <p>Necrotising enterocolitis.</p> </li> <li> <p>Retinopathy of prematurity.</p> </li> <li> <p>Chronic lung disease (need for supplemental oxygen therapy at 36 weeks' postmenstrual age). </p> </li> <li> <p>Admission to neonatal intensive care unit.</p> </li> <li> <p>Neonatal length of hospital stay.</p> </li> <li> <p>Quality of life in childhood (measured by validated instruments).</p> </li> </ul> </p> </section> <section id="CD004452-sec-0072"> <h6 class="title">Maternal outcomes</h6> <p> <ul id="CD004452-list-0018"> <li> <p>Serious maternal outcome.</p> </li> <li> <p>Maternal adverse effects requiring cessation of treatment.</p> </li> <li> <p>Quality of life after the birth (measured by validated instruments).</p> </li> </ul> </p> </section> </section> </section> <section id="CD004452-sec-0073"> <h4 class="title">Sensitivity analysis</h4> <p>We planned sensitivity analyses to explore the effect of study quality assessed by concealment of allocation, high attrition rates (greater than 20%), or both. The intention was to exclude poor‐quality studies (including those assessed as low or unknown risk of bias) from the analyses in order to assess whether this made any difference to the overall result. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD004452-sec-0074" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD004452-sec-0074"></div> <section id="CD004452-sec-0075"> <h3 class="title">Description of studies</h3> <section id="CD004452-sec-0076"> <h4 class="title">Results of the search</h4> <p>In this review, 29 studies were identified as potentially eligible for inclusion. Nine studies were excluded (<a href="./references#CD004452-bbs2-0015" title="Al‐OmariWR , Al‐ShammaaHB , Al‐TikritiEM , AhmedKW . Atosiban and nifedipine in acute tocolysis: a comparative study. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2006;128(1‐2):129‐34. Al‐OmariWR , Al‐TikriE , Al‐ShammaaH . Atosiban and nifedipine in acute tocolysis, comparative study. XVIIIth European Congress of Obstetrics and Gynaecology; May 12‐15; Athens, Greece. 2004:103. ">Al‐Omari 2006</a>; <a href="./references#CD004452-bbs2-0016" title="deHeusR , MulderEJ , DerksJB , KorverPH , vanWolfswinkelL , VisserGH . A prospective randomized trial of acute tocolysis in term labour with atosiban or ritodrine. European Journal of Obstetrics, Gynecology, and Reproductive Biology2008;139(2):139‐45. ">de Heus 2008</a>; <a href="./references#CD004452-bbs2-0017" title="GagnonD , MartensL , CreasyG , HenkeC . An economic analysis of atosiban maintenance therapy in preterm labor. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S181. ">Gagnon 1998</a>; <a href="./references#CD004452-bbs2-0018" title="Anonymous . TREASURE (Tractocile efficacy assessment survey in Europe). Trial to commence in July. http://www.ferring.com/ (accessed 24 May 2004). HussleinP , RouraLC , DudenhausenJ , HelmerH , FrydmanR , RizzoN , et al. Clinical practice evaluation of atosiban in preterm labour management in six European countries. BJOG: an international journal of obstetrics and gynaecology2006;113(Suppl 3):105‐10. ">Husslein 2006</a>; <a href="./references#CD004452-bbs2-0019" title="HussleinP , Cabero RouraL , DudenhausenJW , HelmerH , FrydmanR , RizzoN , et al. Atosiban versus usual care for the management of preterm labor. Journal of Perinatal Medicine2007;35(4):305‐13. ">Husslein 2007</a>; <a href="./references#CD004452-bbs2-0020" title="PoppitiR , NazzaroG , DePlacidoG , PalmieriT , LocciM . Prevention of preterm delivery in twin pregnancies with atosiban. Journal of Maternal‐Fetal &amp; Neonatal Medicine2009;22(Suppl 1):61. ">Poppiti 2009</a>; <a href="./references#CD004452-bbs2-0021" title="SteinwallM , BossmarT , BrouardR , LaudanskiT , OlofssonP , UrbanR , et al. The effect of relcovaptan (SR 49059), an orally active vasopressin V1a receptor antagonist, on uterine contractions in preterm labor. Gynecological Endocrinology2005;20(2):104‐5. ">Steinwall 2005</a>; <a href="./references#CD004452-bbs2-0022" title="ValenzuelaG , DiazA , GermainA , FosterT , HayashiR , Seron‐FerreM . Estradiol levels are increased before and after preterm labor treatment with an oxytocin (OT) antagonist: evidence for chronic activation of the mechanism of labor. Acta Obstetricia et Gynecologica Scandinavica1997;76(167):88. ">Valenzuela 1997</a>; <a href="./references#CD004452-bbs2-0023" title="Sanchez‐RamosL , ValenzuelaG , RomeroR , SilverH , KoltunW , MillarL , et al. A double‐blind placebo‐controlled trial of oxytocin receptor antagonist (antocin) maintenance therapy in patients with preterm labor. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S30. ValenzuelaGJ , Sanchez‐RamosL , RomeroR , SilverHM , KoltunWD , MillarL , et al. Maintenance treatment of preterm labor with the oxytocin antagonist atosiban. The atosiban ptl‐098 study group. American Journal of Obstetrics and Gynecology2000;182(5):1184‐90. ">Valenzuela 2000</a>). Another five studies are awaiting classification pending additional information from authors (<a href="./references#CD004452-bbs2-0024" title="deHeusR , MulderEJ , DerksJB , VisserGH . The effects of the tocolytics atosiban and nifedipine on fetal movements, heart rate and blood flow. Journal of Maternal‐Fetal &amp; Neonatal Medicine2009;22(6):485‐90. ">de Heus 2009</a>; <a href="./references#CD004452-bbs2-0025" title="LenzenV , BartzC , RathWH . Atosiban versus fenoterol treatment of pre‐term labour: randomised, prospective, multicentre study [Atosiban versus fenoterol zur behandlung vorzeitiger wehen: randomisierte, prospektive multizenterstudie]. Archives of Gynecology and Obstetrics2012;286(Suppl 1):S197‐S198. ">Lenzen 2012</a>; <a href="./references#CD004452-bbs2-0026" title="NeriI , MonariF , ValensiseH , FacchinettiF , BellafronteM , VolpeA . Computerized evaluation of fetal heart rate during tocolytic treatment: comparison between atosiban and ritodrine. Journal of Maternal‐Fetal and Neonatal Medicine2008;21(Suppl 1):22. NeriI , MonariF , ValensiseH , VasapolloB , FacchinettiF , VolpeA . Computerized evaluation of fetal heart rate during tocolytic treatment: comparison between atosiban and ritodrine. American Journal of Perinatology2009;26(4):259‐63. ">Neri 2009</a>; <a href="./references#CD004452-bbs2-0027" title="RenzoDGC , MignosaMM , RosatiA , BurnelliL , EpicocoG , LuziG . Can we effectively arrest premature labour in women with multiple gestations or other high‐risk factors?. 4th World Congress on Controversies in Obstetrics, Gynecology &amp; Infertility; 2003 April 24‐27; Berlin, Germany. 2003:286‐90. ">Renzo 2003</a>; <a href="./references#CD004452-bbs2-0028" title="Anonymous . The safety, tolerability and metabolism of GSK221149A, in pregnant women (34‐36 weeks), in preterm labor. ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 21 June 2007). SnidowJ , MillerH , ValenzuelaG , ThorntonS , StierB , ClaytonL , et al. A multicenter, randomized, double‐blind, placebo‐controlled phase 2 trial of retosiban, a selective oxytocin receptor antagonist, for the management of preterm labor. American Journal of Obstetrics and Gynecology2013;208(1 Suppl 1):S155. ">Snidow 2013</a>). For further information please <i>see</i><a href="./references#CD004452-sec-0161" title="">Characteristics of studies awaiting classification</a>. One study is ongoing (<a href="./references#CD004452-bbs2-0029" title="HeidaK . Nifedipine versus Atosiban in the treatment of threatened preterm labour: APOSTEL III. http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=2947 (accessed 6 January 2014). ">APOSTEL III</a>). </p> <p>In this review update, an additional eight studies, involving 790 women testing the effects of oxytocin receptor antagonists for tocolysis in preterm labour, have been included, giving a total of 14 included studies, involving 2485 women. </p> </section> <section id="CD004452-sec-0077"> <h4 class="title">Included studies</h4> <p>Fourteen studies, involving 2485 women, are included.</p> <p>Four studies (854 women) compared an oxytocin receptor antagonists with placebo (<a href="./references#CD004452-bbs2-0004" title="GoodwinTM , PaulR , SilverH , SpellacyW , ParsonsM , ChezR , et al. The effect of the oxytocin antagonist atosiban on preterm uterine activity in the human. American Journal of Obstetrics and Gynecology1994;170:474‐8. GoodwinTM , PaulRH , SilverH , ParsonsM , ChezR , SpellacyW , et al. Safety and efficacy of the oxytocin antagonist atosiban in threatened preterm labor: initial US trial. American Journal of Obstetrics and Gynecology1992;166:359. ">Goodwin 1994</a>; <a href="./references#CD004452-bbs2-0010" title="RichterON , DornC , van deVondelP , UlrichU , SchmollingJ . Tocolysis with atosiban: experience in the management of premature labor before 24 weeks of pregnancy. Archives of Gynecology and Obstetrics2005;272(1):26‐30. ">Richter 2005</a>; <a href="./references#CD004452-bbs2-0011" title="GoodwinTM . 1st International preterm labour congress. Strategies to prevent the morbidity and mortality associated with prematurity; 2002 June 27‐30. Le Montreux Palace, Montreux Switzerland. 2002. GoodwinTM . Long‐term safety with oxytocin antagonists. 4th World Congress on Controversies in Obstetrics, Gynecology and Infertility; 2003 April 24‐27; Berlin, Germany. 2003:291. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes at 6 and 12 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes up to 24 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. RomeroR , SibaiBM , Sanchez‐RamosL , ValenzuelaGJ , VeilleJC , TaborB , et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double‐blind, placebo‐controlled trial with tocolytic rescue. American Journal of Obstetrics and Gynecology2000;182(5):1173‐83. SibaiB , RomeroR , Sanchex‐RamosL , ValenzuelaG , VeilleJ , TaborB , et al. A double‐blind placebo‐controlled trial of an oxytocin‐receptor antagonist (antocin) in the treatment of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S2. SilverH , ValenzuelaG , Sanchez‐RamosL , RomeroR , SibaiB , GoodwinT , et al. Maternal side effects and safety of the oxytocin receptor antagonist antocin. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S45. ">Romero 2000</a>; <a href="./references#CD004452-bbs2-0014" title="ArceJC . A proof of concept study assessing the effect of four different stage bolus intravenous doses of FE200440 and placebo on stopping preterm labor (ongoing trial). ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 21 March 2006). ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of a selective oxytocin antagonist (barusiban) in threatened preterm labour: a randomized, double‐blind, placebo‐controlled trial. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA. 2008:Abstract no: 129. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban on plasma concentrations and uterine contractility in threatened preterm labour: a randomised, double‐blind, placebo‐controlled trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2008;93(Suppl 1):Fa11‐Fa12. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2009;200(6):627.e1‐627.e10. ">Thornton 2009</a>). Eight studies compared an oxytocin receptor antagonist (atosiban) with betamimetics (<a href="./references#CD004452-bbs2-0001" title="CabarFR , BittarRE , GomesCM , ZugabM . Atosiban as a tocolytic agent: a new proposal of a therapeutic approach. Revista Brasileira de Ginecologia y Obstetricia2008;30(2):87‐92. ">Cabar 2008</a>; <a href="./references#CD004452-bbs2-0002" title="The European Atosiban Study Group. The oxytocin antagonist atosiban versus the ß‐agonist terbutaline in the treatment of preterm labor: a randomized, double‐blind, controlled study. Acta Obstetricia et Gynecologica Scandinavica2001;80:413‐22. The Worldwide Atosiban versus Beta‐antagonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. BJOG2001;108:133‐42. ">European 2001</a>; <a href="./references#CD004452-bbs2-0003" title="French/Australian Atosiban Investigators Group. Treatment of preterm labor with the oxytocin antagonist atosiban: a double‐blind, randomized, controlled comparison with salbutamol. European Journal Obstetrics, Gynecology and Reproductive Biology2001;98:177‐85. The Worldwide Atosiban versus Beta‐antagonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. BJOG2001;108:133‐42. ">French/Australian 2001</a>; <a href="./references#CD004452-bbs2-0005" title="GoodwinTM , ValenzuelaG , SilverH , HayashiR , CreasyGW , LaneR . Treatment of preterm labor with the oxytocin antagonist atosiban. American Journal of Perinatology1996;13(3):143‐6. GoodwinTM , ValenzuelaGJ , SilverH , CreasyG , Atosiban Study Group. Dose ranging study of the oxytocin antagonist atosiban in the treatment of preterm labor. Obstetrics &amp; Gynecology1996;88(3):331‐6. ">Goodwin 1996</a>; <a href="./references#CD004452-bbs2-0007" title="LinCH , LinSY , ShyuMK , ChenSU , LeeCN . Randomized trial of oxytocin antagonist atosiban versus beta‐adrenergic agonists  in the treatment of spontaneous preterm labor in Taiwanese women. Journal of the Formosan Medical Association = Taiwan Yi Zhi2009;108(6):493‐501. ">Lin 2009</a>; <a href="./references#CD004452-bbs2-0008" title="MoutquinJ , RabinoviciJ . Comparison of atosiban versus ritodrine in the treatment of pre‐term labour. Acta Obstetrica et Gynecologica Scandinavica1997;76(167):33. MoutquinJM , ShermanD , CohenH , MohidePT , Hochner‐CelnikierD , FejginM , et al. Double‐blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study. American Journal of Obstetrics and Gynecology2000;182(5):1191‐9. ">Moutquin 2000</a>; <a href="./references#CD004452-bbs2-0009" title="NonnenmacherA , HoppH , DudenhausenJ . Effectiveness and safety of atosiban vs. pulsatile administration of fenoterol in the treatment of preterm labour. Zeitschrift fur Geburtshilfe und Neonatologie2009;213(5):201‐6. ">Nonnenmacher 2009</a>; <a href="./references#CD004452-bbs2-0013" title="ShimJY , ParkYW , YoonBH , ChoYK , YangJH , LeeY , et al. Multicentre, parallel group, randomised, single‐blind study of the safety and efficacy of atosiban versus ritodrine in the treatment of acute preterm labour in Korean women. BJOG2006;113(11):1228‐34. ">Shim 2006</a>). Two studies compared an oxytocin receptor antagonist (atosiban) with a calcium channel blocker (CCB) (nifedipine) (<a href="./references#CD004452-bbs2-0006" title="KashanianM , AkbarianAR , SoltanzadehM . Atosiban and nifedipin for the treatment of preterm labor. International Journal of Gynecology &amp; Obstetrics2005;91(1):10‐4. KashanianM , SoltanzadehM , Sheikh AnsariN . Atosiban and nifedipin for the treatment of preterm labor. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):69. ">Kashanian 2005</a>; <a href="./references#CD004452-bbs2-0012" title="GarmiG . Nifedipine compared to atosiban for treating preterm labor [ClinicalTrials.gov (http://clinicaltrials.gov/)]. accessed 9 April 2008. SalimR , GarmiG , NachumZ , ZafranN , BaramS , ShalevE . Nifedipine compared with atosiban for treating preterm labor: A randomized controlled trial. Obstetrics and Gynecology2012;120(6):1323‐31. ">Salim 2012</a>). </p> <section id="CD004452-sec-0078"> <h5 class="title">Participants</h5> <p>The participants in these studies were reasonably homogenous. In the placebo‐controlled studies, the minimum gestational age at inclusion was 20 weeks, and the maximum gestational age at inclusion was 37 weeks. In the studies comparing atosiban with betamimetic agents, the minimum gestational age at study entry ranged from 20 to 23 weeks and the maximum from 33 to 35 weeks. The presence of ruptured membranes was an exclusion criterion in all studies, except one (<a href="./references#CD004452-bbs2-0009" title="NonnenmacherA , HoppH , DudenhausenJ . Effectiveness and safety of atosiban vs. pulsatile administration of fenoterol in the treatment of preterm labour. Zeitschrift fur Geburtshilfe und Neonatologie2009;213(5):201‐6. ">Nonnenmacher 2009</a>). Exclusion of women with ruptured membranes reflects the clinical uncertainty about the role of tocolytic agents in this situation because infection is more likely to be present and delay in delivery may harm the mother and baby. In all studies, standard maternal and fetal contraindications to tocolysis were reported, e.g. pre‐eclampsia and gestational hypertension. Exclusion criteria also included the use of non‐steroidal anti‐inflammatory agents 12 hours prior to randomisation in five studies (<a href="./references#CD004452-bbs2-0002" title="The European Atosiban Study Group. The oxytocin antagonist atosiban versus the ß‐agonist terbutaline in the treatment of preterm labor: a randomized, double‐blind, controlled study. Acta Obstetricia et Gynecologica Scandinavica2001;80:413‐22. The Worldwide Atosiban versus Beta‐antagonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. BJOG2001;108:133‐42. ">European 2001</a>; <a href="./references#CD004452-bbs2-0003" title="French/Australian Atosiban Investigators Group. Treatment of preterm labor with the oxytocin antagonist atosiban: a double‐blind, randomized, controlled comparison with salbutamol. European Journal Obstetrics, Gynecology and Reproductive Biology2001;98:177‐85. The Worldwide Atosiban versus Beta‐antagonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. BJOG2001;108:133‐42. ">French/Australian 2001</a>; <a href="./references#CD004452-bbs2-0007" title="LinCH , LinSY , ShyuMK , ChenSU , LeeCN . Randomized trial of oxytocin antagonist atosiban versus beta‐adrenergic agonists  in the treatment of spontaneous preterm labor in Taiwanese women. Journal of the Formosan Medical Association = Taiwan Yi Zhi2009;108(6):493‐501. ">Lin 2009</a>; <a href="./references#CD004452-bbs2-0008" title="MoutquinJ , RabinoviciJ . Comparison of atosiban versus ritodrine in the treatment of pre‐term labour. Acta Obstetrica et Gynecologica Scandinavica1997;76(167):33. MoutquinJM , ShermanD , CohenH , MohidePT , Hochner‐CelnikierD , FejginM , et al. Double‐blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study. American Journal of Obstetrics and Gynecology2000;182(5):1191‐9. ">Moutquin 2000</a>; <a href="./references#CD004452-bbs2-0013" title="ShimJY , ParkYW , YoonBH , ChoYK , YangJH , LeeY , et al. Multicentre, parallel group, randomised, single‐blind study of the safety and efficacy of atosiban versus ritodrine in the treatment of acute preterm labour in Korean women. BJOG2006;113(11):1228‐34. ">Shim 2006</a>), and prior tocolytic therapy within 72 hours in one study (<a href="./references#CD004452-bbs2-0005" title="GoodwinTM , ValenzuelaG , SilverH , HayashiR , CreasyGW , LaneR . Treatment of preterm labor with the oxytocin antagonist atosiban. American Journal of Perinatology1996;13(3):143‐6. GoodwinTM , ValenzuelaGJ , SilverH , CreasyG , Atosiban Study Group. Dose ranging study of the oxytocin antagonist atosiban in the treatment of preterm labor. Obstetrics &amp; Gynecology1996;88(3):331‐6. ">Goodwin 1996</a>) and within seven days in one study (<a href="./references#CD004452-bbs2-0014" title="ArceJC . A proof of concept study assessing the effect of four different stage bolus intravenous doses of FE200440 and placebo on stopping preterm labor (ongoing trial). ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 21 March 2006). ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of a selective oxytocin antagonist (barusiban) in threatened preterm labour: a randomized, double‐blind, placebo‐controlled trial. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA. 2008:Abstract no: 129. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban on plasma concentrations and uterine contractility in threatened preterm labour: a randomised, double‐blind, placebo‐controlled trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2008;93(Suppl 1):Fa11‐Fa12. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2009;200(6):627.e1‐627.e10. ">Thornton 2009</a>). High‐order multiple gestations (triplets or more) were reported as excluded in six studies (<a href="./references#CD004452-bbs2-0002" title="The European Atosiban Study Group. The oxytocin antagonist atosiban versus the ß‐agonist terbutaline in the treatment of preterm labor: a randomized, double‐blind, controlled study. Acta Obstetricia et Gynecologica Scandinavica2001;80:413‐22. The Worldwide Atosiban versus Beta‐antagonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. BJOG2001;108:133‐42. ">European 2001</a>; <a href="./references#CD004452-bbs2-0003" title="French/Australian Atosiban Investigators Group. Treatment of preterm labor with the oxytocin antagonist atosiban: a double‐blind, randomized, controlled comparison with salbutamol. European Journal Obstetrics, Gynecology and Reproductive Biology2001;98:177‐85. The Worldwide Atosiban versus Beta‐antagonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. BJOG2001;108:133‐42. ">French/Australian 2001</a>; <a href="./references#CD004452-bbs2-0007" title="LinCH , LinSY , ShyuMK , ChenSU , LeeCN . Randomized trial of oxytocin antagonist atosiban versus beta‐adrenergic agonists  in the treatment of spontaneous preterm labor in Taiwanese women. Journal of the Formosan Medical Association = Taiwan Yi Zhi2009;108(6):493‐501. ">Lin 2009</a>; <a href="./references#CD004452-bbs2-0008" title="MoutquinJ , RabinoviciJ . Comparison of atosiban versus ritodrine in the treatment of pre‐term labour. Acta Obstetrica et Gynecologica Scandinavica1997;76(167):33. MoutquinJM , ShermanD , CohenH , MohidePT , Hochner‐CelnikierD , FejginM , et al. Double‐blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study. American Journal of Obstetrics and Gynecology2000;182(5):1191‐9. ">Moutquin 2000</a>; <a href="./references#CD004452-bbs2-0010" title="RichterON , DornC , van deVondelP , UlrichU , SchmollingJ . Tocolysis with atosiban: experience in the management of premature labor before 24 weeks of pregnancy. Archives of Gynecology and Obstetrics2005;272(1):26‐30. ">Richter 2005</a>; <a href="./references#CD004452-bbs2-0012" title="GarmiG . Nifedipine compared to atosiban for treating preterm labor [ClinicalTrials.gov (http://clinicaltrials.gov/)]. accessed 9 April 2008. SalimR , GarmiG , NachumZ , ZafranN , BaramS , ShalevE . Nifedipine compared with atosiban for treating preterm labor: A randomized controlled trial. Obstetrics and Gynecology2012;120(6):1323‐31. ">Salim 2012</a>) and all multiple pregnancies were excluded in three studies (<a href="./references#CD004452-bbs2-0005" title="GoodwinTM , ValenzuelaG , SilverH , HayashiR , CreasyGW , LaneR . Treatment of preterm labor with the oxytocin antagonist atosiban. American Journal of Perinatology1996;13(3):143‐6. GoodwinTM , ValenzuelaGJ , SilverH , CreasyG , Atosiban Study Group. Dose ranging study of the oxytocin antagonist atosiban in the treatment of preterm labor. Obstetrics &amp; Gynecology1996;88(3):331‐6. ">Goodwin 1996</a>; <a href="./references#CD004452-bbs2-0013" title="ShimJY , ParkYW , YoonBH , ChoYK , YangJH , LeeY , et al. Multicentre, parallel group, randomised, single‐blind study of the safety and efficacy of atosiban versus ritodrine in the treatment of acute preterm labour in Korean women. BJOG2006;113(11):1228‐34. ">Shim 2006</a>; <a href="./references#CD004452-bbs2-0014" title="ArceJC . A proof of concept study assessing the effect of four different stage bolus intravenous doses of FE200440 and placebo on stopping preterm labor (ongoing trial). ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 21 March 2006). ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of a selective oxytocin antagonist (barusiban) in threatened preterm labour: a randomized, double‐blind, placebo‐controlled trial. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA. 2008:Abstract no: 129. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban on plasma concentrations and uterine contractility in threatened preterm labour: a randomised, double‐blind, placebo‐controlled trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2008;93(Suppl 1):Fa11‐Fa12. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2009;200(6):627.e1‐627.e10. ">Thornton 2009</a>). </p> </section> <section id="CD004452-sec-0079"> <h5 class="title">Tocolysis</h5> <p>Three studies compared atosiban with placebo (<a href="./references#CD004452-bbs2-0004" title="GoodwinTM , PaulR , SilverH , SpellacyW , ParsonsM , ChezR , et al. The effect of the oxytocin antagonist atosiban on preterm uterine activity in the human. American Journal of Obstetrics and Gynecology1994;170:474‐8. GoodwinTM , PaulRH , SilverH , ParsonsM , ChezR , SpellacyW , et al. Safety and efficacy of the oxytocin antagonist atosiban in threatened preterm labor: initial US trial. American Journal of Obstetrics and Gynecology1992;166:359. ">Goodwin 1994</a>; <a href="./references#CD004452-bbs2-0010" title="RichterON , DornC , van deVondelP , UlrichU , SchmollingJ . Tocolysis with atosiban: experience in the management of premature labor before 24 weeks of pregnancy. Archives of Gynecology and Obstetrics2005;272(1):26‐30. ">Richter 2005</a>; <a href="./references#CD004452-bbs2-0011" title="GoodwinTM . 1st International preterm labour congress. Strategies to prevent the morbidity and mortality associated with prematurity; 2002 June 27‐30. Le Montreux Palace, Montreux Switzerland. 2002. GoodwinTM . Long‐term safety with oxytocin antagonists. 4th World Congress on Controversies in Obstetrics, Gynecology and Infertility; 2003 April 24‐27; Berlin, Germany. 2003:291. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes at 6 and 12 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes up to 24 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. RomeroR , SibaiBM , Sanchez‐RamosL , ValenzuelaGJ , VeilleJC , TaborB , et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double‐blind, placebo‐controlled trial with tocolytic rescue. American Journal of Obstetrics and Gynecology2000;182(5):1173‐83. SibaiB , RomeroR , Sanchex‐RamosL , ValenzuelaG , VeilleJ , TaborB , et al. A double‐blind placebo‐controlled trial of an oxytocin‐receptor antagonist (antocin) in the treatment of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S2. SilverH , ValenzuelaG , Sanchez‐RamosL , RomeroR , SibaiB , GoodwinT , et al. Maternal side effects and safety of the oxytocin receptor antagonist antocin. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S45. ">Romero 2000</a>), one study compared barusiban with placebo (<a href="./references#CD004452-bbs2-0014" title="ArceJC . A proof of concept study assessing the effect of four different stage bolus intravenous doses of FE200440 and placebo on stopping preterm labor (ongoing trial). ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 21 March 2006). ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of a selective oxytocin antagonist (barusiban) in threatened preterm labour: a randomized, double‐blind, placebo‐controlled trial. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA. 2008:Abstract no: 129. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban on plasma concentrations and uterine contractility in threatened preterm labour: a randomised, double‐blind, placebo‐controlled trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2008;93(Suppl 1):Fa11‐Fa12. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2009;200(6):627.e1‐627.e10. ">Thornton 2009</a>), two studies compared atosiban with a CCB (nifedipine) (<a href="./references#CD004452-bbs2-0006" title="KashanianM , AkbarianAR , SoltanzadehM . Atosiban and nifedipin for the treatment of preterm labor. International Journal of Gynecology &amp; Obstetrics2005;91(1):10‐4. KashanianM , SoltanzadehM , Sheikh AnsariN . Atosiban and nifedipin for the treatment of preterm labor. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):69. ">Kashanian 2005</a>; <a href="./references#CD004452-bbs2-0012" title="GarmiG . Nifedipine compared to atosiban for treating preterm labor [ClinicalTrials.gov (http://clinicaltrials.gov/)]. accessed 9 April 2008. SalimR , GarmiG , NachumZ , ZafranN , BaramS , ShalevE . Nifedipine compared with atosiban for treating preterm labor: A randomized controlled trial. Obstetrics and Gynecology2012;120(6):1323‐31. ">Salim 2012</a>) and eight studies compared atosiban with betamimetics (ritodrine, fenoterol, salbutamol, terbutaline) (<a href="./references#CD004452-bbs2-0001" title="CabarFR , BittarRE , GomesCM , ZugabM . Atosiban as a tocolytic agent: a new proposal of a therapeutic approach. Revista Brasileira de Ginecologia y Obstetricia2008;30(2):87‐92. ">Cabar 2008</a>; <a href="./references#CD004452-bbs2-0002" title="The European Atosiban Study Group. The oxytocin antagonist atosiban versus the ß‐agonist terbutaline in the treatment of preterm labor: a randomized, double‐blind, controlled study. Acta Obstetricia et Gynecologica Scandinavica2001;80:413‐22. The Worldwide Atosiban versus Beta‐antagonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. BJOG2001;108:133‐42. ">European 2001</a>; <a href="./references#CD004452-bbs2-0003" title="French/Australian Atosiban Investigators Group. Treatment of preterm labor with the oxytocin antagonist atosiban: a double‐blind, randomized, controlled comparison with salbutamol. European Journal Obstetrics, Gynecology and Reproductive Biology2001;98:177‐85. The Worldwide Atosiban versus Beta‐antagonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. BJOG2001;108:133‐42. ">French/Australian 2001</a>; <a href="./references#CD004452-bbs2-0005" title="GoodwinTM , ValenzuelaG , SilverH , HayashiR , CreasyGW , LaneR . Treatment of preterm labor with the oxytocin antagonist atosiban. American Journal of Perinatology1996;13(3):143‐6. GoodwinTM , ValenzuelaGJ , SilverH , CreasyG , Atosiban Study Group. Dose ranging study of the oxytocin antagonist atosiban in the treatment of preterm labor. Obstetrics &amp; Gynecology1996;88(3):331‐6. ">Goodwin 1996</a>; <a href="./references#CD004452-bbs2-0007" title="LinCH , LinSY , ShyuMK , ChenSU , LeeCN . Randomized trial of oxytocin antagonist atosiban versus beta‐adrenergic agonists  in the treatment of spontaneous preterm labor in Taiwanese women. Journal of the Formosan Medical Association = Taiwan Yi Zhi2009;108(6):493‐501. ">Lin 2009</a>; <a href="./references#CD004452-bbs2-0008" title="MoutquinJ , RabinoviciJ . Comparison of atosiban versus ritodrine in the treatment of pre‐term labour. Acta Obstetrica et Gynecologica Scandinavica1997;76(167):33. MoutquinJM , ShermanD , CohenH , MohidePT , Hochner‐CelnikierD , FejginM , et al. Double‐blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study. American Journal of Obstetrics and Gynecology2000;182(5):1191‐9. ">Moutquin 2000</a>; <a href="./references#CD004452-bbs2-0009" title="NonnenmacherA , HoppH , DudenhausenJ . Effectiveness and safety of atosiban vs. pulsatile administration of fenoterol in the treatment of preterm labour. Zeitschrift fur Geburtshilfe und Neonatologie2009;213(5):201‐6. ">Nonnenmacher 2009</a>; <a href="./references#CD004452-bbs2-0013" title="ShimJY , ParkYW , YoonBH , ChoYK , YangJH , LeeY , et al. Multicentre, parallel group, randomised, single‐blind study of the safety and efficacy of atosiban versus ritodrine in the treatment of acute preterm labour in Korean women. BJOG2006;113(11):1228‐34. ">Shim 2006</a>). </p> <p>In the placebo‐controlled studies, two studies (<a href="./references#CD004452-bbs2-0010" title="RichterON , DornC , van deVondelP , UlrichU , SchmollingJ . Tocolysis with atosiban: experience in the management of premature labor before 24 weeks of pregnancy. Archives of Gynecology and Obstetrics2005;272(1):26‐30. ">Richter 2005</a>; <a href="./references#CD004452-bbs2-0011" title="GoodwinTM . 1st International preterm labour congress. Strategies to prevent the morbidity and mortality associated with prematurity; 2002 June 27‐30. Le Montreux Palace, Montreux Switzerland. 2002. GoodwinTM . Long‐term safety with oxytocin antagonists. 4th World Congress on Controversies in Obstetrics, Gynecology and Infertility; 2003 April 24‐27; Berlin, Germany. 2003:291. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes at 6 and 12 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes up to 24 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. RomeroR , SibaiBM , Sanchez‐RamosL , ValenzuelaGJ , VeilleJC , TaborB , et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double‐blind, placebo‐controlled trial with tocolytic rescue. American Journal of Obstetrics and Gynecology2000;182(5):1173‐83. SibaiB , RomeroR , Sanchex‐RamosL , ValenzuelaG , VeilleJ , TaborB , et al. A double‐blind placebo‐controlled trial of an oxytocin‐receptor antagonist (antocin) in the treatment of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S2. SilverH , ValenzuelaG , Sanchez‐RamosL , RomeroR , SibaiB , GoodwinT , et al. Maternal side effects and safety of the oxytocin receptor antagonist antocin. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S45. ">Romero 2000</a>) administered atosiban as a initial bolus dose of 6.75 mg intravenously (i.v.) followed by an infusion of 300 µg/min for three hours, then 100 µg/minutes for 45 hours. In <a href="./references#CD004452-bbs2-0011" title="GoodwinTM . 1st International preterm labour congress. Strategies to prevent the morbidity and mortality associated with prematurity; 2002 June 27‐30. Le Montreux Palace, Montreux Switzerland. 2002. GoodwinTM . Long‐term safety with oxytocin antagonists. 4th World Congress on Controversies in Obstetrics, Gynecology and Infertility; 2003 April 24‐27; Berlin, Germany. 2003:291. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes at 6 and 12 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes up to 24 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. RomeroR , SibaiBM , Sanchez‐RamosL , ValenzuelaGJ , VeilleJC , TaborB , et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double‐blind, placebo‐controlled trial with tocolytic rescue. American Journal of Obstetrics and Gynecology2000;182(5):1173‐83. SibaiB , RomeroR , Sanchex‐RamosL , ValenzuelaG , VeilleJ , TaborB , et al. A double‐blind placebo‐controlled trial of an oxytocin‐receptor antagonist (antocin) in the treatment of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S2. SilverH , ValenzuelaG , Sanchez‐RamosL , RomeroR , SibaiB , GoodwinT , et al. Maternal side effects and safety of the oxytocin receptor antagonist antocin. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S45. ">Romero 2000</a>, maintenance therapy was thereafter administered via subcutaneous injections up to 36 weeks. One study (<a href="./references#CD004452-bbs2-0004" title="GoodwinTM , PaulR , SilverH , SpellacyW , ParsonsM , ChezR , et al. The effect of the oxytocin antagonist atosiban on preterm uterine activity in the human. American Journal of Obstetrics and Gynecology1994;170:474‐8. GoodwinTM , PaulRH , SilverH , ParsonsM , ChezR , SpellacyW , et al. Safety and efficacy of the oxytocin antagonist atosiban in threatened preterm labor: initial US trial. American Journal of Obstetrics and Gynecology1992;166:359. ">Goodwin 1994</a>) administered atosiban as a initial bolus dose of 6.75 mg i.v. followed by an infusion of 300 µg/minutes for two hours. One study administered barusiban as a single bolus dose (1 mL of either 0.3 mg, 1 mg, 3 mg or 10 mg barusiban, i.v.). Two of the placebo‐controlled studies included rescue tocolysis as a part of the study protocol. In <a href="./references#CD004452-bbs2-0004" title="GoodwinTM , PaulR , SilverH , SpellacyW , ParsonsM , ChezR , et al. The effect of the oxytocin antagonist atosiban on preterm uterine activity in the human. American Journal of Obstetrics and Gynecology1994;170:474‐8. GoodwinTM , PaulRH , SilverH , ParsonsM , ChezR , SpellacyW , et al. Safety and efficacy of the oxytocin antagonist atosiban in threatened preterm labor: initial US trial. American Journal of Obstetrics and Gynecology1992;166:359. ">Goodwin 1994</a>, the primary aim was to determine the effect of atosiban on uterine activity during an infusion limited to two hours. In the atosiban group, 19.6% of the participants required an additional rescue tocolytic agent versus 32% in the placebo group. In this study (<a href="./references#CD004452-bbs2-0004" title="GoodwinTM , PaulR , SilverH , SpellacyW , ParsonsM , ChezR , et al. The effect of the oxytocin antagonist atosiban on preterm uterine activity in the human. American Journal of Obstetrics and Gynecology1994;170:474‐8. GoodwinTM , PaulRH , SilverH , ParsonsM , ChezR , SpellacyW , et al. Safety and efficacy of the oxytocin antagonist atosiban in threatened preterm labor: initial US trial. American Journal of Obstetrics and Gynecology1992;166:359. ">Goodwin 1994</a>), maintenance therapy after the two hour infusion was not instituted. In <a href="./references#CD004452-bbs2-0004" title="GoodwinTM , PaulR , SilverH , SpellacyW , ParsonsM , ChezR , et al. The effect of the oxytocin antagonist atosiban on preterm uterine activity in the human. American Journal of Obstetrics and Gynecology1994;170:474‐8. GoodwinTM , PaulRH , SilverH , ParsonsM , ChezR , SpellacyW , et al. Safety and efficacy of the oxytocin antagonist atosiban in threatened preterm labor: initial US trial. American Journal of Obstetrics and Gynecology1992;166:359. ">Goodwin 1994</a>, of the 120 women enrolled, 29 (11 atosiban and 18 placebo) required additional tocolysis with magnesium sulphate (n = 23) or subcutaneous terbutaline (n = 6). There is, however, no description of the doses or duration of this additional tocolysis. In <a href="./references#CD004452-bbs2-0011" title="GoodwinTM . 1st International preterm labour congress. Strategies to prevent the morbidity and mortality associated with prematurity; 2002 June 27‐30. Le Montreux Palace, Montreux Switzerland. 2002. GoodwinTM . Long‐term safety with oxytocin antagonists. 4th World Congress on Controversies in Obstetrics, Gynecology and Infertility; 2003 April 24‐27; Berlin, Germany. 2003:291. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes at 6 and 12 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes up to 24 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. RomeroR , SibaiBM , Sanchez‐RamosL , ValenzuelaGJ , VeilleJC , TaborB , et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double‐blind, placebo‐controlled trial with tocolytic rescue. American Journal of Obstetrics and Gynecology2000;182(5):1173‐83. SibaiB , RomeroR , Sanchex‐RamosL , ValenzuelaG , VeilleJ , TaborB , et al. A double‐blind placebo‐controlled trial of an oxytocin‐receptor antagonist (antocin) in the treatment of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S2. SilverH , ValenzuelaG , Sanchez‐RamosL , RomeroR , SibaiB , GoodwinT , et al. Maternal side effects and safety of the oxytocin receptor antagonist antocin. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S45. ">Romero 2000</a>, rescue therapy was given in 42% of the atosiban group and in 51% of the placebo group. Participants received rescue tocolytic therapy with an alternate tocolytic of the investigator's choice after discontinuation of the study drug. Rescue tocolysis was considered in this study when preterm labour has progressed after at least one hour of observation and either of the following occurred: (1) cervical effacement of ≥ 75% (≤ 0.5 cm) with no decrease in the frequency or intensity of contractions and continued cervical change (at least a 1 cm change in dilatation or effacement); or (2) cervical dilatation of ≥ 4 cm with a 1 cm increase since the last cervical examination. Maintenance therapy was started with either atosiban or placebo in women who achieved uterine quiescence with a subcutaneous infusion of 0.004 mL (30 µg/minute for atosiban) and was ceased at the end of the 36<sup>th</sup> week of gestation, at delivery, or if progression of labour necessitated an alternate tocolytic agent. In the third placebo‐controlled study (<a href="./references#CD004452-bbs2-0010" title="RichterON , DornC , van deVondelP , UlrichU , SchmollingJ . Tocolysis with atosiban: experience in the management of premature labor before 24 weeks of pregnancy. Archives of Gynecology and Obstetrics2005;272(1):26‐30. ">Richter 2005</a>), rescue tocolysis was not performed. In cases of successful tocolysis but with persisted cervical dilatation, the woman was informed of the option of a cerclage and/or total occlusion of the cervix. One study (<a href="./references#CD004452-bbs2-0014" title="ArceJC . A proof of concept study assessing the effect of four different stage bolus intravenous doses of FE200440 and placebo on stopping preterm labor (ongoing trial). ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 21 March 2006). ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of a selective oxytocin antagonist (barusiban) in threatened preterm labour: a randomized, double‐blind, placebo‐controlled trial. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA. 2008:Abstract no: 129. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban on plasma concentrations and uterine contractility in threatened preterm labour: a randomised, double‐blind, placebo‐controlled trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2008;93(Suppl 1):Fa11‐Fa12. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2009;200(6):627.e1‐627.e10. ">Thornton 2009</a>) did not allow any tocolytics as rescue therapy. </p> <p>In the studies comparing atosiban with nifedipine, one study (<a href="./references#CD004452-bbs2-0012" title="GarmiG . Nifedipine compared to atosiban for treating preterm labor [ClinicalTrials.gov (http://clinicaltrials.gov/)]. accessed 9 April 2008. SalimR , GarmiG , NachumZ , ZafranN , BaramS , ShalevE . Nifedipine compared with atosiban for treating preterm labor: A randomized controlled trial. Obstetrics and Gynecology2012;120(6):1323‐31. ">Salim 2012</a>), administered atosiban as a initial bolus dose of 6.75 mg i.v. followed by an infusion of 300 µg/minute for three hours, then 100 µg/minute for 45 hours. The other study (<a href="./references#CD004452-bbs2-0006" title="KashanianM , AkbarianAR , SoltanzadehM . Atosiban and nifedipin for the treatment of preterm labor. International Journal of Gynecology &amp; Obstetrics2005;91(1):10‐4. KashanianM , SoltanzadehM , Sheikh AnsariN . Atosiban and nifedipin for the treatment of preterm labor. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):69. ">Kashanian 2005</a>) administered atosiban as an i.v. infusion of 300 µg/minute up to 12 hours, or six hours after contractions ceased. In one of the studies comparing atosiban with nifedipine (<a href="./references#CD004452-bbs2-0006" title="KashanianM , AkbarianAR , SoltanzadehM . Atosiban and nifedipin for the treatment of preterm labor. International Journal of Gynecology &amp; Obstetrics2005;91(1):10‐4. KashanianM , SoltanzadehM , Sheikh AnsariN . Atosiban and nifedipin for the treatment of preterm labor. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):69. ">Kashanian 2005</a>), rescue tocolysis was not performed. Nifedipine was given at an initial dose of 10 mg (one capsule) sublingually every 20 minutes for four doses. Maintenance dose with nifedipine was continued orally (20 mg) every six hours for the first 24 hours, and then every eight hours for the following 24 hours, and finally 10 mg every eight hours for the last 24 hours. In the other nifedipine‐controlled study (<a href="./references#CD004452-bbs2-0012" title="GarmiG . Nifedipine compared to atosiban for treating preterm labor [ClinicalTrials.gov (http://clinicaltrials.gov/)]. accessed 9 April 2008. SalimR , GarmiG , NachumZ , ZafranN , BaramS , ShalevE . Nifedipine compared with atosiban for treating preterm labor: A randomized controlled trial. Obstetrics and Gynecology2012;120(6):1323‐31. ">Salim 2012</a>), rescue tocolysis was performed if progression of labour was determined after one hour but before 48 hours, or if adverse effects of the drug were noted, a cross‐over of the study drugs was performed and the alternative tocolytic drug (i.e. rescue treatment) was initiated. Nifedipine was given as a loading dose of 20 mg orally followed by another two doses of 20 mg, 20 to 30 minutes apart as needed. Maintenance was started after six hours with 20 to 40 mg four times daily for a total of 48 hours. If tocolysis failed from both drugs before 48 hours or admission at a gestational age below 28 weeks, indomethacin as a second rescue agent was started. Initial dose of indomethacin was two 100 mg per rectum tablets, one hour apart, followed by oral tablets of 25 mg four times daily up to a total of 48 hours. </p> <p>In most of the studies comparing atosiban with betamimetics (<a href="./references#CD004452-bbs2-0001" title="CabarFR , BittarRE , GomesCM , ZugabM . Atosiban as a tocolytic agent: a new proposal of a therapeutic approach. Revista Brasileira de Ginecologia y Obstetricia2008;30(2):87‐92. ">Cabar 2008</a>; <a href="./references#CD004452-bbs2-0002" title="The European Atosiban Study Group. The oxytocin antagonist atosiban versus the ß‐agonist terbutaline in the treatment of preterm labor: a randomized, double‐blind, controlled study. Acta Obstetricia et Gynecologica Scandinavica2001;80:413‐22. The Worldwide Atosiban versus Beta‐antagonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. BJOG2001;108:133‐42. ">European 2001</a>; <a href="./references#CD004452-bbs2-0003" title="French/Australian Atosiban Investigators Group. Treatment of preterm labor with the oxytocin antagonist atosiban: a double‐blind, randomized, controlled comparison with salbutamol. European Journal Obstetrics, Gynecology and Reproductive Biology2001;98:177‐85. The Worldwide Atosiban versus Beta‐antagonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. BJOG2001;108:133‐42. ">French/Australian 2001</a>; <a href="./references#CD004452-bbs2-0007" title="LinCH , LinSY , ShyuMK , ChenSU , LeeCN . Randomized trial of oxytocin antagonist atosiban versus beta‐adrenergic agonists  in the treatment of spontaneous preterm labor in Taiwanese women. Journal of the Formosan Medical Association = Taiwan Yi Zhi2009;108(6):493‐501. ">Lin 2009</a>; <a href="./references#CD004452-bbs2-0008" title="MoutquinJ , RabinoviciJ . Comparison of atosiban versus ritodrine in the treatment of pre‐term labour. Acta Obstetrica et Gynecologica Scandinavica1997;76(167):33. MoutquinJM , ShermanD , CohenH , MohidePT , Hochner‐CelnikierD , FejginM , et al. Double‐blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study. American Journal of Obstetrics and Gynecology2000;182(5):1191‐9. ">Moutquin 2000</a>; <a href="./references#CD004452-bbs2-0009" title="NonnenmacherA , HoppH , DudenhausenJ . Effectiveness and safety of atosiban vs. pulsatile administration of fenoterol in the treatment of preterm labour. Zeitschrift fur Geburtshilfe und Neonatologie2009;213(5):201‐6. ">Nonnenmacher 2009</a>; <a href="./references#CD004452-bbs2-0013" title="ShimJY , ParkYW , YoonBH , ChoYK , YangJH , LeeY , et al. Multicentre, parallel group, randomised, single‐blind study of the safety and efficacy of atosiban versus ritodrine in the treatment of acute preterm labour in Korean women. BJOG2006;113(11):1228‐34. ">Shim 2006</a>), an initial bolus dose of 6.75 mg (i.v.) atosiban was given, followed by a continuous infusion of 300 µg/minute for three hours, then 100 µg/minute for a maximum of 15 to 48 hours. One study (<a href="./references#CD004452-bbs2-0005" title="GoodwinTM , ValenzuelaG , SilverH , HayashiR , CreasyGW , LaneR . Treatment of preterm labor with the oxytocin antagonist atosiban. American Journal of Perinatology1996;13(3):143‐6. GoodwinTM , ValenzuelaGJ , SilverH , CreasyG , Atosiban Study Group. Dose ranging study of the oxytocin antagonist atosiban in the treatment of preterm labor. Obstetrics &amp; Gynecology1996;88(3):331‐6. ">Goodwin 1996</a>) tested four atosiban regimens: 6.5 mg bolus dose followed by infusion 300 µg/mL, two mg bolus dose followed by infusion of 100 µg/mL, 0.6 mg bolus dose followed by infusion of 30 µg/minute. All treatments were continued up to 12 hours. In the studies comparing atosiban with betamimetics, betamimetic therapy was administered i.v. for a maximum of 48 hours. Rescue tocolytic therapy was reported as a part of the study protocol for all studies in this comparison. In the European study (<a href="./references#CD004452-bbs2-0002" title="The European Atosiban Study Group. The oxytocin antagonist atosiban versus the ß‐agonist terbutaline in the treatment of preterm labor: a randomized, double‐blind, controlled study. Acta Obstetricia et Gynecologica Scandinavica2001;80:413‐22. The Worldwide Atosiban versus Beta‐antagonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. BJOG2001;108:133‐42. ">European 2001</a>), administration of an alternative tocolytic agent was dependent on both efficacy and tolerability of study medication and could be administered when there was recurrence or progression of preterm labour. In the French/Australian study (<a href="./references#CD004452-bbs2-0003" title="French/Australian Atosiban Investigators Group. Treatment of preterm labor with the oxytocin antagonist atosiban: a double‐blind, randomized, controlled comparison with salbutamol. European Journal Obstetrics, Gynecology and Reproductive Biology2001;98:177‐85. The Worldwide Atosiban versus Beta‐antagonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. BJOG2001;108:133‐42. ">French/Australian 2001</a>), if labour was progressing or women experienced intolerable adverse effects of study drug administration, an alternative tocolytic agent could be given. There were 58% (n = 69) in the atosiban group versus 63.1% (n = 77) in the salbutamol group who needed an alternate tocolytic agent. <a href="./references#CD004452-bbs2-0005" title="GoodwinTM , ValenzuelaG , SilverH , HayashiR , CreasyGW , LaneR . Treatment of preterm labor with the oxytocin antagonist atosiban. American Journal of Perinatology1996;13(3):143‐6. GoodwinTM , ValenzuelaGJ , SilverH , CreasyG , Atosiban Study Group. Dose ranging study of the oxytocin antagonist atosiban in the treatment of preterm labor. Obstetrics &amp; Gynecology1996;88(3):331‐6. ">Goodwin 1996</a> included an alternate tocolytic agent to be used when: (1) the cervix dilated 1 cm or more during therapy; (2) uterine contraction persisted at a same or higher rate; or (3) labour was not controlled, according to the judgement of the investigator. In <a href="./references#CD004452-bbs2-0013" title="ShimJY , ParkYW , YoonBH , ChoYK , YangJH , LeeY , et al. Multicentre, parallel group, randomised, single‐blind study of the safety and efficacy of atosiban versus ritodrine in the treatment of acute preterm labour in Korean women. BJOG2006;113(11):1228‐34. ">Shim 2006</a>, rescue tocolysis could be given if the study drug failed either by progression of labour or intolerable adverse events judged by the investigator. Alternative drugs could be ritodrine or magnesium sulphate, but not atosiban as rescue tocolytic in case of failure for women in the ritodrine group. In <a href="./references#CD004452-bbs2-0007" title="LinCH , LinSY , ShyuMK , ChenSU , LeeCN . Randomized trial of oxytocin antagonist atosiban versus beta‐adrenergic agonists  in the treatment of spontaneous preterm labor in Taiwanese women. Journal of the Formosan Medical Association = Taiwan Yi Zhi2009;108(6):493‐501. ">Lin 2009</a>, re‐treatment with the study drug was allowed when there was recurrence of preterm labour. In <a href="./references#CD004452-bbs2-0008" title="MoutquinJ , RabinoviciJ . Comparison of atosiban versus ritodrine in the treatment of pre‐term labour. Acta Obstetrica et Gynecologica Scandinavica1997;76(167):33. MoutquinJM , ShermanD , CohenH , MohidePT , Hochner‐CelnikierD , FejginM , et al. Double‐blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study. American Journal of Obstetrics and Gynecology2000;182(5):1191‐9. ">Moutquin 2000</a>, an alternative tocolytic agent could be given after the study treatment was stopped if labour was progressing, or if any woman had an intolerable adverse event. Maintenance therapy was used in at least one study in this comparison (<a href="./references#CD004452-bbs2-0005" title="GoodwinTM , ValenzuelaG , SilverH , HayashiR , CreasyGW , LaneR . Treatment of preterm labor with the oxytocin antagonist atosiban. American Journal of Perinatology1996;13(3):143‐6. GoodwinTM , ValenzuelaGJ , SilverH , CreasyG , Atosiban Study Group. Dose ranging study of the oxytocin antagonist atosiban in the treatment of preterm labor. Obstetrics &amp; Gynecology1996;88(3):331‐6. ">Goodwin 1996</a>); however, the details of the regimen were not provided. One study reported that maintenance therapy was not a part of the study protocol (<a href="./references#CD004452-bbs2-0003" title="French/Australian Atosiban Investigators Group. Treatment of preterm labor with the oxytocin antagonist atosiban: a double‐blind, randomized, controlled comparison with salbutamol. European Journal Obstetrics, Gynecology and Reproductive Biology2001;98:177‐85. The Worldwide Atosiban versus Beta‐antagonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. BJOG2001;108:133‐42. ">French/Australian 2001</a>). Maintenance therapy was not used in the remaining six studies where atosiban therapy was administered i.v. for a maximum of 48 hours. </p> <p>Please <i>see</i><a href="./references#CD004452-sec-0159" title="">Characteristics of included studies</a> for further details. </p> </section> <section id="CD004452-sec-0080"> <h5 class="title">Outcome measures</h5> <p>Most of the studies included reported on the important clinical outcome of respiratory distress syndrome (except <a href="./references#CD004452-bbs2-0001" title="CabarFR , BittarRE , GomesCM , ZugabM . Atosiban as a tocolytic agent: a new proposal of a therapeutic approach. Revista Brasileira de Ginecologia y Obstetricia2008;30(2):87‐92. ">Cabar 2008</a>; <a href="./references#CD004452-bbs2-0006" title="KashanianM , AkbarianAR , SoltanzadehM . Atosiban and nifedipin for the treatment of preterm labor. International Journal of Gynecology &amp; Obstetrics2005;91(1):10‐4. KashanianM , SoltanzadehM , Sheikh AnsariN . Atosiban and nifedipin for the treatment of preterm labor. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):69. ">Kashanian 2005</a>; <a href="./references#CD004452-bbs2-0009" title="NonnenmacherA , HoppH , DudenhausenJ . Effectiveness and safety of atosiban vs. pulsatile administration of fenoterol in the treatment of preterm labour. Zeitschrift fur Geburtshilfe und Neonatologie2009;213(5):201‐6. ">Nonnenmacher 2009</a>; <a href="./references#CD004452-bbs2-0010" title="RichterON , DornC , van deVondelP , UlrichU , SchmollingJ . Tocolysis with atosiban: experience in the management of premature labor before 24 weeks of pregnancy. Archives of Gynecology and Obstetrics2005;272(1):26‐30. ">Richter 2005</a>). Many studies also reported maternal adverse drug reaction (<a href="./references#CD004452-bbs2-0002" title="The European Atosiban Study Group. The oxytocin antagonist atosiban versus the ß‐agonist terbutaline in the treatment of preterm labor: a randomized, double‐blind, controlled study. Acta Obstetricia et Gynecologica Scandinavica2001;80:413‐22. The Worldwide Atosiban versus Beta‐antagonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. BJOG2001;108:133‐42. ">European 2001</a>; <a href="./references#CD004452-bbs2-0004" title="GoodwinTM , PaulR , SilverH , SpellacyW , ParsonsM , ChezR , et al. The effect of the oxytocin antagonist atosiban on preterm uterine activity in the human. American Journal of Obstetrics and Gynecology1994;170:474‐8. GoodwinTM , PaulRH , SilverH , ParsonsM , ChezR , SpellacyW , et al. Safety and efficacy of the oxytocin antagonist atosiban in threatened preterm labor: initial US trial. American Journal of Obstetrics and Gynecology1992;166:359. ">Goodwin 1994</a>; <a href="./references#CD004452-bbs2-0006" title="KashanianM , AkbarianAR , SoltanzadehM . Atosiban and nifedipin for the treatment of preterm labor. International Journal of Gynecology &amp; Obstetrics2005;91(1):10‐4. KashanianM , SoltanzadehM , Sheikh AnsariN . Atosiban and nifedipin for the treatment of preterm labor. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):69. ">Kashanian 2005</a>; <a href="./references#CD004452-bbs2-0011" title="GoodwinTM . 1st International preterm labour congress. Strategies to prevent the morbidity and mortality associated with prematurity; 2002 June 27‐30. Le Montreux Palace, Montreux Switzerland. 2002. GoodwinTM . Long‐term safety with oxytocin antagonists. 4th World Congress on Controversies in Obstetrics, Gynecology and Infertility; 2003 April 24‐27; Berlin, Germany. 2003:291. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes at 6 and 12 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes up to 24 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. RomeroR , SibaiBM , Sanchez‐RamosL , ValenzuelaGJ , VeilleJC , TaborB , et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double‐blind, placebo‐controlled trial with tocolytic rescue. American Journal of Obstetrics and Gynecology2000;182(5):1173‐83. SibaiB , RomeroR , Sanchex‐RamosL , ValenzuelaG , VeilleJ , TaborB , et al. A double‐blind placebo‐controlled trial of an oxytocin‐receptor antagonist (antocin) in the treatment of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S2. SilverH , ValenzuelaG , Sanchez‐RamosL , RomeroR , SibaiB , GoodwinT , et al. Maternal side effects and safety of the oxytocin receptor antagonist antocin. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S45. ">Romero 2000</a>; <a href="./references#CD004452-bbs2-0012" title="GarmiG . Nifedipine compared to atosiban for treating preterm labor [ClinicalTrials.gov (http://clinicaltrials.gov/)]. accessed 9 April 2008. SalimR , GarmiG , NachumZ , ZafranN , BaramS , ShalevE . Nifedipine compared with atosiban for treating preterm labor: A randomized controlled trial. Obstetrics and Gynecology2012;120(6):1323‐31. ">Salim 2012</a>; <a href="./references#CD004452-bbs2-0013" title="ShimJY , ParkYW , YoonBH , ChoYK , YangJH , LeeY , et al. Multicentre, parallel group, randomised, single‐blind study of the safety and efficacy of atosiban versus ritodrine in the treatment of acute preterm labour in Korean women. BJOG2006;113(11):1228‐34. ">Shim 2006</a>; <a href="./references#CD004452-bbs2-0014" title="ArceJC . A proof of concept study assessing the effect of four different stage bolus intravenous doses of FE200440 and placebo on stopping preterm labor (ongoing trial). ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 21 March 2006). ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of a selective oxytocin antagonist (barusiban) in threatened preterm labour: a randomized, double‐blind, placebo‐controlled trial. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA. 2008:Abstract no: 129. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban on plasma concentrations and uterine contractility in threatened preterm labour: a randomised, double‐blind, placebo‐controlled trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2008;93(Suppl 1):Fa11‐Fa12. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2009;200(6):627.e1‐627.e10. ">Thornton 2009</a>). The outcome of birth within 48 hours of initiation of treatment was reported in 12 (<a href="./references#CD004452-bbs2-0001" title="CabarFR , BittarRE , GomesCM , ZugabM . Atosiban as a tocolytic agent: a new proposal of a therapeutic approach. Revista Brasileira de Ginecologia y Obstetricia2008;30(2):87‐92. ">Cabar 2008</a>; <a href="./references#CD004452-bbs2-0002" title="The European Atosiban Study Group. The oxytocin antagonist atosiban versus the ß‐agonist terbutaline in the treatment of preterm labor: a randomized, double‐blind, controlled study. Acta Obstetricia et Gynecologica Scandinavica2001;80:413‐22. The Worldwide Atosiban versus Beta‐antagonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. BJOG2001;108:133‐42. ">European 2001</a>; <a href="./references#CD004452-bbs2-0003" title="French/Australian Atosiban Investigators Group. Treatment of preterm labor with the oxytocin antagonist atosiban: a double‐blind, randomized, controlled comparison with salbutamol. European Journal Obstetrics, Gynecology and Reproductive Biology2001;98:177‐85. The Worldwide Atosiban versus Beta‐antagonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. BJOG2001;108:133‐42. ">French/Australian 2001</a>; <a href="./references#CD004452-bbs2-0004" title="GoodwinTM , PaulR , SilverH , SpellacyW , ParsonsM , ChezR , et al. The effect of the oxytocin antagonist atosiban on preterm uterine activity in the human. American Journal of Obstetrics and Gynecology1994;170:474‐8. GoodwinTM , PaulRH , SilverH , ParsonsM , ChezR , SpellacyW , et al. Safety and efficacy of the oxytocin antagonist atosiban in threatened preterm labor: initial US trial. American Journal of Obstetrics and Gynecology1992;166:359. ">Goodwin 1994</a>; <a href="./references#CD004452-bbs2-0005" title="GoodwinTM , ValenzuelaG , SilverH , HayashiR , CreasyGW , LaneR . Treatment of preterm labor with the oxytocin antagonist atosiban. American Journal of Perinatology1996;13(3):143‐6. GoodwinTM , ValenzuelaGJ , SilverH , CreasyG , Atosiban Study Group. Dose ranging study of the oxytocin antagonist atosiban in the treatment of preterm labor. Obstetrics &amp; Gynecology1996;88(3):331‐6. ">Goodwin 1996</a>; <a href="./references#CD004452-bbs2-0006" title="KashanianM , AkbarianAR , SoltanzadehM . Atosiban and nifedipin for the treatment of preterm labor. International Journal of Gynecology &amp; Obstetrics2005;91(1):10‐4. KashanianM , SoltanzadehM , Sheikh AnsariN . Atosiban and nifedipin for the treatment of preterm labor. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):69. ">Kashanian 2005</a>; <a href="./references#CD004452-bbs2-0007" title="LinCH , LinSY , ShyuMK , ChenSU , LeeCN . Randomized trial of oxytocin antagonist atosiban versus beta‐adrenergic agonists  in the treatment of spontaneous preterm labor in Taiwanese women. Journal of the Formosan Medical Association = Taiwan Yi Zhi2009;108(6):493‐501. ">Lin 2009</a>; <a href="./references#CD004452-bbs2-0008" title="MoutquinJ , RabinoviciJ . Comparison of atosiban versus ritodrine in the treatment of pre‐term labour. Acta Obstetrica et Gynecologica Scandinavica1997;76(167):33. MoutquinJM , ShermanD , CohenH , MohidePT , Hochner‐CelnikierD , FejginM , et al. Double‐blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study. American Journal of Obstetrics and Gynecology2000;182(5):1191‐9. ">Moutquin 2000</a>; <a href="./references#CD004452-bbs2-0009" title="NonnenmacherA , HoppH , DudenhausenJ . Effectiveness and safety of atosiban vs. pulsatile administration of fenoterol in the treatment of preterm labour. Zeitschrift fur Geburtshilfe und Neonatologie2009;213(5):201‐6. ">Nonnenmacher 2009</a>; <a href="./references#CD004452-bbs2-0010" title="RichterON , DornC , van deVondelP , UlrichU , SchmollingJ . Tocolysis with atosiban: experience in the management of premature labor before 24 weeks of pregnancy. Archives of Gynecology and Obstetrics2005;272(1):26‐30. ">Richter 2005</a>; <a href="./references#CD004452-bbs2-0012" title="GarmiG . Nifedipine compared to atosiban for treating preterm labor [ClinicalTrials.gov (http://clinicaltrials.gov/)]. accessed 9 April 2008. SalimR , GarmiG , NachumZ , ZafranN , BaramS , ShalevE . Nifedipine compared with atosiban for treating preterm labor: A randomized controlled trial. Obstetrics and Gynecology2012;120(6):1323‐31. ">Salim 2012</a>; <a href="./references#CD004452-bbs2-0013" title="ShimJY , ParkYW , YoonBH , ChoYK , YangJH , LeeY , et al. Multicentre, parallel group, randomised, single‐blind study of the safety and efficacy of atosiban versus ritodrine in the treatment of acute preterm labour in Korean women. BJOG2006;113(11):1228‐34. ">Shim 2006</a>) of the 14 included studies and perinatal mortality in four studies (<a href="./references#CD004452-bbs2-0002" title="The European Atosiban Study Group. The oxytocin antagonist atosiban versus the ß‐agonist terbutaline in the treatment of preterm labor: a randomized, double‐blind, controlled study. Acta Obstetricia et Gynecologica Scandinavica2001;80:413‐22. The Worldwide Atosiban versus Beta‐antagonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. BJOG2001;108:133‐42. ">European 2001</a>; <a href="./references#CD004452-bbs2-0003" title="French/Australian Atosiban Investigators Group. Treatment of preterm labor with the oxytocin antagonist atosiban: a double‐blind, randomized, controlled comparison with salbutamol. European Journal Obstetrics, Gynecology and Reproductive Biology2001;98:177‐85. The Worldwide Atosiban versus Beta‐antagonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. BJOG2001;108:133‐42. ">French/Australian 2001</a>; <a href="./references#CD004452-bbs2-0008" title="MoutquinJ , RabinoviciJ . Comparison of atosiban versus ritodrine in the treatment of pre‐term labour. Acta Obstetrica et Gynecologica Scandinavica1997;76(167):33. MoutquinJM , ShermanD , CohenH , MohidePT , Hochner‐CelnikierD , FejginM , et al. Double‐blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study. American Journal of Obstetrics and Gynecology2000;182(5):1191‐9. ">Moutquin 2000</a>; <a href="./references#CD004452-bbs2-0011" title="GoodwinTM . 1st International preterm labour congress. Strategies to prevent the morbidity and mortality associated with prematurity; 2002 June 27‐30. Le Montreux Palace, Montreux Switzerland. 2002. GoodwinTM . Long‐term safety with oxytocin antagonists. 4th World Congress on Controversies in Obstetrics, Gynecology and Infertility; 2003 April 24‐27; Berlin, Germany. 2003:291. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes at 6 and 12 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes up to 24 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. RomeroR , SibaiBM , Sanchez‐RamosL , ValenzuelaGJ , VeilleJC , TaborB , et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double‐blind, placebo‐controlled trial with tocolytic rescue. American Journal of Obstetrics and Gynecology2000;182(5):1173‐83. SibaiB , RomeroR , Sanchex‐RamosL , ValenzuelaG , VeilleJ , TaborB , et al. A double‐blind placebo‐controlled trial of an oxytocin‐receptor antagonist (antocin) in the treatment of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S2. SilverH , ValenzuelaG , Sanchez‐RamosL , RomeroR , SibaiB , GoodwinT , et al. Maternal side effects and safety of the oxytocin receptor antagonist antocin. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S45. ">Romero 2000</a>). Other important outcomes were inconsistently reported including preterm birth, which was reported in four studies (<a href="./references#CD004452-bbs2-0002" title="The European Atosiban Study Group. The oxytocin antagonist atosiban versus the ß‐agonist terbutaline in the treatment of preterm labor: a randomized, double‐blind, controlled study. Acta Obstetricia et Gynecologica Scandinavica2001;80:413‐22. The Worldwide Atosiban versus Beta‐antagonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. BJOG2001;108:133‐42. ">European 2001</a>; <a href="./references#CD004452-bbs2-0011" title="GoodwinTM . 1st International preterm labour congress. Strategies to prevent the morbidity and mortality associated with prematurity; 2002 June 27‐30. Le Montreux Palace, Montreux Switzerland. 2002. GoodwinTM . Long‐term safety with oxytocin antagonists. 4th World Congress on Controversies in Obstetrics, Gynecology and Infertility; 2003 April 24‐27; Berlin, Germany. 2003:291. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes at 6 and 12 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes up to 24 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. RomeroR , SibaiBM , Sanchez‐RamosL , ValenzuelaGJ , VeilleJC , TaborB , et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double‐blind, placebo‐controlled trial with tocolytic rescue. American Journal of Obstetrics and Gynecology2000;182(5):1173‐83. SibaiB , RomeroR , Sanchex‐RamosL , ValenzuelaG , VeilleJ , TaborB , et al. A double‐blind placebo‐controlled trial of an oxytocin‐receptor antagonist (antocin) in the treatment of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S2. SilverH , ValenzuelaG , Sanchez‐RamosL , RomeroR , SibaiB , GoodwinT , et al. Maternal side effects and safety of the oxytocin receptor antagonist antocin. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S45. ">Romero 2000</a>; <a href="./references#CD004452-bbs2-0012" title="GarmiG . Nifedipine compared to atosiban for treating preterm labor [ClinicalTrials.gov (http://clinicaltrials.gov/)]. accessed 9 April 2008. SalimR , GarmiG , NachumZ , ZafranN , BaramS , ShalevE . Nifedipine compared with atosiban for treating preterm labor: A randomized controlled trial. Obstetrics and Gynecology2012;120(6):1323‐31. ">Salim 2012</a>; <a href="./references#CD004452-bbs2-0014" title="ArceJC . A proof of concept study assessing the effect of four different stage bolus intravenous doses of FE200440 and placebo on stopping preterm labor (ongoing trial). ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 21 March 2006). ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of a selective oxytocin antagonist (barusiban) in threatened preterm labour: a randomized, double‐blind, placebo‐controlled trial. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA. 2008:Abstract no: 129. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban on plasma concentrations and uterine contractility in threatened preterm labour: a randomised, double‐blind, placebo‐controlled trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2008;93(Suppl 1):Fa11‐Fa12. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2009;200(6):627.e1‐627.e10. ">Thornton 2009</a>), and major neonatal morbidity, which was largely not well reported across the studies. </p> <p>Long‐term outcomes up to two years of age were reported as an abstract (<a href="./references#CD004452-bbs2-0047" title="GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes up to 24 months of age after the use of atosiban in the management of preterm labour. 46th ACOG annual meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. ">Goodwin 1998a</a>) for infants enrolled in one placebo‐controlled study (<a href="./references#CD004452-bbs2-0011" title="GoodwinTM . 1st International preterm labour congress. Strategies to prevent the morbidity and mortality associated with prematurity; 2002 June 27‐30. Le Montreux Palace, Montreux Switzerland. 2002. GoodwinTM . Long‐term safety with oxytocin antagonists. 4th World Congress on Controversies in Obstetrics, Gynecology and Infertility; 2003 April 24‐27; Berlin, Germany. 2003:291. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes at 6 and 12 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes up to 24 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. RomeroR , SibaiBM , Sanchez‐RamosL , ValenzuelaGJ , VeilleJC , TaborB , et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double‐blind, placebo‐controlled trial with tocolytic rescue. American Journal of Obstetrics and Gynecology2000;182(5):1173‐83. SibaiB , RomeroR , Sanchex‐RamosL , ValenzuelaG , VeilleJ , TaborB , et al. A double‐blind placebo‐controlled trial of an oxytocin‐receptor antagonist (antocin) in the treatment of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S2. SilverH , ValenzuelaG , Sanchez‐RamosL , RomeroR , SibaiB , GoodwinT , et al. Maternal side effects and safety of the oxytocin receptor antagonist antocin. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S45. ">Romero 2000</a>). Unfortunately, data were not reported in a format suitable for inclusion In this review. The authors have been contacted for further details before publication of the previous version of this review, but no further information has been forthcoming. The following outcomes were assessed: (1) illness, accidents, and physical abnormalities; (2) measurements of infant weight, length, and head circumference; (3) neurological examinations; (4) Bayley II assessment of mental and motor development; and (5) infant deaths. Although the report stated all infants were followed up and infant death up to 12 months was reported, only 55% of the infants who were originally included in the study were assessed for Bayley II Mental and Motor Development Index (Mean ± SD) and neurological examination at two years. One study comparing barusiban and placebo reported long‐term outcomes (<a href="./references#CD004452-bbs2-0014" title="ArceJC . A proof of concept study assessing the effect of four different stage bolus intravenous doses of FE200440 and placebo on stopping preterm labor (ongoing trial). ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 21 March 2006). ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of a selective oxytocin antagonist (barusiban) in threatened preterm labour: a randomized, double‐blind, placebo‐controlled trial. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA. 2008:Abstract no: 129. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban on plasma concentrations and uterine contractility in threatened preterm labour: a randomised, double‐blind, placebo‐controlled trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2008;93(Suppl 1):Fa11‐Fa12. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2009;200(6):627.e1‐627.e10. ">Thornton 2009</a>) for Bayley Scale evaluations of psychomotor developmental index (PDI) and mental developmental index (MDI) and physical growth. The long‐term outcomes were assessed at one year of age (<a href="./references#CD004452-bbs2-0014" title="ArceJC . A proof of concept study assessing the effect of four different stage bolus intravenous doses of FE200440 and placebo on stopping preterm labor (ongoing trial). ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 21 March 2006). ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of a selective oxytocin antagonist (barusiban) in threatened preterm labour: a randomized, double‐blind, placebo‐controlled trial. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA. 2008:Abstract no: 129. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban on plasma concentrations and uterine contractility in threatened preterm labour: a randomised, double‐blind, placebo‐controlled trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2008;93(Suppl 1):Fa11‐Fa12. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2009;200(6):627.e1‐627.e10. ">Thornton 2009</a>) and, as this time point was not prespecified, these data have not been included in this review. </p> <p>In <a href="./references#CD004452-bbs2-0011" title="GoodwinTM . 1st International preterm labour congress. Strategies to prevent the morbidity and mortality associated with prematurity; 2002 June 27‐30. Le Montreux Palace, Montreux Switzerland. 2002. GoodwinTM . Long‐term safety with oxytocin antagonists. 4th World Congress on Controversies in Obstetrics, Gynecology and Infertility; 2003 April 24‐27; Berlin, Germany. 2003:291. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes at 6 and 12 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes up to 24 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. RomeroR , SibaiBM , Sanchez‐RamosL , ValenzuelaGJ , VeilleJC , TaborB , et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double‐blind, placebo‐controlled trial with tocolytic rescue. American Journal of Obstetrics and Gynecology2000;182(5):1173‐83. SibaiB , RomeroR , Sanchex‐RamosL , ValenzuelaG , VeilleJ , TaborB , et al. A double‐blind placebo‐controlled trial of an oxytocin‐receptor antagonist (antocin) in the treatment of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S2. SilverH , ValenzuelaG , Sanchez‐RamosL , RomeroR , SibaiB , GoodwinT , et al. Maternal side effects and safety of the oxytocin receptor antagonist antocin. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S45. ">Romero 2000</a>, data for the outcomes of birth less than 48 hours after trial entry and birth less than seven days after trial entry were reported only for women who did not receive alternative tocolytics and therefore these data were not included in the review. </p> <p>Please <i>see</i><a href="./references#CD004452-sec-0159" title="">Characteristics of included studies</a> for further details. </p> </section> </section> <section id="CD004452-sec-0081"> <h4 class="title">Excluded studies</h4> <p>We excluded nine studies.</p> <p>One study was excluded on the basis of quasi‐random allocation (<a href="./references#CD004452-bbs2-0015" title="Al‐OmariWR , Al‐ShammaaHB , Al‐TikritiEM , AhmedKW . Atosiban and nifedipine in acute tocolysis: a comparative study. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2006;128(1‐2):129‐34. Al‐OmariWR , Al‐TikriE , Al‐ShammaaH . Atosiban and nifedipine in acute tocolysis, comparative study. XVIIIth European Congress of Obstetrics and Gynaecology; May 12‐15; Athens, Greece. 2004:103. ">Al‐Omari 2006</a>). Eight studies were excluded as they did not fulfil the intervention inclusion criteria as follows: A study in term labour (<a href="./references#CD004452-bbs2-0016" title="deHeusR , MulderEJ , DerksJB , KorverPH , vanWolfswinkelL , VisserGH . A prospective randomized trial of acute tocolysis in term labour with atosiban or ritodrine. European Journal of Obstetrics, Gynecology, and Reproductive Biology2008;139(2):139‐45. ">de Heus 2008</a>); studies of maintenance tocolysis (<a href="./references#CD004452-bbs2-0017" title="GagnonD , MartensL , CreasyG , HenkeC . An economic analysis of atosiban maintenance therapy in preterm labor. American Journal of Obstetrics and Gynecology1998;178(1 Pt 2):S181. ">Gagnon 1998</a>; <a href="./references#CD004452-bbs2-0023" title="Sanchez‐RamosL , ValenzuelaG , RomeroR , SilverH , KoltunW , MillarL , et al. A double‐blind placebo‐controlled trial of oxytocin receptor antagonist (antocin) maintenance therapy in patients with preterm labor. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S30. ValenzuelaGJ , Sanchez‐RamosL , RomeroR , SilverHM , KoltunWD , MillarL , et al. Maintenance treatment of preterm labor with the oxytocin antagonist atosiban. The atosiban ptl‐098 study group. American Journal of Obstetrics and Gynecology2000;182(5):1184‐90. ">Valenzuela 2000</a>); no comparison between different dosing regimens or tocolytic treatment (<a href="./references#CD004452-bbs2-0018" title="Anonymous . TREASURE (Tractocile efficacy assessment survey in Europe). Trial to commence in July. http://www.ferring.com/ (accessed 24 May 2004). HussleinP , RouraLC , DudenhausenJ , HelmerH , FrydmanR , RizzoN , et al. Clinical practice evaluation of atosiban in preterm labour management in six European countries. BJOG: an international journal of obstetrics and gynaecology2006;113(Suppl 3):105‐10. ">Husslein 2006</a>); undefined treatment in control group (<a href="./references#CD004452-bbs2-0019" title="HussleinP , Cabero RouraL , DudenhausenJW , HelmerH , FrydmanR , RizzoN , et al. Atosiban versus usual care for the management of preterm labor. Journal of Perinatal Medicine2007;35(4):305‐13. ">Husslein 2007</a>); repeat course treatment with tocolysis (<a href="./references#CD004452-bbs2-0020" title="PoppitiR , NazzaroG , DePlacidoG , PalmieriT , LocciM . Prevention of preterm delivery in twin pregnancies with atosiban. Journal of Maternal‐Fetal &amp; Neonatal Medicine2009;22(Suppl 1):61. ">Poppiti 2009</a>); did not use an oxytocin receptor antagonist (<a href="./references#CD004452-bbs2-0021" title="SteinwallM , BossmarT , BrouardR , LaudanskiT , OlofssonP , UrbanR , et al. The effect of relcovaptan (SR 49059), an orally active vasopressin V1a receptor antagonist, on uterine contractions in preterm labor. Gynecological Endocrinology2005;20(2):104‐5. ">Steinwall 2005</a>); study aimed to measure oestradiol levels before and after treatment (<a href="./references#CD004452-bbs2-0022" title="ValenzuelaG , DiazA , GermainA , FosterT , HayashiR , Seron‐FerreM . Estradiol levels are increased before and after preterm labor treatment with an oxytocin (OT) antagonist: evidence for chronic activation of the mechanism of labor. Acta Obstetricia et Gynecologica Scandinavica1997;76(167):88. ">Valenzuela 1997</a>a). </p> <p>Please <i>see</i><a href="./references#CD004452-sec-0160" title="">Characteristics of excluded studies</a> for further details. </p> </section> </section> <section id="CD004452-sec-0082"> <h3 class="title">Risk of bias in included studies</h3> <p>Overall the quality of the included studies was considered fair to good. Refer to <a href="./references#CD004452-sec-0159" title="">Characteristics of included studies</a> for further details and to <a href="#CD004452-fig-0001">Figure 1</a> and <a href="#CD004452-fig-0002">Figure 2</a> for a summary of 'Risk of bias' assessment. </p> <div class="figure" id="CD004452-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD004452-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD004452-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD004452-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD004452-sec-0083"> <h4 class="title">Allocation</h4> <p>The randomisation sequence generation was judged as adequate in 10 of the 14 included studies (<a href="./references#CD004452-bbs2-0002" title="The European Atosiban Study Group. The oxytocin antagonist atosiban versus the ß‐agonist terbutaline in the treatment of preterm labor: a randomized, double‐blind, controlled study. Acta Obstetricia et Gynecologica Scandinavica2001;80:413‐22. The Worldwide Atosiban versus Beta‐antagonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. BJOG2001;108:133‐42. ">European 2001</a>; <a href="./references#CD004452-bbs2-0003" title="French/Australian Atosiban Investigators Group. Treatment of preterm labor with the oxytocin antagonist atosiban: a double‐blind, randomized, controlled comparison with salbutamol. European Journal Obstetrics, Gynecology and Reproductive Biology2001;98:177‐85. The Worldwide Atosiban versus Beta‐antagonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. BJOG2001;108:133‐42. ">French/Australian 2001</a>; <a href="./references#CD004452-bbs2-0004" title="GoodwinTM , PaulR , SilverH , SpellacyW , ParsonsM , ChezR , et al. The effect of the oxytocin antagonist atosiban on preterm uterine activity in the human. American Journal of Obstetrics and Gynecology1994;170:474‐8. GoodwinTM , PaulRH , SilverH , ParsonsM , ChezR , SpellacyW , et al. Safety and efficacy of the oxytocin antagonist atosiban in threatened preterm labor: initial US trial. American Journal of Obstetrics and Gynecology1992;166:359. ">Goodwin 1994</a>; <a href="./references#CD004452-bbs2-0005" title="GoodwinTM , ValenzuelaG , SilverH , HayashiR , CreasyGW , LaneR . Treatment of preterm labor with the oxytocin antagonist atosiban. American Journal of Perinatology1996;13(3):143‐6. GoodwinTM , ValenzuelaGJ , SilverH , CreasyG , Atosiban Study Group. Dose ranging study of the oxytocin antagonist atosiban in the treatment of preterm labor. Obstetrics &amp; Gynecology1996;88(3):331‐6. ">Goodwin 1996</a>; <a href="./references#CD004452-bbs2-0006" title="KashanianM , AkbarianAR , SoltanzadehM . Atosiban and nifedipin for the treatment of preterm labor. International Journal of Gynecology &amp; Obstetrics2005;91(1):10‐4. KashanianM , SoltanzadehM , Sheikh AnsariN . Atosiban and nifedipin for the treatment of preterm labor. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):69. ">Kashanian 2005</a>; <a href="./references#CD004452-bbs2-0008" title="MoutquinJ , RabinoviciJ . Comparison of atosiban versus ritodrine in the treatment of pre‐term labour. Acta Obstetrica et Gynecologica Scandinavica1997;76(167):33. MoutquinJM , ShermanD , CohenH , MohidePT , Hochner‐CelnikierD , FejginM , et al. Double‐blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study. American Journal of Obstetrics and Gynecology2000;182(5):1191‐9. ">Moutquin 2000</a>; <a href="./references#CD004452-bbs2-0011" title="GoodwinTM . 1st International preterm labour congress. Strategies to prevent the morbidity and mortality associated with prematurity; 2002 June 27‐30. Le Montreux Palace, Montreux Switzerland. 2002. GoodwinTM . Long‐term safety with oxytocin antagonists. 4th World Congress on Controversies in Obstetrics, Gynecology and Infertility; 2003 April 24‐27; Berlin, Germany. 2003:291. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes at 6 and 12 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes up to 24 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. RomeroR , SibaiBM , Sanchez‐RamosL , ValenzuelaGJ , VeilleJC , TaborB , et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double‐blind, placebo‐controlled trial with tocolytic rescue. American Journal of Obstetrics and Gynecology2000;182(5):1173‐83. SibaiB , RomeroR , Sanchex‐RamosL , ValenzuelaG , VeilleJ , TaborB , et al. A double‐blind placebo‐controlled trial of an oxytocin‐receptor antagonist (antocin) in the treatment of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S2. SilverH , ValenzuelaG , Sanchez‐RamosL , RomeroR , SibaiB , GoodwinT , et al. Maternal side effects and safety of the oxytocin receptor antagonist antocin. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S45. ">Romero 2000</a>; <a href="./references#CD004452-bbs2-0012" title="GarmiG . Nifedipine compared to atosiban for treating preterm labor [ClinicalTrials.gov (http://clinicaltrials.gov/)]. accessed 9 April 2008. SalimR , GarmiG , NachumZ , ZafranN , BaramS , ShalevE . Nifedipine compared with atosiban for treating preterm labor: A randomized controlled trial. Obstetrics and Gynecology2012;120(6):1323‐31. ">Salim 2012</a>; <a href="./references#CD004452-bbs2-0013" title="ShimJY , ParkYW , YoonBH , ChoYK , YangJH , LeeY , et al. Multicentre, parallel group, randomised, single‐blind study of the safety and efficacy of atosiban versus ritodrine in the treatment of acute preterm labour in Korean women. BJOG2006;113(11):1228‐34. ">Shim 2006</a>; <a href="./references#CD004452-bbs2-0014" title="ArceJC . A proof of concept study assessing the effect of four different stage bolus intravenous doses of FE200440 and placebo on stopping preterm labor (ongoing trial). ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 21 March 2006). ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of a selective oxytocin antagonist (barusiban) in threatened preterm labour: a randomized, double‐blind, placebo‐controlled trial. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA. 2008:Abstract no: 129. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban on plasma concentrations and uterine contractility in threatened preterm labour: a randomised, double‐blind, placebo‐controlled trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2008;93(Suppl 1):Fa11‐Fa12. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2009;200(6):627.e1‐627.e10. ">Thornton 2009</a>) and therefore assessed as having a low risk of selection bias. In the remaining four studies, the randomisation sequence generation process was unclear. </p> <p>Allocation to treatment was adequately concealed in seven of the 14 included studies (<a href="./references#CD004452-bbs2-0002" title="The European Atosiban Study Group. The oxytocin antagonist atosiban versus the ß‐agonist terbutaline in the treatment of preterm labor: a randomized, double‐blind, controlled study. Acta Obstetricia et Gynecologica Scandinavica2001;80:413‐22. The Worldwide Atosiban versus Beta‐antagonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. BJOG2001;108:133‐42. ">European 2001</a>; <a href="./references#CD004452-bbs2-0003" title="French/Australian Atosiban Investigators Group. Treatment of preterm labor with the oxytocin antagonist atosiban: a double‐blind, randomized, controlled comparison with salbutamol. European Journal Obstetrics, Gynecology and Reproductive Biology2001;98:177‐85. The Worldwide Atosiban versus Beta‐antagonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. BJOG2001;108:133‐42. ">French/Australian 2001</a>; <a href="./references#CD004452-bbs2-0004" title="GoodwinTM , PaulR , SilverH , SpellacyW , ParsonsM , ChezR , et al. The effect of the oxytocin antagonist atosiban on preterm uterine activity in the human. American Journal of Obstetrics and Gynecology1994;170:474‐8. GoodwinTM , PaulRH , SilverH , ParsonsM , ChezR , SpellacyW , et al. Safety and efficacy of the oxytocin antagonist atosiban in threatened preterm labor: initial US trial. American Journal of Obstetrics and Gynecology1992;166:359. ">Goodwin 1994</a>; <a href="./references#CD004452-bbs2-0005" title="GoodwinTM , ValenzuelaG , SilverH , HayashiR , CreasyGW , LaneR . Treatment of preterm labor with the oxytocin antagonist atosiban. American Journal of Perinatology1996;13(3):143‐6. GoodwinTM , ValenzuelaGJ , SilverH , CreasyG , Atosiban Study Group. Dose ranging study of the oxytocin antagonist atosiban in the treatment of preterm labor. Obstetrics &amp; Gynecology1996;88(3):331‐6. ">Goodwin 1996</a>; <a href="./references#CD004452-bbs2-0011" title="GoodwinTM . 1st International preterm labour congress. Strategies to prevent the morbidity and mortality associated with prematurity; 2002 June 27‐30. Le Montreux Palace, Montreux Switzerland. 2002. GoodwinTM . Long‐term safety with oxytocin antagonists. 4th World Congress on Controversies in Obstetrics, Gynecology and Infertility; 2003 April 24‐27; Berlin, Germany. 2003:291. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes at 6 and 12 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes up to 24 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. RomeroR , SibaiBM , Sanchez‐RamosL , ValenzuelaGJ , VeilleJC , TaborB , et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double‐blind, placebo‐controlled trial with tocolytic rescue. American Journal of Obstetrics and Gynecology2000;182(5):1173‐83. SibaiB , RomeroR , Sanchex‐RamosL , ValenzuelaG , VeilleJ , TaborB , et al. A double‐blind placebo‐controlled trial of an oxytocin‐receptor antagonist (antocin) in the treatment of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S2. SilverH , ValenzuelaG , Sanchez‐RamosL , RomeroR , SibaiB , GoodwinT , et al. Maternal side effects and safety of the oxytocin receptor antagonist antocin. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S45. ">Romero 2000</a>; <a href="./references#CD004452-bbs2-0012" title="GarmiG . Nifedipine compared to atosiban for treating preterm labor [ClinicalTrials.gov (http://clinicaltrials.gov/)]. accessed 9 April 2008. SalimR , GarmiG , NachumZ , ZafranN , BaramS , ShalevE . Nifedipine compared with atosiban for treating preterm labor: A randomized controlled trial. Obstetrics and Gynecology2012;120(6):1323‐31. ">Salim 2012</a>; <a href="./references#CD004452-bbs2-0014" title="ArceJC . A proof of concept study assessing the effect of four different stage bolus intravenous doses of FE200440 and placebo on stopping preterm labor (ongoing trial). ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 21 March 2006). ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of a selective oxytocin antagonist (barusiban) in threatened preterm labour: a randomized, double‐blind, placebo‐controlled trial. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA. 2008:Abstract no: 129. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban on plasma concentrations and uterine contractility in threatened preterm labour: a randomised, double‐blind, placebo‐controlled trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2008;93(Suppl 1):Fa11‐Fa12. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2009;200(6):627.e1‐627.e10. ">Thornton 2009</a>) and therefore assessed as having low risk of selection bias. In the remaining studies the allocation process was unclear. </p> </section> <section id="CD004452-sec-0084"> <h4 class="title">Blinding</h4> <p>Blinding of the intervention and outcome assessment was performed in seven of the 14 included studies (<a href="./references#CD004452-bbs2-0002" title="The European Atosiban Study Group. The oxytocin antagonist atosiban versus the ß‐agonist terbutaline in the treatment of preterm labor: a randomized, double‐blind, controlled study. Acta Obstetricia et Gynecologica Scandinavica2001;80:413‐22. The Worldwide Atosiban versus Beta‐antagonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. BJOG2001;108:133‐42. ">European 2001</a>; <a href="./references#CD004452-bbs2-0003" title="French/Australian Atosiban Investigators Group. Treatment of preterm labor with the oxytocin antagonist atosiban: a double‐blind, randomized, controlled comparison with salbutamol. European Journal Obstetrics, Gynecology and Reproductive Biology2001;98:177‐85. The Worldwide Atosiban versus Beta‐antagonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. BJOG2001;108:133‐42. ">French/Australian 2001</a>; <a href="./references#CD004452-bbs2-0004" title="GoodwinTM , PaulR , SilverH , SpellacyW , ParsonsM , ChezR , et al. The effect of the oxytocin antagonist atosiban on preterm uterine activity in the human. American Journal of Obstetrics and Gynecology1994;170:474‐8. GoodwinTM , PaulRH , SilverH , ParsonsM , ChezR , SpellacyW , et al. Safety and efficacy of the oxytocin antagonist atosiban in threatened preterm labor: initial US trial. American Journal of Obstetrics and Gynecology1992;166:359. ">Goodwin 1994</a>; <a href="./references#CD004452-bbs2-0008" title="MoutquinJ , RabinoviciJ . Comparison of atosiban versus ritodrine in the treatment of pre‐term labour. Acta Obstetrica et Gynecologica Scandinavica1997;76(167):33. MoutquinJM , ShermanD , CohenH , MohidePT , Hochner‐CelnikierD , FejginM , et al. Double‐blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study. American Journal of Obstetrics and Gynecology2000;182(5):1191‐9. ">Moutquin 2000</a>; <a href="./references#CD004452-bbs2-0011" title="GoodwinTM . 1st International preterm labour congress. Strategies to prevent the morbidity and mortality associated with prematurity; 2002 June 27‐30. Le Montreux Palace, Montreux Switzerland. 2002. GoodwinTM . Long‐term safety with oxytocin antagonists. 4th World Congress on Controversies in Obstetrics, Gynecology and Infertility; 2003 April 24‐27; Berlin, Germany. 2003:291. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes at 6 and 12 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes up to 24 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. RomeroR , SibaiBM , Sanchez‐RamosL , ValenzuelaGJ , VeilleJC , TaborB , et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double‐blind, placebo‐controlled trial with tocolytic rescue. American Journal of Obstetrics and Gynecology2000;182(5):1173‐83. SibaiB , RomeroR , Sanchex‐RamosL , ValenzuelaG , VeilleJ , TaborB , et al. A double‐blind placebo‐controlled trial of an oxytocin‐receptor antagonist (antocin) in the treatment of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S2. SilverH , ValenzuelaG , Sanchez‐RamosL , RomeroR , SibaiB , GoodwinT , et al. Maternal side effects and safety of the oxytocin receptor antagonist antocin. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S45. ">Romero 2000</a>; <a href="./references#CD004452-bbs2-0013" title="ShimJY , ParkYW , YoonBH , ChoYK , YangJH , LeeY , et al. Multicentre, parallel group, randomised, single‐blind study of the safety and efficacy of atosiban versus ritodrine in the treatment of acute preterm labour in Korean women. BJOG2006;113(11):1228‐34. ">Shim 2006</a>; <a href="./references#CD004452-bbs2-0014" title="ArceJC . A proof of concept study assessing the effect of four different stage bolus intravenous doses of FE200440 and placebo on stopping preterm labor (ongoing trial). ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 21 March 2006). ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of a selective oxytocin antagonist (barusiban) in threatened preterm labour: a randomized, double‐blind, placebo‐controlled trial. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA. 2008:Abstract no: 129. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban on plasma concentrations and uterine contractility in threatened preterm labour: a randomised, double‐blind, placebo‐controlled trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2008;93(Suppl 1):Fa11‐Fa12. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2009;200(6):627.e1‐627.e10. ">Thornton 2009</a>). These studies were placebo controlled. For one study, the blinding of the intervention process was unclear (<a href="./references#CD004452-bbs2-0001" title="CabarFR , BittarRE , GomesCM , ZugabM . Atosiban as a tocolytic agent: a new proposal of a therapeutic approach. Revista Brasileira de Ginecologia y Obstetricia2008;30(2):87‐92. ">Cabar 2008</a>). In one study, while a saline infusion control group was used, as different dosing regimens were used, the study was assessed as having a high risk of bias(<a href="./references#CD004452-bbs2-0010" title="RichterON , DornC , van deVondelP , UlrichU , SchmollingJ . Tocolysis with atosiban: experience in the management of premature labor before 24 weeks of pregnancy. Archives of Gynecology and Obstetrics2005;272(1):26‐30. ">Richter 2005</a>). For the remaining studies, the lack of blinding of the intervention may be, in part, as a result of the difficulties with adequately blinding such interventions, i.e. presentation of the intervention as either oral versus intravenous and the well‐known side effects of certain interventions. </p> </section> <section id="CD004452-sec-0085"> <h4 class="title">Incomplete outcome data</h4> <p>The majority (13 of the 14 included studies) had minimal or no attrition and were therefore assessed as having a low risk of attrition bias. For the remaining study, it was unclear whether outcome data were complete (<a href="./references#CD004452-bbs2-0001" title="CabarFR , BittarRE , GomesCM , ZugabM . Atosiban as a tocolytic agent: a new proposal of a therapeutic approach. Revista Brasileira de Ginecologia y Obstetricia2008;30(2):87‐92. ">Cabar 2008</a>). </p> </section> <section id="CD004452-sec-0086"> <h4 class="title">Selective reporting</h4> <p>In 12 of the 14 included studies, no reporting bias was evident (<a href="./references#CD004452-bbs2-0002" title="The European Atosiban Study Group. The oxytocin antagonist atosiban versus the ß‐agonist terbutaline in the treatment of preterm labor: a randomized, double‐blind, controlled study. Acta Obstetricia et Gynecologica Scandinavica2001;80:413‐22. The Worldwide Atosiban versus Beta‐antagonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. BJOG2001;108:133‐42. ">European 2001</a>; <a href="./references#CD004452-bbs2-0003" title="French/Australian Atosiban Investigators Group. Treatment of preterm labor with the oxytocin antagonist atosiban: a double‐blind, randomized, controlled comparison with salbutamol. European Journal Obstetrics, Gynecology and Reproductive Biology2001;98:177‐85. The Worldwide Atosiban versus Beta‐antagonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. BJOG2001;108:133‐42. ">French/Australian 2001</a>; <a href="./references#CD004452-bbs2-0004" title="GoodwinTM , PaulR , SilverH , SpellacyW , ParsonsM , ChezR , et al. The effect of the oxytocin antagonist atosiban on preterm uterine activity in the human. American Journal of Obstetrics and Gynecology1994;170:474‐8. GoodwinTM , PaulRH , SilverH , ParsonsM , ChezR , SpellacyW , et al. Safety and efficacy of the oxytocin antagonist atosiban in threatened preterm labor: initial US trial. American Journal of Obstetrics and Gynecology1992;166:359. ">Goodwin 1994</a>; <a href="./references#CD004452-bbs2-0005" title="GoodwinTM , ValenzuelaG , SilverH , HayashiR , CreasyGW , LaneR . Treatment of preterm labor with the oxytocin antagonist atosiban. American Journal of Perinatology1996;13(3):143‐6. GoodwinTM , ValenzuelaGJ , SilverH , CreasyG , Atosiban Study Group. Dose ranging study of the oxytocin antagonist atosiban in the treatment of preterm labor. Obstetrics &amp; Gynecology1996;88(3):331‐6. ">Goodwin 1996</a>; <a href="./references#CD004452-bbs2-0007" title="LinCH , LinSY , ShyuMK , ChenSU , LeeCN . Randomized trial of oxytocin antagonist atosiban versus beta‐adrenergic agonists  in the treatment of spontaneous preterm labor in Taiwanese women. Journal of the Formosan Medical Association = Taiwan Yi Zhi2009;108(6):493‐501. ">Lin 2009</a>; <a href="./references#CD004452-bbs2-0008" title="MoutquinJ , RabinoviciJ . Comparison of atosiban versus ritodrine in the treatment of pre‐term labour. Acta Obstetrica et Gynecologica Scandinavica1997;76(167):33. MoutquinJM , ShermanD , CohenH , MohidePT , Hochner‐CelnikierD , FejginM , et al. Double‐blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study. American Journal of Obstetrics and Gynecology2000;182(5):1191‐9. ">Moutquin 2000</a>; <a href="./references#CD004452-bbs2-0009" title="NonnenmacherA , HoppH , DudenhausenJ . Effectiveness and safety of atosiban vs. pulsatile administration of fenoterol in the treatment of preterm labour. Zeitschrift fur Geburtshilfe und Neonatologie2009;213(5):201‐6. ">Nonnenmacher 2009</a>; <a href="./references#CD004452-bbs2-0010" title="RichterON , DornC , van deVondelP , UlrichU , SchmollingJ . Tocolysis with atosiban: experience in the management of premature labor before 24 weeks of pregnancy. Archives of Gynecology and Obstetrics2005;272(1):26‐30. ">Richter 2005</a>; <a href="./references#CD004452-bbs2-0011" title="GoodwinTM . 1st International preterm labour congress. Strategies to prevent the morbidity and mortality associated with prematurity; 2002 June 27‐30. Le Montreux Palace, Montreux Switzerland. 2002. GoodwinTM . Long‐term safety with oxytocin antagonists. 4th World Congress on Controversies in Obstetrics, Gynecology and Infertility; 2003 April 24‐27; Berlin, Germany. 2003:291. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes at 6 and 12 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes up to 24 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. RomeroR , SibaiBM , Sanchez‐RamosL , ValenzuelaGJ , VeilleJC , TaborB , et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double‐blind, placebo‐controlled trial with tocolytic rescue. American Journal of Obstetrics and Gynecology2000;182(5):1173‐83. SibaiB , RomeroR , Sanchex‐RamosL , ValenzuelaG , VeilleJ , TaborB , et al. A double‐blind placebo‐controlled trial of an oxytocin‐receptor antagonist (antocin) in the treatment of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S2. SilverH , ValenzuelaG , Sanchez‐RamosL , RomeroR , SibaiB , GoodwinT , et al. Maternal side effects and safety of the oxytocin receptor antagonist antocin. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S45. ">Romero 2000</a>; <a href="./references#CD004452-bbs2-0012" title="GarmiG . Nifedipine compared to atosiban for treating preterm labor [ClinicalTrials.gov (http://clinicaltrials.gov/)]. accessed 9 April 2008. SalimR , GarmiG , NachumZ , ZafranN , BaramS , ShalevE . Nifedipine compared with atosiban for treating preterm labor: A randomized controlled trial. Obstetrics and Gynecology2012;120(6):1323‐31. ">Salim 2012</a>; <a href="./references#CD004452-bbs2-0013" title="ShimJY , ParkYW , YoonBH , ChoYK , YangJH , LeeY , et al. Multicentre, parallel group, randomised, single‐blind study of the safety and efficacy of atosiban versus ritodrine in the treatment of acute preterm labour in Korean women. BJOG2006;113(11):1228‐34. ">Shim 2006</a>; <a href="./references#CD004452-bbs2-0014" title="ArceJC . A proof of concept study assessing the effect of four different stage bolus intravenous doses of FE200440 and placebo on stopping preterm labor (ongoing trial). ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 21 March 2006). ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of a selective oxytocin antagonist (barusiban) in threatened preterm labour: a randomized, double‐blind, placebo‐controlled trial. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA. 2008:Abstract no: 129. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban on plasma concentrations and uterine contractility in threatened preterm labour: a randomised, double‐blind, placebo‐controlled trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2008;93(Suppl 1):Fa11‐Fa12. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2009;200(6):627.e1‐627.e10. ">Thornton 2009</a>) and these studies were judged to be at low risk of bias. In the remaining two studies it was unclear whether reporting bias was present (<a href="./references#CD004452-bbs2-0001" title="CabarFR , BittarRE , GomesCM , ZugabM . Atosiban as a tocolytic agent: a new proposal of a therapeutic approach. Revista Brasileira de Ginecologia y Obstetricia2008;30(2):87‐92. ">Cabar 2008</a>; <a href="./references#CD004452-bbs2-0006" title="KashanianM , AkbarianAR , SoltanzadehM . Atosiban and nifedipin for the treatment of preterm labor. International Journal of Gynecology &amp; Obstetrics2005;91(1):10‐4. KashanianM , SoltanzadehM , Sheikh AnsariN . Atosiban and nifedipin for the treatment of preterm labor. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):69. ">Kashanian 2005</a>). </p> </section> <section id="CD004452-sec-0087"> <h4 class="title">Other potential sources of bias</h4> <p>In eight of the 14 included studies, no other potential sources of bias were apparent <a href="./references#CD004452-bbs2-0002" title="The European Atosiban Study Group. The oxytocin antagonist atosiban versus the ß‐agonist terbutaline in the treatment of preterm labor: a randomized, double‐blind, controlled study. Acta Obstetricia et Gynecologica Scandinavica2001;80:413‐22. The Worldwide Atosiban versus Beta‐antagonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. BJOG2001;108:133‐42. ">European 2001</a>; <a href="./references#CD004452-bbs2-0003" title="French/Australian Atosiban Investigators Group. Treatment of preterm labor with the oxytocin antagonist atosiban: a double‐blind, randomized, controlled comparison with salbutamol. European Journal Obstetrics, Gynecology and Reproductive Biology2001;98:177‐85. The Worldwide Atosiban versus Beta‐antagonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. BJOG2001;108:133‐42. ">French/Australian 2001</a>; <a href="./references#CD004452-bbs2-0007" title="LinCH , LinSY , ShyuMK , ChenSU , LeeCN . Randomized trial of oxytocin antagonist atosiban versus beta‐adrenergic agonists  in the treatment of spontaneous preterm labor in Taiwanese women. Journal of the Formosan Medical Association = Taiwan Yi Zhi2009;108(6):493‐501. ">Lin 2009</a>; <a href="./references#CD004452-bbs2-0008" title="MoutquinJ , RabinoviciJ . Comparison of atosiban versus ritodrine in the treatment of pre‐term labour. Acta Obstetrica et Gynecologica Scandinavica1997;76(167):33. MoutquinJM , ShermanD , CohenH , MohidePT , Hochner‐CelnikierD , FejginM , et al. Double‐blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study. American Journal of Obstetrics and Gynecology2000;182(5):1191‐9. ">Moutquin 2000</a>; <a href="./references#CD004452-bbs2-0009" title="NonnenmacherA , HoppH , DudenhausenJ . Effectiveness and safety of atosiban vs. pulsatile administration of fenoterol in the treatment of preterm labour. Zeitschrift fur Geburtshilfe und Neonatologie2009;213(5):201‐6. ">Nonnenmacher 2009</a>; <a href="./references#CD004452-bbs2-0010" title="RichterON , DornC , van deVondelP , UlrichU , SchmollingJ . Tocolysis with atosiban: experience in the management of premature labor before 24 weeks of pregnancy. Archives of Gynecology and Obstetrics2005;272(1):26‐30. ">Richter 2005</a>; <a href="./references#CD004452-bbs2-0012" title="GarmiG . Nifedipine compared to atosiban for treating preterm labor [ClinicalTrials.gov (http://clinicaltrials.gov/)]. accessed 9 April 2008. SalimR , GarmiG , NachumZ , ZafranN , BaramS , ShalevE . Nifedipine compared with atosiban for treating preterm labor: A randomized controlled trial. Obstetrics and Gynecology2012;120(6):1323‐31. ">Salim 2012</a>; <a href="./references#CD004452-bbs2-0014" title="ArceJC . A proof of concept study assessing the effect of four different stage bolus intravenous doses of FE200440 and placebo on stopping preterm labor (ongoing trial). ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 21 March 2006). ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of a selective oxytocin antagonist (barusiban) in threatened preterm labour: a randomized, double‐blind, placebo‐controlled trial. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA. 2008:Abstract no: 129. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban on plasma concentrations and uterine contractility in threatened preterm labour: a randomised, double‐blind, placebo‐controlled trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2008;93(Suppl 1):Fa11‐Fa12. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2009;200(6):627.e1‐627.e10. ">Thornton 2009</a>) based on baseline characteristics being similar and no other biases were evident. In four studies, the risk of other bias was unclear (<a href="./references#CD004452-bbs2-0001" title="CabarFR , BittarRE , GomesCM , ZugabM . Atosiban as a tocolytic agent: a new proposal of a therapeutic approach. Revista Brasileira de Ginecologia y Obstetricia2008;30(2):87‐92. ">Cabar 2008</a>; <a href="./references#CD004452-bbs2-0005" title="GoodwinTM , ValenzuelaG , SilverH , HayashiR , CreasyGW , LaneR . Treatment of preterm labor with the oxytocin antagonist atosiban. American Journal of Perinatology1996;13(3):143‐6. GoodwinTM , ValenzuelaGJ , SilverH , CreasyG , Atosiban Study Group. Dose ranging study of the oxytocin antagonist atosiban in the treatment of preterm labor. Obstetrics &amp; Gynecology1996;88(3):331‐6. ">Goodwin 1996</a>; <a href="./references#CD004452-bbs2-0006" title="KashanianM , AkbarianAR , SoltanzadehM . Atosiban and nifedipin for the treatment of preterm labor. International Journal of Gynecology &amp; Obstetrics2005;91(1):10‐4. KashanianM , SoltanzadehM , Sheikh AnsariN . Atosiban and nifedipin for the treatment of preterm labor. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):69. ">Kashanian 2005</a>; <a href="./references#CD004452-bbs2-0013" title="ShimJY , ParkYW , YoonBH , ChoYK , YangJH , LeeY , et al. Multicentre, parallel group, randomised, single‐blind study of the safety and efficacy of atosiban versus ritodrine in the treatment of acute preterm labour in Korean women. BJOG2006;113(11):1228‐34. ">Shim 2006</a>). In two studies, the risk of other bias was judged to be high (<a href="./references#CD004452-bbs2-0004" title="GoodwinTM , PaulR , SilverH , SpellacyW , ParsonsM , ChezR , et al. The effect of the oxytocin antagonist atosiban on preterm uterine activity in the human. American Journal of Obstetrics and Gynecology1994;170:474‐8. GoodwinTM , PaulRH , SilverH , ParsonsM , ChezR , SpellacyW , et al. Safety and efficacy of the oxytocin antagonist atosiban in threatened preterm labor: initial US trial. American Journal of Obstetrics and Gynecology1992;166:359. ">Goodwin 1994</a>; <a href="./references#CD004452-bbs2-0011" title="GoodwinTM . 1st International preterm labour congress. Strategies to prevent the morbidity and mortality associated with prematurity; 2002 June 27‐30. Le Montreux Palace, Montreux Switzerland. 2002. GoodwinTM . Long‐term safety with oxytocin antagonists. 4th World Congress on Controversies in Obstetrics, Gynecology and Infertility; 2003 April 24‐27; Berlin, Germany. 2003:291. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes at 6 and 12 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes up to 24 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. RomeroR , SibaiBM , Sanchez‐RamosL , ValenzuelaGJ , VeilleJC , TaborB , et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double‐blind, placebo‐controlled trial with tocolytic rescue. American Journal of Obstetrics and Gynecology2000;182(5):1173‐83. SibaiB , RomeroR , Sanchex‐RamosL , ValenzuelaG , VeilleJ , TaborB , et al. A double‐blind placebo‐controlled trial of an oxytocin‐receptor antagonist (antocin) in the treatment of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S2. SilverH , ValenzuelaG , Sanchez‐RamosL , RomeroR , SibaiB , GoodwinT , et al. Maternal side effects and safety of the oxytocin receptor antagonist antocin. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S45. ">Romero 2000</a>). These two studies (<a href="./references#CD004452-bbs2-0004" title="GoodwinTM , PaulR , SilverH , SpellacyW , ParsonsM , ChezR , et al. The effect of the oxytocin antagonist atosiban on preterm uterine activity in the human. American Journal of Obstetrics and Gynecology1994;170:474‐8. GoodwinTM , PaulRH , SilverH , ParsonsM , ChezR , SpellacyW , et al. Safety and efficacy of the oxytocin antagonist atosiban in threatened preterm labor: initial US trial. American Journal of Obstetrics and Gynecology1992;166:359. ">Goodwin 1994</a>; <a href="./references#CD004452-bbs2-0011" title="GoodwinTM . 1st International preterm labour congress. Strategies to prevent the morbidity and mortality associated with prematurity; 2002 June 27‐30. Le Montreux Palace, Montreux Switzerland. 2002. GoodwinTM . Long‐term safety with oxytocin antagonists. 4th World Congress on Controversies in Obstetrics, Gynecology and Infertility; 2003 April 24‐27; Berlin, Germany. 2003:291. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes at 6 and 12 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes up to 24 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. RomeroR , SibaiBM , Sanchez‐RamosL , ValenzuelaGJ , VeilleJC , TaborB , et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double‐blind, placebo‐controlled trial with tocolytic rescue. American Journal of Obstetrics and Gynecology2000;182(5):1173‐83. SibaiB , RomeroR , Sanchex‐RamosL , ValenzuelaG , VeilleJ , TaborB , et al. A double‐blind placebo‐controlled trial of an oxytocin‐receptor antagonist (antocin) in the treatment of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S2. SilverH , ValenzuelaG , Sanchez‐RamosL , RomeroR , SibaiB , GoodwinT , et al. Maternal side effects and safety of the oxytocin receptor antagonist antocin. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S45. ">Romero 2000</a>) included women of lower gestational age in the atosiban group compared with the placebo group. One of these studies (<a href="./references#CD004452-bbs2-0004" title="GoodwinTM , PaulR , SilverH , SpellacyW , ParsonsM , ChezR , et al. The effect of the oxytocin antagonist atosiban on preterm uterine activity in the human. American Journal of Obstetrics and Gynecology1994;170:474‐8. GoodwinTM , PaulRH , SilverH , ParsonsM , ChezR , SpellacyW , et al. Safety and efficacy of the oxytocin antagonist atosiban in threatened preterm labor: initial US trial. American Journal of Obstetrics and Gynecology1992;166:359. ">Goodwin 1994</a>) also recruited women from five different centres, and the inclusion criteria differed between the centres, which may have introduced bias. In the <a href="./references#CD004452-bbs2-0011" title="GoodwinTM . 1st International preterm labour congress. Strategies to prevent the morbidity and mortality associated with prematurity; 2002 June 27‐30. Le Montreux Palace, Montreux Switzerland. 2002. GoodwinTM . Long‐term safety with oxytocin antagonists. 4th World Congress on Controversies in Obstetrics, Gynecology and Infertility; 2003 April 24‐27; Berlin, Germany. 2003:291. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes at 6 and 12 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes up to 24 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. RomeroR , SibaiBM , Sanchez‐RamosL , ValenzuelaGJ , VeilleJC , TaborB , et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double‐blind, placebo‐controlled trial with tocolytic rescue. American Journal of Obstetrics and Gynecology2000;182(5):1173‐83. SibaiB , RomeroR , Sanchex‐RamosL , ValenzuelaG , VeilleJ , TaborB , et al. A double‐blind placebo‐controlled trial of an oxytocin‐receptor antagonist (antocin) in the treatment of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S2. SilverH , ValenzuelaG , Sanchez‐RamosL , RomeroR , SibaiB , GoodwinT , et al. Maternal side effects and safety of the oxytocin receptor antagonist antocin. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S45. ">Romero 2000</a> trial, there were nearly twice as many atosiban‐treated patients enrolled at &lt; 26 weeks’ gestation. Among the women enrolled at less than 26 weeks' gestation, the number who had advanced cervical dilation was higher in the atosiban group compared with the placebo group. </p> <section id="CD004452-sec-0088"> <h5 class="title">Assessment of studies that included multiple pregnancies</h5> <p>Seven studies included data from women with a multiple pregnancy (<a href="./references#CD004452-bbs2-0002" title="The European Atosiban Study Group. The oxytocin antagonist atosiban versus the ß‐agonist terbutaline in the treatment of preterm labor: a randomized, double‐blind, controlled study. Acta Obstetricia et Gynecologica Scandinavica2001;80:413‐22. The Worldwide Atosiban versus Beta‐antagonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. BJOG2001;108:133‐42. ">European 2001</a>; <a href="./references#CD004452-bbs2-0003" title="French/Australian Atosiban Investigators Group. Treatment of preterm labor with the oxytocin antagonist atosiban: a double‐blind, randomized, controlled comparison with salbutamol. European Journal Obstetrics, Gynecology and Reproductive Biology2001;98:177‐85. The Worldwide Atosiban versus Beta‐antagonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. BJOG2001;108:133‐42. ">French/Australian 2001</a>; <a href="./references#CD004452-bbs2-0004" title="GoodwinTM , PaulR , SilverH , SpellacyW , ParsonsM , ChezR , et al. The effect of the oxytocin antagonist atosiban on preterm uterine activity in the human. American Journal of Obstetrics and Gynecology1994;170:474‐8. GoodwinTM , PaulRH , SilverH , ParsonsM , ChezR , SpellacyW , et al. Safety and efficacy of the oxytocin antagonist atosiban in threatened preterm labor: initial US trial. American Journal of Obstetrics and Gynecology1992;166:359. ">Goodwin 1994</a>; <a href="./references#CD004452-bbs2-0008" title="MoutquinJ , RabinoviciJ . Comparison of atosiban versus ritodrine in the treatment of pre‐term labour. Acta Obstetrica et Gynecologica Scandinavica1997;76(167):33. MoutquinJM , ShermanD , CohenH , MohidePT , Hochner‐CelnikierD , FejginM , et al. Double‐blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study. American Journal of Obstetrics and Gynecology2000;182(5):1191‐9. ">Moutquin 2000</a>; <a href="./references#CD004452-bbs2-0009" title="NonnenmacherA , HoppH , DudenhausenJ . Effectiveness and safety of atosiban vs. pulsatile administration of fenoterol in the treatment of preterm labour. Zeitschrift fur Geburtshilfe und Neonatologie2009;213(5):201‐6. ">Nonnenmacher 2009</a>; <a href="./references#CD004452-bbs2-0011" title="GoodwinTM . 1st International preterm labour congress. Strategies to prevent the morbidity and mortality associated with prematurity; 2002 June 27‐30. Le Montreux Palace, Montreux Switzerland. 2002. GoodwinTM . Long‐term safety with oxytocin antagonists. 4th World Congress on Controversies in Obstetrics, Gynecology and Infertility; 2003 April 24‐27; Berlin, Germany. 2003:291. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes at 6 and 12 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes up to 24 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. RomeroR , SibaiBM , Sanchez‐RamosL , ValenzuelaGJ , VeilleJC , TaborB , et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double‐blind, placebo‐controlled trial with tocolytic rescue. American Journal of Obstetrics and Gynecology2000;182(5):1173‐83. SibaiB , RomeroR , Sanchex‐RamosL , ValenzuelaG , VeilleJ , TaborB , et al. A double‐blind placebo‐controlled trial of an oxytocin‐receptor antagonist (antocin) in the treatment of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S2. SilverH , ValenzuelaG , Sanchez‐RamosL , RomeroR , SibaiB , GoodwinT , et al. Maternal side effects and safety of the oxytocin receptor antagonist antocin. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S45. ">Romero 2000</a>; <a href="./references#CD004452-bbs2-0012" title="GarmiG . Nifedipine compared to atosiban for treating preterm labor [ClinicalTrials.gov (http://clinicaltrials.gov/)]. accessed 9 April 2008. SalimR , GarmiG , NachumZ , ZafranN , BaramS , ShalevE . Nifedipine compared with atosiban for treating preterm labor: A randomized controlled trial. Obstetrics and Gynecology2012;120(6):1323‐31. ">Salim 2012</a>). Two of these studies (<a href="./references#CD004452-bbs2-0004" title="GoodwinTM , PaulR , SilverH , SpellacyW , ParsonsM , ChezR , et al. The effect of the oxytocin antagonist atosiban on preterm uterine activity in the human. American Journal of Obstetrics and Gynecology1994;170:474‐8. GoodwinTM , PaulRH , SilverH , ParsonsM , ChezR , SpellacyW , et al. Safety and efficacy of the oxytocin antagonist atosiban in threatened preterm labor: initial US trial. American Journal of Obstetrics and Gynecology1992;166:359. ">Goodwin 1994</a>; <a href="./references#CD004452-bbs2-0011" title="GoodwinTM . 1st International preterm labour congress. Strategies to prevent the morbidity and mortality associated with prematurity; 2002 June 27‐30. Le Montreux Palace, Montreux Switzerland. 2002. GoodwinTM . Long‐term safety with oxytocin antagonists. 4th World Congress on Controversies in Obstetrics, Gynecology and Infertility; 2003 April 24‐27; Berlin, Germany. 2003:291. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes at 6 and 12 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes up to 24 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. RomeroR , SibaiBM , Sanchez‐RamosL , ValenzuelaGJ , VeilleJC , TaborB , et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double‐blind, placebo‐controlled trial with tocolytic rescue. American Journal of Obstetrics and Gynecology2000;182(5):1173‐83. SibaiB , RomeroR , Sanchex‐RamosL , ValenzuelaG , VeilleJ , TaborB , et al. A double‐blind placebo‐controlled trial of an oxytocin‐receptor antagonist (antocin) in the treatment of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S2. SilverH , ValenzuelaG , Sanchez‐RamosL , RomeroR , SibaiB , GoodwinT , et al. Maternal side effects and safety of the oxytocin receptor antagonist antocin. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S45. ">Romero 2000</a>) compared ORA (atosiban) versus placebo, one study (<a href="./references#CD004452-bbs2-0012" title="GarmiG . Nifedipine compared to atosiban for treating preterm labor [ClinicalTrials.gov (http://clinicaltrials.gov/)]. accessed 9 April 2008. SalimR , GarmiG , NachumZ , ZafranN , BaramS , ShalevE . Nifedipine compared with atosiban for treating preterm labor: A randomized controlled trial. Obstetrics and Gynecology2012;120(6):1323‐31. ">Salim 2012</a>) compared ORA versus CCB, and four studies compared ORA (atosiban) versus betamimetics (<a href="./references#CD004452-bbs2-0009" title="NonnenmacherA , HoppH , DudenhausenJ . Effectiveness and safety of atosiban vs. pulsatile administration of fenoterol in the treatment of preterm labour. Zeitschrift fur Geburtshilfe und Neonatologie2009;213(5):201‐6. ">Nonnenmacher 2009</a>; <a href="./references#CD004452-bbs2-0002" title="The European Atosiban Study Group. The oxytocin antagonist atosiban versus the ß‐agonist terbutaline in the treatment of preterm labor: a randomized, double‐blind, controlled study. Acta Obstetricia et Gynecologica Scandinavica2001;80:413‐22. The Worldwide Atosiban versus Beta‐antagonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. BJOG2001;108:133‐42. ">European 2001</a>; <a href="./references#CD004452-bbs2-0003" title="French/Australian Atosiban Investigators Group. Treatment of preterm labor with the oxytocin antagonist atosiban: a double‐blind, randomized, controlled comparison with salbutamol. European Journal Obstetrics, Gynecology and Reproductive Biology2001;98:177‐85. The Worldwide Atosiban versus Beta‐antagonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. BJOG2001;108:133‐42. ">French/Australian 2001</a>; <a href="./references#CD004452-bbs2-0008" title="MoutquinJ , RabinoviciJ . Comparison of atosiban versus ritodrine in the treatment of pre‐term labour. Acta Obstetrica et Gynecologica Scandinavica1997;76(167):33. MoutquinJM , ShermanD , CohenH , MohidePT , Hochner‐CelnikierD , FejginM , et al. Double‐blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study. American Journal of Obstetrics and Gynecology2000;182(5):1191‐9. ">Moutquin 2000</a>). As described previously (<a href="#CD004452-sec-0030">Methods</a>), we have adjusted for clustering in the analyses of infant outcomes. </p> </section> </section> </section> <section id="CD004452-sec-0089"> <h3 class="title" id="CD004452-sec-0089">Effects of interventions</h3> <p>Two main comparisons were undertaken as follows.</p> <p>Comparison 1: Oxytocin receptor antagonists compared with placebo further subgrouped by type of oxytocin receptor antagonist.<br/> Comparison 2: Oxytocin receptor antagonists compared with other classes of tocolytic agents by type of other tocolytic agent. </p> <p>We did not undertake other planned subgroup analyses by population characteristics and by intervention due to insufficient data. </p> <section id="CD004452-sec-0090"> <h4 class="title">Comparison 1: Oxytocin receptor antagonists (ORA) compared with placebo, further subgrouped by type of ORA </h4> <p>Four studies are included in this analysis. Three studies including 691 women comparing atosiban and placebo (<a href="./references#CD004452-bbs2-0004" title="GoodwinTM , PaulR , SilverH , SpellacyW , ParsonsM , ChezR , et al. The effect of the oxytocin antagonist atosiban on preterm uterine activity in the human. American Journal of Obstetrics and Gynecology1994;170:474‐8. GoodwinTM , PaulRH , SilverH , ParsonsM , ChezR , SpellacyW , et al. Safety and efficacy of the oxytocin antagonist atosiban in threatened preterm labor: initial US trial. American Journal of Obstetrics and Gynecology1992;166:359. ">Goodwin 1994</a>; <a href="./references#CD004452-bbs2-0010" title="RichterON , DornC , van deVondelP , UlrichU , SchmollingJ . Tocolysis with atosiban: experience in the management of premature labor before 24 weeks of pregnancy. Archives of Gynecology and Obstetrics2005;272(1):26‐30. ">Richter 2005</a>; <a href="./references#CD004452-bbs2-0011" title="GoodwinTM . 1st International preterm labour congress. Strategies to prevent the morbidity and mortality associated with prematurity; 2002 June 27‐30. Le Montreux Palace, Montreux Switzerland. 2002. GoodwinTM . Long‐term safety with oxytocin antagonists. 4th World Congress on Controversies in Obstetrics, Gynecology and Infertility; 2003 April 24‐27; Berlin, Germany. 2003:291. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes at 6 and 12 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes up to 24 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. RomeroR , SibaiBM , Sanchez‐RamosL , ValenzuelaGJ , VeilleJC , TaborB , et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double‐blind, placebo‐controlled trial with tocolytic rescue. American Journal of Obstetrics and Gynecology2000;182(5):1173‐83. SibaiB , RomeroR , Sanchex‐RamosL , ValenzuelaG , VeilleJ , TaborB , et al. A double‐blind placebo‐controlled trial of an oxytocin‐receptor antagonist (antocin) in the treatment of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S2. SilverH , ValenzuelaG , Sanchez‐RamosL , RomeroR , SibaiB , GoodwinT , et al. Maternal side effects and safety of the oxytocin receptor antagonist antocin. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S45. ">Romero 2000</a>) and one study (163 women) (<a href="./references#CD004452-bbs2-0014" title="ArceJC . A proof of concept study assessing the effect of four different stage bolus intravenous doses of FE200440 and placebo on stopping preterm labor (ongoing trial). ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 21 March 2006). ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of a selective oxytocin antagonist (barusiban) in threatened preterm labour: a randomized, double‐blind, placebo‐controlled trial. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA. 2008:Abstract no: 129. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban on plasma concentrations and uterine contractility in threatened preterm labour: a randomised, double‐blind, placebo‐controlled trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2008;93(Suppl 1):Fa11‐Fa12. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2009;200(6):627.e1‐627.e10. ">Thornton 2009</a>) comparing barusiban with placebo are included in this comparison. For the comparison between atosiban and placebo, the Romero and Goodwin studies (<a href="./references#CD004452-bbs2-0004" title="GoodwinTM , PaulR , SilverH , SpellacyW , ParsonsM , ChezR , et al. The effect of the oxytocin antagonist atosiban on preterm uterine activity in the human. American Journal of Obstetrics and Gynecology1994;170:474‐8. GoodwinTM , PaulRH , SilverH , ParsonsM , ChezR , SpellacyW , et al. Safety and efficacy of the oxytocin antagonist atosiban in threatened preterm labor: initial US trial. American Journal of Obstetrics and Gynecology1992;166:359. ">Goodwin 1994</a>; <a href="./references#CD004452-bbs2-0011" title="GoodwinTM . 1st International preterm labour congress. Strategies to prevent the morbidity and mortality associated with prematurity; 2002 June 27‐30. Le Montreux Palace, Montreux Switzerland. 2002. GoodwinTM . Long‐term safety with oxytocin antagonists. 4th World Congress on Controversies in Obstetrics, Gynecology and Infertility; 2003 April 24‐27; Berlin, Germany. 2003:291. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes at 6 and 12 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes up to 24 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. RomeroR , SibaiBM , Sanchez‐RamosL , ValenzuelaGJ , VeilleJC , TaborB , et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double‐blind, placebo‐controlled trial with tocolytic rescue. American Journal of Obstetrics and Gynecology2000;182(5):1173‐83. SibaiB , RomeroR , Sanchex‐RamosL , ValenzuelaG , VeilleJ , TaborB , et al. A double‐blind placebo‐controlled trial of an oxytocin‐receptor antagonist (antocin) in the treatment of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S2. SilverH , ValenzuelaG , Sanchez‐RamosL , RomeroR , SibaiB , GoodwinT , et al. Maternal side effects and safety of the oxytocin receptor antagonist antocin. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S45. ">Romero 2000</a>) contributed the majority of data (651 women) and the Richter study (<a href="./references#CD004452-bbs2-0010" title="RichterON , DornC , van deVondelP , UlrichU , SchmollingJ . Tocolysis with atosiban: experience in the management of premature labor before 24 weeks of pregnancy. Archives of Gynecology and Obstetrics2005;272(1):26‐30. ">Richter 2005</a>; 40 women) contributed to two outcomes only; stillbirth and birth less than 48 hours after trial entry. </p> <section id="CD004452-sec-0091"> <h5 class="title">Primary outcomes</h5> <p><b>Birth less than 48 hours after trial entry</b> (<a href="./references#CD004452-fig-0003" title="">Analysis 1.1</a>) </p> <p>Comparing ORA (atosiban) with placebo, no difference was shown in birth less within 48 hours after trial entry (average risk ratio (RR) 1.05, 95% confidence interval (CI) 0.15 to 7.43; random‐effects, Tau² = 1.08, Chi² = 2.14, df = 1 (P = 0.14), I² = 53%) (two studies with 152 women) <a href="./references#CD004452-fig-0003" title="">Analysis 1.1</a>. A moderate degree of statistically heterogeneity was evident for this outcome measure. However, upon exploration of the possible reasons for the heterogeneity by examining clinical features of the studies, we considered an overall summary was meaningful using a random‐effects analysis. </p> <p>No data were available for the subgroup of barusiban versus placebo.</p> <p><b>Perinatal mortality, Stillbirth, Neonatal death and Infant death</b> (<a href="./references#CD004452-fig-0004" title="">Analysis 1.2</a>) (<a href="./references#CD004452-fig-0005" title="">Analysis 1.3</a>) (<a href="./references#CD004452-fig-0006" title="">Analysis 1.4</a>) (<a href="./references#CD004452-fig-0007" title="">Analysis 1.5</a>) </p> <p>Comparing ORA versus placebo no difference was shown in perinatal mortality (RR 2.25, 95% CI 0.79 to 6.38; two studies with 729 infants) (<a href="./references#CD004452-fig-0004" title="">Analysis 1.2</a>), stillbirth (average RR 0.40, 95% CI 0.04 to 4.47 random‐effects; four studies with 883 infants) (<a href="./references#CD004452-fig-0005" title="">Analysis 1.3</a>), or neonatal death (RR 4.09, 95% CI 0.88 to 19.07; two studies with 729 infants) (<a href="./references#CD004452-fig-0006" title="">Analysis 1.4</a>). These findings are driven by the subgroup of trials comparing atosiban versus placebo as no events were reported for the barusiban subgroup including a single trial (<a href="./references#CD004452-bbs2-0014" title="ArceJC . A proof of concept study assessing the effect of four different stage bolus intravenous doses of FE200440 and placebo on stopping preterm labor (ongoing trial). ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 21 March 2006). ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of a selective oxytocin antagonist (barusiban) in threatened preterm labour: a randomized, double‐blind, placebo‐controlled trial. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA. 2008:Abstract no: 129. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban on plasma concentrations and uterine contractility in threatened preterm labour: a randomised, double‐blind, placebo‐controlled trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2008;93(Suppl 1):Fa11‐Fa12. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2009;200(6):627.e1‐627.e10. ">Thornton 2009</a>). </p> <p>A moderate degree of statistical heterogeneity was evident for the outcome measure of stillbirth (Heterogeneity: Tau² = 1.82; Chi² = 2.33, df = 1 (P = 0.13); I² = 57%). However, upon exploration of the possible reasons for the heterogeneity by examining clinical features of the studies, we considered an overall summary was meaningful using a random‐effects analysis. </p> <p>Infant death (up to 12 months) was increased with the use of the ORA atosiban in one trial (<a href="./references#CD004452-bbs2-0011" title="GoodwinTM . 1st International preterm labour congress. Strategies to prevent the morbidity and mortality associated with prematurity; 2002 June 27‐30. Le Montreux Palace, Montreux Switzerland. 2002. GoodwinTM . Long‐term safety with oxytocin antagonists. 4th World Congress on Controversies in Obstetrics, Gynecology and Infertility; 2003 April 24‐27; Berlin, Germany. 2003:291. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes at 6 and 12 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes up to 24 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. RomeroR , SibaiBM , Sanchez‐RamosL , ValenzuelaGJ , VeilleJC , TaborB , et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double‐blind, placebo‐controlled trial with tocolytic rescue. American Journal of Obstetrics and Gynecology2000;182(5):1173‐83. SibaiB , RomeroR , Sanchex‐RamosL , ValenzuelaG , VeilleJ , TaborB , et al. A double‐blind placebo‐controlled trial of an oxytocin‐receptor antagonist (antocin) in the treatment of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S2. SilverH , ValenzuelaG , Sanchez‐RamosL , RomeroR , SibaiB , GoodwinT , et al. Maternal side effects and safety of the oxytocin receptor antagonist antocin. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S45. ">Romero 2000</a>; 566 infants) (RR 6.13, 95% CI 1.38 to 27.13; number needed to treat for harm (NNTH) 28, 95% CI 6 to 377) (<a href="./references#CD004452-fig-0007" title="">Analysis 1.5</a>). </p> <p>As mentioned in <a href="#CD004452-sec-0087">Other potential sources of bias</a>, it is likely that the adverse infant outcomes associated with atosiban in the <a href="./references#CD004452-bbs2-0011" title="GoodwinTM . 1st International preterm labour congress. Strategies to prevent the morbidity and mortality associated with prematurity; 2002 June 27‐30. Le Montreux Palace, Montreux Switzerland. 2002. GoodwinTM . Long‐term safety with oxytocin antagonists. 4th World Congress on Controversies in Obstetrics, Gynecology and Infertility; 2003 April 24‐27; Berlin, Germany. 2003:291. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes at 6 and 12 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes up to 24 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. RomeroR , SibaiBM , Sanchez‐RamosL , ValenzuelaGJ , VeilleJC , TaborB , et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double‐blind, placebo‐controlled trial with tocolytic rescue. American Journal of Obstetrics and Gynecology2000;182(5):1173‐83. SibaiB , RomeroR , Sanchex‐RamosL , ValenzuelaG , VeilleJ , TaborB , et al. A double‐blind placebo‐controlled trial of an oxytocin‐receptor antagonist (antocin) in the treatment of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S2. SilverH , ValenzuelaG , Sanchez‐RamosL , RomeroR , SibaiB , GoodwinT , et al. Maternal side effects and safety of the oxytocin receptor antagonist antocin. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S45. ">Romero 2000</a> trial are due to an imbalance in randomisation which resulted in more women under 26 weeks' gestation and fewer over 32 weeks assigned to the atosiban group. It is of note that in the publication of the trial results, the authors used the denominator of women who were enrolled less than 28 weeks' gestation and reported a non‐statistically significant increase in birth less than 28 weeks' gestation. </p> <p><b>Serious maternal outcome</b> (<a href="./references#CD004452-fig-0008" title="">Analysis 1.6</a>) </p> <p>One study <a href="./references#CD004452-bbs2-0011" title="GoodwinTM . 1st International preterm labour congress. Strategies to prevent the morbidity and mortality associated with prematurity; 2002 June 27‐30. Le Montreux Palace, Montreux Switzerland. 2002. GoodwinTM . Long‐term safety with oxytocin antagonists. 4th World Congress on Controversies in Obstetrics, Gynecology and Infertility; 2003 April 24‐27; Berlin, Germany. 2003:291. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes at 6 and 12 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes up to 24 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. RomeroR , SibaiBM , Sanchez‐RamosL , ValenzuelaGJ , VeilleJC , TaborB , et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double‐blind, placebo‐controlled trial with tocolytic rescue. American Journal of Obstetrics and Gynecology2000;182(5):1173‐83. SibaiB , RomeroR , Sanchex‐RamosL , ValenzuelaG , VeilleJ , TaborB , et al. A double‐blind placebo‐controlled trial of an oxytocin‐receptor antagonist (antocin) in the treatment of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S2. SilverH , ValenzuelaG , Sanchez‐RamosL , RomeroR , SibaiB , GoodwinT , et al. Maternal side effects and safety of the oxytocin receptor antagonist antocin. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S45. ">Romero 2000</a> comparing ORA (atosiban only) with placebo (501 women) reported that no maternal deaths occurred during the trial period. </p> <p>No data were available on other serious maternal outcomes or the other primary outcomes measure of very preterm birth before 34 weeks' gestation or long‐term outcomes for the child. </p> </section> <section id="CD004452-sec-0092"> <h5 class="title">Secondary outcomes</h5> <section id="CD004452-sec-0093"> <h6 class="title">For the infant/child</h6> <p><b>Preterm birth</b> (before 37 weeks gestation) (<a href="./references#CD004452-fig-0012" title="">Analysis 1.10</a>) and <b>Extremely preterm birth (before completion of 28 weeks of gestation)</b> (<a href="./references#CD004452-fig-0013" title="">Analysis 1.11</a>) </p> <p>Comparing ORA versus placebo, no difference was found in preterm birth (before 37 weeks' gestation) (RR 1.13, 95% CI 0.97 to 1.32; two studies with 664 women). (<a href="./references#CD004452-fig-0012" title="">Analysis 1.10</a>). </p> <p>Comparing ORA (atosiban only) with placebo, one trial (<a href="./references#CD004452-bbs2-0011" title="GoodwinTM . 1st International preterm labour congress. Strategies to prevent the morbidity and mortality associated with prematurity; 2002 June 27‐30. Le Montreux Palace, Montreux Switzerland. 2002. GoodwinTM . Long‐term safety with oxytocin antagonists. 4th World Congress on Controversies in Obstetrics, Gynecology and Infertility; 2003 April 24‐27; Berlin, Germany. 2003:291. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes at 6 and 12 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes up to 24 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. RomeroR , SibaiBM , Sanchez‐RamosL , ValenzuelaGJ , VeilleJC , TaborB , et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double‐blind, placebo‐controlled trial with tocolytic rescue. American Journal of Obstetrics and Gynecology2000;182(5):1173‐83. SibaiB , RomeroR , Sanchex‐RamosL , ValenzuelaG , VeilleJ , TaborB , et al. A double‐blind placebo‐controlled trial of an oxytocin‐receptor antagonist (antocin) in the treatment of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S2. SilverH , ValenzuelaG , Sanchez‐RamosL , RomeroR , SibaiB , GoodwinT , et al. Maternal side effects and safety of the oxytocin receptor antagonist antocin. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S45. ">Romero 2000</a>) (501 women) showed an increase in extremely preterm birth (before completion of 28 weeks of gestation) (RR 3.11, 95% CI 1.02 to 9.51; NNTH 31, 95% CI 8 to 3188). </p> <p>No data were available for the subgroup of barusiban versus placebo.</p> <p>No differences were evident according to type of ORA.</p> <p><b>Gestational age</b> (<a href="./references#CD004452-fig-0014" title="">Analysis 1.12</a>) and <b>Birthweight</b> (<a href="./references#CD004452-fig-0015" title="">Analysis 1.13</a>) </p> <p>No difference was shown in gestational age at birth comparing ORA (atosiban only) with placebo (mean difference (MD) ‐0.50 weeks, 95% CI ‐1.57 to 0.57; one study with 112 women) (<a href="./references#CD004452-fig-0014" title="">Analysis 1.12</a>). ORA (atosiban) was associated with lower birthweight (MD ‐138.86 g, 95% CI ‐250.53 to ‐27.18; two studies with 676 infants) (<a href="./references#CD004452-fig-0015" title="">Analysis 1.13</a>), however the clinical importance of this difference (139 g) is questionable. </p> <p>No data were available for the subgroup of barusiban versus placebo.</p> <p><b>Neonatal morbidity</b> </p> <p>No difference was shown when comparing ORA versus placebo overall (or by type of ORA where data were available for these comparisons) for the following outcomes measures. </p> <p><b>Respiratory distress syndrome</b> (<a href="./references#CD004452-fig-0016" title="">Analysis 1.14</a>) </p> <p>For the comparison ORA versus placebo, no difference was shown in respiratory distress syndrome (RR 1.32; 95% CI 0.96 to 1.82; three studies with 836 infants). </p> <p><b>Intraventricular haemorrhage</b> (<a href="./references#CD004452-fig-0017" title="">Analysis 1.15</a>) </p> <p> <ul id="CD004452-list-0019"> <li> <p>ORA (atosiban only) versus placebo: RR 0.85, 95% CI 0.45 to 1.62 (one study with 475 infants). </p> </li> </ul> </p> <p><b>Necrotising enterocolitis</b> (<a href="./references#CD004452-fig-0018" title="">Analysis 1.16</a>) </p> <p> <ul id="CD004452-list-0020"> <li> <p>ORA (atosiban only) versus placebo: RR 0.21, 95% CI 0.02 to 1.76 (one study with 559 infants). </p> </li> </ul> </p> <p><b>Neonatal jaundice</b> (<a href="./references#CD004452-fig-0019" title="">Analysis 1.17</a>) </p> <p> <ul id="CD004452-list-0021"> <li> <p>ORA (barusiban only) versus placebo: RR 1.31, 95% CI 0.86 to 1.99 (one study with 163 infants). </p> </li> </ul> </p> <p><b>Admission to neonatal intensive care unit (</b><a href="./references#CD004452-fig-0020" title="">Analysis 1.18</a>) </p> <p> <ul id="CD004452-list-0022"> <li> <p>ORA (atosiban only) versus placebo: RR 1.09, 95% CI 0.89 to 1.34 (one study with 544 infants). </p> </li> </ul> </p> </section> <section id="CD004452-sec-0094"> <h6 class="title">For the woman</h6> <p><b>Maternal adverse effects</b> (<a href="./references#CD004452-fig-0009" title="">Analysis 1.7</a>) </p> <p> <ul id="CD004452-list-0023"> <li> <p>ORA (atosiban only) resulted in a significant increase in maternal adverse effects (RR 1.54, 95% CI 1.02 to 2.32; two studies with 613 women; NNTH 18, 95% CI 8 to 480); representing 19% of women having an adverse effect in the ORA group versus 14% in the placebo. </p> </li> </ul> </p> <p><b>Maternal adverse effects requiring cessation of treatment</b> (<a href="./references#CD004452-fig-0010" title="">Analysis 1.8</a>) </p> <p>Maternal adverse effects requiring cessation of treatment was increased for the ORA group when compared to placebo (RR 4.02, 95% CI 2.05 to 7.85; NNTH 12; 95% CI 5 to 33; three studies with 776 women); representing 16% of women having an adverse effect in the ORA group versus 4% in the placebo. </p> <p>These findings are driven by the subgroup of trials comparing atosiban versus placebo as no events were reported for the barusiban subgroup including a single trial (<a href="./references#CD004452-bbs2-0014" title="ArceJC . A proof of concept study assessing the effect of four different stage bolus intravenous doses of FE200440 and placebo on stopping preterm labor (ongoing trial). ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 21 March 2006). ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of a selective oxytocin antagonist (barusiban) in threatened preterm labour: a randomized, double‐blind, placebo‐controlled trial. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA. 2008:Abstract no: 129. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban on plasma concentrations and uterine contractility in threatened preterm labour: a randomised, double‐blind, placebo‐controlled trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2008;93(Suppl 1):Fa11‐Fa12. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2009;200(6):627.e1‐627.e10. ">Thornton 2009</a>). </p> <p><b>Caesarean section</b> (<a href="./references#CD004452-fig-0011" title="">Analysis 1.9</a>) </p> <p>No difference was shown in caesarean section birth comparing atosiban with placebo (RR 1.63, 95% CI 0.73 to 3.61; one study with 112 women). </p> </section> </section> </section> <section id="CD004452-sec-0095"> <h4 class="title">Comparison 2: Oxytocin receptor antagonists (ORA) compared with other tocolytic agents by type of other tocolytic agent </h4> <p>Eight studies (with 1402 women) are included in the comparison between ORA (atosiban only) and betamimetics (<a href="./references#CD004452-bbs2-0001" title="CabarFR , BittarRE , GomesCM , ZugabM . Atosiban as a tocolytic agent: a new proposal of a therapeutic approach. Revista Brasileira de Ginecologia y Obstetricia2008;30(2):87‐92. ">Cabar 2008</a>; <a href="./references#CD004452-bbs2-0002" title="The European Atosiban Study Group. The oxytocin antagonist atosiban versus the ß‐agonist terbutaline in the treatment of preterm labor: a randomized, double‐blind, controlled study. Acta Obstetricia et Gynecologica Scandinavica2001;80:413‐22. The Worldwide Atosiban versus Beta‐antagonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. BJOG2001;108:133‐42. ">European 2001</a>; <a href="./references#CD004452-bbs2-0003" title="French/Australian Atosiban Investigators Group. Treatment of preterm labor with the oxytocin antagonist atosiban: a double‐blind, randomized, controlled comparison with salbutamol. European Journal Obstetrics, Gynecology and Reproductive Biology2001;98:177‐85. The Worldwide Atosiban versus Beta‐antagonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. BJOG2001;108:133‐42. ">French/Australian 2001</a>; <a href="./references#CD004452-bbs2-0005" title="GoodwinTM , ValenzuelaG , SilverH , HayashiR , CreasyGW , LaneR . Treatment of preterm labor with the oxytocin antagonist atosiban. American Journal of Perinatology1996;13(3):143‐6. GoodwinTM , ValenzuelaGJ , SilverH , CreasyG , Atosiban Study Group. Dose ranging study of the oxytocin antagonist atosiban in the treatment of preterm labor. Obstetrics &amp; Gynecology1996;88(3):331‐6. ">Goodwin 1996</a>; <a href="./references#CD004452-bbs2-0007" title="LinCH , LinSY , ShyuMK , ChenSU , LeeCN . Randomized trial of oxytocin antagonist atosiban versus beta‐adrenergic agonists  in the treatment of spontaneous preterm labor in Taiwanese women. Journal of the Formosan Medical Association = Taiwan Yi Zhi2009;108(6):493‐501. ">Lin 2009</a>; <a href="./references#CD004452-bbs2-0008" title="MoutquinJ , RabinoviciJ . Comparison of atosiban versus ritodrine in the treatment of pre‐term labour. Acta Obstetrica et Gynecologica Scandinavica1997;76(167):33. MoutquinJM , ShermanD , CohenH , MohidePT , Hochner‐CelnikierD , FejginM , et al. Double‐blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study. American Journal of Obstetrics and Gynecology2000;182(5):1191‐9. ">Moutquin 2000</a>; <a href="./references#CD004452-bbs2-0009" title="NonnenmacherA , HoppH , DudenhausenJ . Effectiveness and safety of atosiban vs. pulsatile administration of fenoterol in the treatment of preterm labour. Zeitschrift fur Geburtshilfe und Neonatologie2009;213(5):201‐6. ">Nonnenmacher 2009</a>; <a href="./references#CD004452-bbs2-0013" title="ShimJY , ParkYW , YoonBH , ChoYK , YangJH , LeeY , et al. Multicentre, parallel group, randomised, single‐blind study of the safety and efficacy of atosiban versus ritodrine in the treatment of acute preterm labour in Korean women. BJOG2006;113(11):1228‐34. ">Shim 2006</a>). Two studies including 225 women are included in the comparison of ORA (atosiban only) and calcium channel blockers (CCB) (nifedipine only) (<a href="./references#CD004452-bbs2-0006" title="KashanianM , AkbarianAR , SoltanzadehM . Atosiban and nifedipin for the treatment of preterm labor. International Journal of Gynecology &amp; Obstetrics2005;91(1):10‐4. KashanianM , SoltanzadehM , Sheikh AnsariN . Atosiban and nifedipin for the treatment of preterm labor. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):69. ">Kashanian 2005</a>; <a href="./references#CD004452-bbs2-0012" title="GarmiG . Nifedipine compared to atosiban for treating preterm labor [ClinicalTrials.gov (http://clinicaltrials.gov/)]. accessed 9 April 2008. SalimR , GarmiG , NachumZ , ZafranN , BaramS , ShalevE . Nifedipine compared with atosiban for treating preterm labor: A randomized controlled trial. Obstetrics and Gynecology2012;120(6):1323‐31. ">Salim 2012</a>). All studies used the ORA atosiban. </p> <section id="CD004452-sec-0096"> <h5 class="title">Primary outcomes</h5> <p><b>Birth less than 48 hours after trial entry</b> (<a href="./references#CD004452-fig-0021" title="">Analysis 2.1</a>) </p> <p>No statistically significant differences were shown within or across subgroups.</p> <p> <ul id="CD004452-list-0024"> <li> <p>ORA versus betamimetics: RR 0.89, 95% CI 0.66 to 1.22 (eight studies with 1389 women).</p> </li> <li> <p>ORA versus CCB: average: RR 1.09, 95% CI 0.44 to 2.73 (two studies with 225 women).</p> </li> </ul> </p> <p>Moderate heterogeneity was present for the ORA versus CCB comparison (Tau² = 0.22; Chi² = 2.04, df = 1 (P = 0.15); I² = 51%); however, upon exploration of the possible reasons for heterogeneity by examining clinical features of the studies, we considered an overall summary was meaningful using a random‐effects analysis. </p> <p><b>Very preterm birth (before completion of 34 weeks of gestation)</b> (<a href="./references#CD004452-fig-0023" title="">Analysis 2.3</a>) </p> <p> <ul id="CD004452-list-0025"> <li> <p>ORA versus betamimetics: no data were available.</p> </li> <li> <p>ORA versus CCB: no statistically significant difference was shown (RR 1.70, 95% CI 0.89 to 3.23; one study with 145 women). </p> </li> </ul> </p> <p><b>Perinatal mortality</b> (<a href="./references#CD004452-fig-0022" title="">Analysis 2.2</a>), <b>Stillbirth</b> (<a href="./references#CD004452-fig-0024" title="">Analysis 2.4</a>) and <b>Neonatal death</b> (<a href="./references#CD004452-fig-0025" title="">Analysis 2.5</a>). </p> <p>No statistically significant differences were shown within or across subgroups</p> <p> <ul id="CD004452-list-0026"> <li> <p>ORA versus betamimetics: perinatal mortality (RR 0.55, 95% CI 0.21 to 1.48; three studies with 816 infants) (<a href="./references#CD004452-fig-0022" title="">Analysis 2.2</a>), stillbirth (RR 0.56, 95% CI 0.05 to 6.05; four studies with 861 infants) (<a href="./references#CD004452-fig-0024" title="">Analysis 2.4</a>) or neonatal death (RR 0.67, 95% CI 0.28 to 1.61; five studies with 1236 infants) (<a href="./references#CD004452-fig-0025" title="">Analysis 2.5</a>). </p> </li> <li> <p>ORA versus CCB: the single trial in this comparison (<a href="./references#CD004452-bbs2-0012" title="GarmiG . Nifedipine compared to atosiban for treating preterm labor [ClinicalTrials.gov (http://clinicaltrials.gov/)]. accessed 9 April 2008. SalimR , GarmiG , NachumZ , ZafranN , BaramS , ShalevE . Nifedipine compared with atosiban for treating preterm labor: A randomized controlled trial. Obstetrics and Gynecology2012;120(6):1323‐31. ">Salim 2012</a>, 179 infants), reported that no neonatal deaths occurred during the trial period. No data were available on stillbirth or perinatal mortality. </p> </li> </ul> </p> <p><b>Serious maternal outcome</b> (<a href="./references#CD004452-fig-0026" title="">Analysis 2.6</a>) </p> <p> <ul id="CD004452-list-0027"> <li> <p>ORA versus betamimetics: one study with 45 women (<a href="./references#CD004452-bbs2-0007" title="LinCH , LinSY , ShyuMK , ChenSU , LeeCN . Randomized trial of oxytocin antagonist atosiban versus beta‐adrenergic agonists  in the treatment of spontaneous preterm labor in Taiwanese women. Journal of the Formosan Medical Association = Taiwan Yi Zhi2009;108(6):493‐501. ">Lin 2009</a>) reported that no maternal deaths occurred during the trial period. </p> </li> <li> <p>ORA versus CCB: no data were available.</p> </li> </ul> </p> <p>No other data were available on other serious maternal outcomes or long‐term outcomes for the child. </p> </section> <section id="CD004452-sec-0097"> <h5 class="title">Secondary outcomes</h5> <section id="CD004452-sec-0098"> <h6 class="title">For the infant/child</h6> <p><b>Interval between trial entry and birth</b> (<a href="./references#CD004452-fig-0030" title="">Analysis 2.10</a>) </p> <p> <ul id="CD004452-list-0028"> <li> <p>ORA versus betamimetics: an increase in the Interval between trial entry and birth was shown with the use of ORA (MD 22.90 days, 95% CI 18.03 to 27.77; one study with 80 women) (<a href="./references#CD004452-bbs2-0001" title="CabarFR , BittarRE , GomesCM , ZugabM . Atosiban as a tocolytic agent: a new proposal of a therapeutic approach. Revista Brasileira de Ginecologia y Obstetricia2008;30(2):87‐92. ">Cabar 2008</a>). </p> </li> <li> <p>ORA versus CCB: no difference was shown in the interval between trial entry and birth (<a href="./references#CD004452-bbs2-0012" title="GarmiG . Nifedipine compared to atosiban for treating preterm labor [ClinicalTrials.gov (http://clinicaltrials.gov/)]. accessed 9 April 2008. SalimR , GarmiG , NachumZ , ZafranN , BaramS , ShalevE . Nifedipine compared with atosiban for treating preterm labor: A randomized controlled trial. Obstetrics and Gynecology2012;120(6):1323‐31. ">Salim 2012</a>) (MD ‐5.70 days, 95% CI ‐12.36 to 0.96; one study with 145 women) (<a href="./references#CD004452-bbs2-0012" title="GarmiG . Nifedipine compared to atosiban for treating preterm labor [ClinicalTrials.gov (http://clinicaltrials.gov/)]. accessed 9 April 2008. SalimR , GarmiG , NachumZ , ZafranN , BaramS , ShalevE . Nifedipine compared with atosiban for treating preterm labor: A randomized controlled trial. Obstetrics and Gynecology2012;120(6):1323‐31. ">Salim 2012</a>). </p> </li> </ul> </p> <p>These results were statistically significantly different across subgroups; test for subgroup differences:Chi² = 46.16, df = 1 (P &lt; 0.01), I² = 97.8%. </p> <p><b>Preterm birth (before completion of 37 weeks of gestation)</b> (<a href="./references#CD004452-fig-0031" title="">Analysis 2.11</a>) </p> <p> <ul id="CD004452-list-0029"> <li> <p>ORA versus betamimetics: no data were available.</p> </li> <li> <p>ORA versus CCB: in a single study (145 women) ORA (atosiban) resulted in significantly more preterm births compared with CCB (RR 1.56, 95% CI 1.13 to 2.14; NNTH 5, 95% CI 19 to 3). </p> </li> </ul> </p> <p><b>Extremely preterm birth (before completion of 28 weeks of gestation)</b> (<a href="./references#CD004452-fig-0032" title="">Analysis 2.12</a>) </p> <p>No statistically significant differences were shown within or across subgroups.</p> <p> <ul id="CD004452-list-0030"> <li> <p>ORA versus betamimetics: RR 0.84, 95% CI 0.37 to 1.92 (one study with 244 women).</p> </li> <li> <p>ORA versus CCB: RR 2.14, 95% CI 0.20 to 23.11 (one study with 145 women).</p> </li> </ul> </p> <p><b>Gestational age at birth</b> (<a href="./references#CD004452-fig-0033" title="">Analysis 2.13</a>) </p> <p> <ul id="CD004452-list-0031"> <li> <p>ORA versus betamimetics: no difference was shown in gestational age at birth (MD 0.13 weeks, 95% CI ‐0.32 to 0.59; six studies with 1005 women). </p> </li> <li> <p>ORA versus CCB: a lower mean gestational age for ORA group (atosiban) compared with CCB (MD ‐1.20 weeks, 95% CI ‐2.15 to ‐0.25; one study with 145 women). </p> </li> </ul> </p> <p>These results were statistically significantly different across subgroups; test for subgroup differences: Chi² = 6.18, df = 1 (P = 0.01), I² = 83.8%. </p> <p><b>Birthweight</b> (<a href="./references#CD004452-fig-0034" title="">Analysis 2.14</a>) </p> <p>No statistically significant differences were shown within or across subgroups.</p> <p> <ul id="CD004452-list-0032"> <li> <p>ORA versus betamimetics: MD 27.16 g, 95% CI ‐55.46 to 109.77 (seven studies with 1184 infants). </p> </li> <li> <p>ORA versus CCB: no difference was shown MD ‐82.00 weeks, 95% CI ‐270.78 to 106.78; (one study with 178 infants). </p> </li> </ul> </p> <p><b>Apgar score less than seven at five minutes</b> (<a href="./references#CD004452-fig-0035" title="">Analysis 2.15</a>) </p> <p>No statistically significant differences were shown within or across subgroups.</p> <p> <ul id="CD004452-list-0033"> <li> <p>ORA versus betamimetics: RR 0.79, 95% CI 0.47 to 1.33 (five studies with 1008 infants).</p> </li> <li> <p>ORA versus CCB: RR 0.54, 95% CI 0.05 to 5.86 (one study with 179 infants).</p> </li> </ul> </p> <p><b>Respiratory distress syndrome</b> (<a href="./references#CD004452-fig-0036" title="">Analysis 2.16</a>) </p> <p>No statistically significant differences were shown within or across subgroups.</p> <p> <ul id="CD004452-list-0034"> <li> <p>ORA versus betamimetics: (average RR 1.08; 95% CI 0.70 to 1.65; random‐effects; six studies with 1280 infants). Moderate heterogeneity was evident (Tau² = 0.11, Chi² = 7.98, df = 4 (P = 0.09), I² = 50%) which was driven by one study (<a href="./references#CD004452-bbs2-0002" title="The European Atosiban Study Group. The oxytocin antagonist atosiban versus the ß‐agonist terbutaline in the treatment of preterm labor: a randomized, double‐blind, controlled study. Acta Obstetricia et Gynecologica Scandinavica2001;80:413‐22. The Worldwide Atosiban versus Beta‐antagonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. BJOG2001;108:133‐42. ">European 2001</a>). However, as no clear reason for the heterogeneity could be identified, we considered an overall summary was meaningful using a random‐effects analysis. </p> </li> <li> <p>ORA versus CCB: (RR 1.39, 95% CI 0.54 to 3.57; one study with 179 infants).</p> </li> </ul> </p> <p><b>Use of mechanical ventilation</b> (<a href="./references#CD004452-fig-0037" title="">Analysis 2.17</a>) </p> <p>No statistically significant differences were shown within or across subgroups.</p> <p> <ul id="CD004452-list-0035"> <li> <p>ORA versus betamimetics: RR 3.00, 95% CI 0.63 to 14.30 (one study with 126 infants).</p> </li> <li> <p>ORA versus CCB: RR 1.41, 95% CI 0.65 to 3.04 (one study with 179 infants).</p> </li> </ul> </p> <p><b>Duration of mechanical ventilation</b> (<a href="./references#CD004452-fig-0038" title="">Analysis 2.18</a>) </p> <p>No statistically significant differences were shown.</p> <p> <ul id="CD004452-list-0036"> <li> <p>ORA versus betamimetics: MD ‐1.30 days, 95% CI ‐3.82 to 1.22 (one study with 32 infants).</p> </li> <li> <p>ORA versus CCB: no data were available.</p> </li> </ul> </p> <p><b>Intraventricular haemorrhage</b> (<a href="./references#CD004452-fig-0039" title="">Analysis 2.19</a>) </p> <p>No statistically significant differences were shown.</p> <p> <ul id="CD004452-list-0037"> <li> <p>ORA versus betamimetics: RR 1.12, 95% CI 0.48 to 2.58 (two studies with 359 infants).</p> </li> <li> <p>ORA versus CCB: RR 2.16, 95% CI 0.41 to 11.51 (one study with 179 infants).</p> </li> </ul> </p> <p><b>Necrotising enterocolitis</b> (<a href="./references#CD004452-fig-0040" title="">Analysis 2.20</a>) </p> <p>No statistically significant differences were shown within or across subgroups.</p> <p> <ul id="CD004452-list-0038"> <li> <p>ORA versus betamimetics: RR 0.24, 95% CI 0.02 to 3.74 (one study with 292 infants).</p> </li> <li> <p>ORA versus CCB: RR 9.72, 95% CI 0.53 to 178.00 (one study with 179 infants).</p> </li> </ul> </p> <p>These results were statistically significantly different across subgroups; test for subgroup differences: Chi² = 3.30, df = 1 (P = 0.07), I² = 69.7% </p> <p><b>Retinopathy of prematurity</b> (<a href="./references#CD004452-fig-0041" title="">Analysis 2.21</a>) </p> <p>No statistically significant differences were shown.</p> <p> <ul id="CD004452-list-0039"> <li> <p>ORA versus betamimetics: no data were available.</p> </li> <li> <p>ORA versus CCB: RR 2.16, 95% CI 0.20 to 23.43 (one study with 179 infants).</p> </li> </ul> </p> <p><b>Neonatal sepsis</b> (<a href="./references#CD004452-fig-0042" title="">Analysis 2.22</a>) </p> <p>No statistically significant differences were shown within or across subgroups.</p> <p> <ul id="CD004452-list-0040"> <li> <p>ORA versus betamimetics: RR 0.91, 95% CI 0.56 to 1.46 (four studies with 1109 infants).</p> </li> <li> <p>ORA versus CCB: RR 0.72, 95% CI 0.12 to 4.21 (one study with 179 infants).</p> </li> </ul> </p> <p><b>Admission to neonatal intensive care unit</b> (<a href="./references#CD004452-fig-0043" title="">Analysis 2.23</a>) </p> <p> <ul id="CD004452-list-0041"> <li> <p>ORA versus betamimetics: no difference in admission to neonatal intensive care unit was shown (RR 0.90, 95% CI 0.78 to 1.04; five studies with 1062 infants). </p> </li> <li> <p>ORA versus CCB: an increase in admission to neonatal intensive care unit was shown for the ORA (atosiban) group (RR 1.70, 95% CI 1.17 to 2.47; NNTH 5, 95% CI 3 to 19; one study with 179 infants). </p> </li> </ul> </p> <p><b>Neonatal length of hospital stay</b> (<a href="./references#CD004452-fig-0044" title="">Analysis 2.24</a>) </p> <p>No statistically significant differences were shown within or across subgroups.</p> <p> <ul id="CD004452-list-0042"> <li> <p>ORA versus betamimetics: MD 0.10 days, 95% CI ‐5.13 to 5.33 (one study with 41 infants).</p> </li> <li> <p>ORA versus CCB: MD 5.40 days, 95% CI ‐0.04 to 10.84 (one study with 179 infants).</p> </li> </ul> </p> </section> <section id="CD004452-sec-0099"> <h6 class="title">For the woman</h6> <p><b>Maternal adverse effects</b> (<a href="./references#CD004452-fig-0027" title="">Analysis 2.7</a>) </p> <p> <ul id="CD004452-list-0043"> <li> <p>ORA versus betamimetics: maternal adverse effects were reported by two studies comparing ORA (atosiban) with betamimetics. Due to substantial statistical heterogeneity when these data were combined (I² = 95%) results are reported separately. While both studies showed a reduction in these events, in one study comparing ORA (atosiban) with betamimetics (terbutaline) (<a href="./references#CD004452-bbs2-0002" title="The European Atosiban Study Group. The oxytocin antagonist atosiban versus the ß‐agonist terbutaline in the treatment of preterm labor: a randomized, double‐blind, controlled study. Acta Obstetricia et Gynecologica Scandinavica2001;80:413‐22. The Worldwide Atosiban versus Beta‐antagonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. BJOG2001;108:133‐42. ">European 2001</a>), the reduction was not statistically significant (RR 0.77, 95% CI 0.56 to 1.07). In the other study comparing ORA (atosiban) with betamimetics (ritodrine) (<a href="./references#CD004452-bbs2-0013" title="ShimJY , ParkYW , YoonBH , ChoYK , YangJH , LeeY , et al. Multicentre, parallel group, randomised, single‐blind study of the safety and efficacy of atosiban versus ritodrine in the treatment of acute preterm labour in Korean women. BJOG2006;113(11):1228‐34. ">Shim 2006</a>), a statistically significant substantial reduction was shown for ORA (atosiban) (RR 0.11, 95% CI 0.05 to 0.26; NNTB 2, 95% CI 1 to 2). </p> </li> <li> <p>ORA versus CCB: a reduction was shown in maternal adverse effects comparing ORA (atosiban) versus calcium channel blockers (RR 0.38, 95% CI 0.21 to 0.68; NNTB 6, 95% CI 5 to 11; two studies with 225 women). </p> </li> </ul> </p> <p><b>Maternal adverse effects requiring cessation of treatment</b> (<a href="./references#CD004452-fig-0028" title="">Analysis 2.8</a>) </p> <p> <ul id="CD004452-list-0044"> <li> <p>ORA versus betamimetics: a reduction in maternal adverse effects requiring cessation of treatment was shown for ORA (atosiban) compared with betamimetics (RR 0.05, 95% CI 0.02 to 0.11; NNTB 6, 95% CI 6 to 6; five studies with 1161 women). </p> </li> <li> <p>ORA versus CCB: no difference in maternal adverse effects requiring cessation of treatment was shown for ORA (atosiban) compared with CCB (RR 0.36, 95% CI 0.01 to 8.62; one study with 145 women). </p> </li> </ul> </p> <p><b>Caesarean section</b> (<a href="./references#CD004452-fig-0029" title="">Analysis 2.9</a>) </p> <p>No statistically significant differences were shown within or across subgroups.</p> <p> <ul id="CD004452-list-0045"> <li> <p>ORA versus betamimetic: RR 0.87, 95% CI 0.50 to 1.52 (one study with 247 women).</p> </li> <li> <p>ORA versus CCB: RR 1.34, 95% CI 0.37 to 4.79 (one study with 145 women).</p> </li> </ul> </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD004452-sec-0100" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD004452-sec-0100"></div> <section id="CD004452-sec-0101"> <h3 class="title" id="CD004452-sec-0101">Summary of main results</h3> <p>Fourteen trials involving 2485 women contributed data to the review. We compared oxytocin receptor antagonists (ORA) with placebo (by type of ORA), with betamimetics and with calcium channel blockers (CCB) (all studies using nifedipine). Apart from one small study which used barusiban, all included studies used the ORA atosiban. </p> <p>In this review, ORA (mainly atosiban) were not shown to prolong pregnancy or improve short‐term neonatal outcomes compared with either placebo or other tocolytics, i.e. betamimetic and CCB. The ORA atosiban was used in all placebo‐controlled trials apart from one small trial which used barusiban and the lack of data did not allow adequate examination of possible differential effects by type of ORA. </p> <p>Sixteen per cent of women receiving ORA had an adverse effect requiring cessation of treatment compared with 4% of those who received placebo. ORA resulted in fewer maternal adverse effects than betamimetics or CCB. </p> <p>Data from one study (<a href="./references#CD004452-bbs2-0011" title="GoodwinTM . 1st International preterm labour congress. Strategies to prevent the morbidity and mortality associated with prematurity; 2002 June 27‐30. Le Montreux Palace, Montreux Switzerland. 2002. GoodwinTM . Long‐term safety with oxytocin antagonists. 4th World Congress on Controversies in Obstetrics, Gynecology and Infertility; 2003 April 24‐27; Berlin, Germany. 2003:291. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes at 6 and 12 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes up to 24 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. RomeroR , SibaiBM , Sanchez‐RamosL , ValenzuelaGJ , VeilleJC , TaborB , et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double‐blind, placebo‐controlled trial with tocolytic rescue. American Journal of Obstetrics and Gynecology2000;182(5):1173‐83. SibaiB , RomeroR , Sanchex‐RamosL , ValenzuelaG , VeilleJ , TaborB , et al. A double‐blind placebo‐controlled trial of an oxytocin‐receptor antagonist (antocin) in the treatment of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S2. SilverH , ValenzuelaG , Sanchez‐RamosL , RomeroR , SibaiB , GoodwinT , et al. Maternal side effects and safety of the oxytocin receptor antagonist antocin. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S45. ">Romero 2000</a>), which compared ORA with placebo, showed an increase in births less than 28 weeks' gestation and deaths to 12 months of age (0.7% in placebo group versus 4.2% in the ORA group), indicating that on average one additional infant death would occur for every 29 women (and up to 380) receiving ORA. However, this finding may be confounded due to randomisation of more women with pregnancy less than 26 weeks' gestation to the atosiban group. </p> <p>In one small study (145 infants) <a href="./references#CD004452-bbs2-0012" title="GarmiG . Nifedipine compared to atosiban for treating preterm labor [ClinicalTrials.gov (http://clinicaltrials.gov/)]. accessed 9 April 2008. SalimR , GarmiG , NachumZ , ZafranN , BaramS , ShalevE . Nifedipine compared with atosiban for treating preterm labor: A randomized controlled trial. Obstetrics and Gynecology2012;120(6):1323‐31. ">Salim 2012</a>, which did not blind the intervention, an increase in the number of preterm births (before 37 weeks' gestation) (RR 1.56, 95% CI 1.13 to 2.14; NNTH 5, 95% CI 3 to 19), a lower gestational age at birth (MD ‐1.2 weeks, 95% CI ‐2.15 to ‐0.25) and an increase in admission to neonatal intensive care unit (RR 1.70, 95% CI 1.16 to 2.49; NNTH 5, 95% CI 3 to 20) was shown. </p> </section> <section id="CD004452-sec-0102"> <h3 class="title" id="CD004452-sec-0102">Overall completeness and applicability of evidence</h3> <p>Although ORA result in fewer maternal side effects than other tocolytics, there is no evidence of benefit for the infant when compared with other tocolytics or placebo. Limitations of the review findings include, minimal neonatal outcome data, no long‐term infant outcomes and overall suboptima trial quality. </p> <p>Short‐term outcomes of birth within 48 hours, perinatal mortality, preterm birth (less ss than 37 weeks), respiratory distress syndrome, admission to neonatal care and maternal adverse drug reaction were the most frequently reported outcomes. Data on a number of clinically important neonatal outcomes were limited and the only included longer‐term outcome (reported by one study) was infant mortality. </p> <p>An increase in births less than 28 weeks' gestation and deaths to 12 months of age was shown for ORA when compared with placebo. However, because the adverse outcomes are nearly entirely the result of one study (<a href="./references#CD004452-bbs2-0011" title="GoodwinTM . 1st International preterm labour congress. Strategies to prevent the morbidity and mortality associated with prematurity; 2002 June 27‐30. Le Montreux Palace, Montreux Switzerland. 2002. GoodwinTM . Long‐term safety with oxytocin antagonists. 4th World Congress on Controversies in Obstetrics, Gynecology and Infertility; 2003 April 24‐27; Berlin, Germany. 2003:291. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes at 6 and 12 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes up to 24 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. RomeroR , SibaiBM , Sanchez‐RamosL , ValenzuelaGJ , VeilleJC , TaborB , et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double‐blind, placebo‐controlled trial with tocolytic rescue. American Journal of Obstetrics and Gynecology2000;182(5):1173‐83. SibaiB , RomeroR , Sanchex‐RamosL , ValenzuelaG , VeilleJ , TaborB , et al. A double‐blind placebo‐controlled trial of an oxytocin‐receptor antagonist (antocin) in the treatment of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S2. SilverH , ValenzuelaG , Sanchez‐RamosL , RomeroR , SibaiB , GoodwinT , et al. Maternal side effects and safety of the oxytocin receptor antagonist antocin. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S45. ">Romero 2000</a>), and because of a paucity of further trials comparing atosiban with placebo, no definite conclusion can be drawn about whether atosiban is beneficial or harmful compared with placebo. Neurological follow‐up data from this study (although not included in this review) showed no difference between the atosiban and placebo groups at the age of six months, one year, and two years of age. However, this result should be interpreted with caution due to the potential for bias resulting from high loss to follow‐up. </p> <p>A plausible explanation for the increase in adverse infant outcome in the atosiban group could be a chance imbalance in the allocation of women with threatened preterm labour in very early gestation (under 26 weeks) with significantly more women in this subgroup being allocated to the atosiban group. The mean gestational age on admission was statistically significantly greater for the placebo group than for the atosiban group, and there were nearly twice as many atosiban‐treated patients enrolled at &lt; 26 weeks’ gestation. Among the women enrolled at less than 26 weeks' gestation, the number who had advanced cervical dilation was higher in the atosiban group compared with the placebo group. In the same study (<a href="./references#CD004452-bbs2-0011" title="GoodwinTM . 1st International preterm labour congress. Strategies to prevent the morbidity and mortality associated with prematurity; 2002 June 27‐30. Le Montreux Palace, Montreux Switzerland. 2002. GoodwinTM . Long‐term safety with oxytocin antagonists. 4th World Congress on Controversies in Obstetrics, Gynecology and Infertility; 2003 April 24‐27; Berlin, Germany. 2003:291. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes at 6 and 12 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes up to 24 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. RomeroR , SibaiBM , Sanchez‐RamosL , ValenzuelaGJ , VeilleJC , TaborB , et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double‐blind, placebo‐controlled trial with tocolytic rescue. American Journal of Obstetrics and Gynecology2000;182(5):1173‐83. SibaiB , RomeroR , Sanchex‐RamosL , ValenzuelaG , VeilleJ , TaborB , et al. A double‐blind placebo‐controlled trial of an oxytocin‐receptor antagonist (antocin) in the treatment of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S2. SilverH , ValenzuelaG , Sanchez‐RamosL , RomeroR , SibaiB , GoodwinT , et al. Maternal side effects and safety of the oxytocin receptor antagonist antocin. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S45. ">Romero 2000</a>), there were more births before 28 weeks' gestation in the atosiban group compared with placebo, which is not surprising given the short prolongation of pregnancy that most tocolytics can achieve. Another explanation, which was suggested by the US Food and Drug Administration (FDA), is that fetal vasopressin receptor blockade by atosiban could give changes in maternal amniotic fluid volume, with resultant alterations to fetal renal development, and secondary alterations to fetal lung development (<a href="./references#CD004452-bbs2-0041" title="Advisory Committee for Reproductive Health Drugs. Issue‐NDA 20‐797 Antocin, (atosiban injection) for use in the management of preterm labor. Centre for Drug Evaluation and Research, Food and Drug Administration. Gaithersburg, Maryland April 201998:83‐5. ">FDA 1998a</a>). A similar increase in adverse events among infants exposed to atosiban was reported to the FDA for one study of maintenance therapy (<a href="./references#CD004452-bbs2-0023" title="Sanchez‐RamosL , ValenzuelaG , RomeroR , SilverH , KoltunW , MillarL , et al. A double‐blind placebo‐controlled trial of oxytocin receptor antagonist (antocin) maintenance therapy in patients with preterm labor. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S30. ValenzuelaGJ , Sanchez‐RamosL , RomeroR , SilverHM , KoltunWD , MillarL , et al. Maintenance treatment of preterm labor with the oxytocin antagonist atosiban. The atosiban ptl‐098 study group. American Journal of Obstetrics and Gynecology2000;182(5):1184‐90. ">Valenzuela 2000</a>) comparing placebo and atosiban (<a href="./references#CD004452-bbs2-0042" title="Advisory Committee for Reproductive Health Drugs. Issue‐NDA 20‐797 Antocin, (atosiban injection) for use in the management of preterm labor. Centre for Drug Evaluation and Research, Food and Drug Administration. Gaithersburg, Maryland April 201998:81. ">FDA 1998b</a>). </p> <p>The study comparing barusiban versus placebo (<a href="./references#CD004452-bbs2-0014" title="ArceJC . A proof of concept study assessing the effect of four different stage bolus intravenous doses of FE200440 and placebo on stopping preterm labor (ongoing trial). ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 21 March 2006). ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of a selective oxytocin antagonist (barusiban) in threatened preterm labour: a randomized, double‐blind, placebo‐controlled trial. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA. 2008:Abstract no: 129. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban on plasma concentrations and uterine contractility in threatened preterm labour: a randomised, double‐blind, placebo‐controlled trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2008;93(Suppl 1):Fa11‐Fa12. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2009;200(6):627.e1‐627.e10. ">Thornton 2009</a>) presented long‐term follow‐up data for mental development performance and psychomotor performance at one year of age (not included in this review). Although the findings were not significant, the results suggested mildly delayed psychomotor development in 4% in the barusiban group and 8% in the placebo group (<a href="./references#CD004452-bbs2-0014" title="ArceJC . A proof of concept study assessing the effect of four different stage bolus intravenous doses of FE200440 and placebo on stopping preterm labor (ongoing trial). ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 21 March 2006). ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of a selective oxytocin antagonist (barusiban) in threatened preterm labour: a randomized, double‐blind, placebo‐controlled trial. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA. 2008:Abstract no: 129. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban on plasma concentrations and uterine contractility in threatened preterm labour: a randomised, double‐blind, placebo‐controlled trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2008;93(Suppl 1):Fa11‐Fa12. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2009;200(6):627.e1‐627.e10. ">Thornton 2009</a>). None of the infants in the placebo group and 3% of infants in the barusiban group were classified as having significantly delayed psychomotor performance (<a href="./references#CD004452-bbs2-0014" title="ArceJC . A proof of concept study assessing the effect of four different stage bolus intravenous doses of FE200440 and placebo on stopping preterm labor (ongoing trial). ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 21 March 2006). ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of a selective oxytocin antagonist (barusiban) in threatened preterm labour: a randomized, double‐blind, placebo‐controlled trial. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA. 2008:Abstract no: 129. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban on plasma concentrations and uterine contractility in threatened preterm labour: a randomised, double‐blind, placebo‐controlled trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2008;93(Suppl 1):Fa11‐Fa12. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2009;200(6):627.e1‐627.e10. ">Thornton 2009</a>). In addition, there was mildly delayed mental performance in 8% of infants in the placebo group and 10% in the barusiban group (<a href="./references#CD004452-bbs2-0014" title="ArceJC . A proof of concept study assessing the effect of four different stage bolus intravenous doses of FE200440 and placebo on stopping preterm labor (ongoing trial). ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 21 March 2006). ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of a selective oxytocin antagonist (barusiban) in threatened preterm labour: a randomized, double‐blind, placebo‐controlled trial. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA. 2008:Abstract no: 129. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban on plasma concentrations and uterine contractility in threatened preterm labour: a randomised, double‐blind, placebo‐controlled trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2008;93(Suppl 1):Fa11‐Fa12. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2009;200(6):627.e1‐627.e10. ">Thornton 2009</a>). Based on the findings in this clinical trial (<a href="./references#CD004452-bbs2-0014" title="ArceJC . A proof of concept study assessing the effect of four different stage bolus intravenous doses of FE200440 and placebo on stopping preterm labor (ongoing trial). ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 21 March 2006). ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of a selective oxytocin antagonist (barusiban) in threatened preterm labour: a randomized, double‐blind, placebo‐controlled trial. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA. 2008:Abstract no: 129. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban on plasma concentrations and uterine contractility in threatened preterm labour: a randomised, double‐blind, placebo‐controlled trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2008;93(Suppl 1):Fa11‐Fa12. ThorntonS , GoodwinTM , GreisenG , HedegaardM , ArceJC . The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2009;200(6):627.e1‐627.e10. ">Thornton 2009</a>), barusiban is currently not in use for inhibition of preterm labour. </p> <p>It is also possible that rescue treatment confounded the estimation of the true effects of atosiban when compared with placebo. In the study by Romero et al (<a href="./references#CD004452-bbs2-0011" title="GoodwinTM . 1st International preterm labour congress. Strategies to prevent the morbidity and mortality associated with prematurity; 2002 June 27‐30. Le Montreux Palace, Montreux Switzerland. 2002. GoodwinTM . Long‐term safety with oxytocin antagonists. 4th World Congress on Controversies in Obstetrics, Gynecology and Infertility; 2003 April 24‐27; Berlin, Germany. 2003:291. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes at 6 and 12 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes up to 24 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. RomeroR , SibaiBM , Sanchez‐RamosL , ValenzuelaGJ , VeilleJC , TaborB , et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double‐blind, placebo‐controlled trial with tocolytic rescue. American Journal of Obstetrics and Gynecology2000;182(5):1173‐83. SibaiB , RomeroR , Sanchex‐RamosL , ValenzuelaG , VeilleJ , TaborB , et al. A double‐blind placebo‐controlled trial of an oxytocin‐receptor antagonist (antocin) in the treatment of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S2. SilverH , ValenzuelaG , Sanchez‐RamosL , RomeroR , SibaiB , GoodwinT , et al. Maternal side effects and safety of the oxytocin receptor antagonist antocin. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S45. ">Romero 2000</a>), rescue tocolysis was given in 43% of the atosiban group and in 51% of the placebo group. In one placebo‐controlled study (<a href="./references#CD004452-bbs2-0004" title="GoodwinTM , PaulR , SilverH , SpellacyW , ParsonsM , ChezR , et al. The effect of the oxytocin antagonist atosiban on preterm uterine activity in the human. American Journal of Obstetrics and Gynecology1994;170:474‐8. GoodwinTM , PaulRH , SilverH , ParsonsM , ChezR , SpellacyW , et al. Safety and efficacy of the oxytocin antagonist atosiban in threatened preterm labor: initial US trial. American Journal of Obstetrics and Gynecology1992;166:359. ">Goodwin 1994</a>), rescue tocolysis was used in 20% and 32% of the participants in the atosiban and placebo groups respectively after a short infusion of study medication (two hours). </p> <p>While data are limited on important clinical outcomes when comparing ORA with other tocolytics; eight studies (1402 women) comparing ORA (atosiban only) with betamimetics and two (225 women) comparing ORA (atosiban) with CCB did not show clear benefit other than reduced maternal adverse effects. </p> <p>The difficulty in demonstrating that ORA is an effective tocolytic may relate to its mechanism of action (<a href="./references#CD004452-bbs2-0041" title="Advisory Committee for Reproductive Health Drugs. Issue‐NDA 20‐797 Antocin, (atosiban injection) for use in the management of preterm labor. Centre for Drug Evaluation and Research, Food and Drug Administration. Gaithersburg, Maryland April 201998:83‐5. ">FDA 1998a</a>). It interacts with oxytocic receptors in myometrial cells, the density of which is gestation dependent. It is possible that ORA is more effective for women in preterm labour at higher gestations, whereas the pressing clinical need is for tocolytics effective at lower gestations, where delay in delivery has greater potential to improve the outcomes for neonates. </p> </section> <section id="CD004452-sec-0103"> <h3 class="title" id="CD004452-sec-0103">Quality of the evidence</h3> <p>While three of the four placebo‐controlled trials were considered of good quality (allocation to treatment and intervention were blinded), four of the eight trials comparing ORA with betamimetic and both trials comparing ORA with CCB trials considered of low quality (no blinding of the intervention and often no blinding of allocation to treatment). </p> <p>Sample attrition was not considered a serious source of bias as the majority (13 of the 14 included studies) had minimal or no attrition. In 12 of the 14 included studies, no reporting bias was evident and in the remaining studies it was unclear. </p> <p>For the majority of trials no other sources of bias was evident. However, in four studies, the risk of other bias was considered to be unclear (<a href="./references#CD004452-bbs2-0001" title="CabarFR , BittarRE , GomesCM , ZugabM . Atosiban as a tocolytic agent: a new proposal of a therapeutic approach. Revista Brasileira de Ginecologia y Obstetricia2008;30(2):87‐92. ">Cabar 2008</a>; <a href="./references#CD004452-bbs2-0005" title="GoodwinTM , ValenzuelaG , SilverH , HayashiR , CreasyGW , LaneR . Treatment of preterm labor with the oxytocin antagonist atosiban. American Journal of Perinatology1996;13(3):143‐6. GoodwinTM , ValenzuelaGJ , SilverH , CreasyG , Atosiban Study Group. Dose ranging study of the oxytocin antagonist atosiban in the treatment of preterm labor. Obstetrics &amp; Gynecology1996;88(3):331‐6. ">Goodwin 1996</a>; <a href="./references#CD004452-bbs2-0006" title="KashanianM , AkbarianAR , SoltanzadehM . Atosiban and nifedipin for the treatment of preterm labor. International Journal of Gynecology &amp; Obstetrics2005;91(1):10‐4. KashanianM , SoltanzadehM , Sheikh AnsariN . Atosiban and nifedipin for the treatment of preterm labor. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):69. ">Kashanian 2005</a>; <a href="./references#CD004452-bbs2-0013" title="ShimJY , ParkYW , YoonBH , ChoYK , YangJH , LeeY , et al. Multicentre, parallel group, randomised, single‐blind study of the safety and efficacy of atosiban versus ritodrine in the treatment of acute preterm labour in Korean women. BJOG2006;113(11):1228‐34. ">Shim 2006</a>) and in two studies, the risk of other bias was judged to be high (<a href="./references#CD004452-bbs2-0004" title="GoodwinTM , PaulR , SilverH , SpellacyW , ParsonsM , ChezR , et al. The effect of the oxytocin antagonist atosiban on preterm uterine activity in the human. American Journal of Obstetrics and Gynecology1994;170:474‐8. GoodwinTM , PaulRH , SilverH , ParsonsM , ChezR , SpellacyW , et al. Safety and efficacy of the oxytocin antagonist atosiban in threatened preterm labor: initial US trial. American Journal of Obstetrics and Gynecology1992;166:359. ">Goodwin 1994</a>; <a href="./references#CD004452-bbs2-0011" title="GoodwinTM . 1st International preterm labour congress. Strategies to prevent the morbidity and mortality associated with prematurity; 2002 June 27‐30. Le Montreux Palace, Montreux Switzerland. 2002. GoodwinTM . Long‐term safety with oxytocin antagonists. 4th World Congress on Controversies in Obstetrics, Gynecology and Infertility; 2003 April 24‐27; Berlin, Germany. 2003:291. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes at 6 and 12 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. GoodwinTM , RandallH , PerryK , MenardMK , BauerC , ShangoldG , et al. A report on infant outcomes up to 24 months after the use of atosiban in the management of preterm labor. 46th ACOG Annual Meeting; 1998 May 9‐13; New Orleans, Louisiana. 1998. RomeroR , SibaiBM , Sanchez‐RamosL , ValenzuelaGJ , VeilleJC , TaborB , et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double‐blind, placebo‐controlled trial with tocolytic rescue. American Journal of Obstetrics and Gynecology2000;182(5):1173‐83. SibaiB , RomeroR , Sanchex‐RamosL , ValenzuelaG , VeilleJ , TaborB , et al. A double‐blind placebo‐controlled trial of an oxytocin‐receptor antagonist (antocin) in the treatment of preterm labor. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S2. SilverH , ValenzuelaG , Sanchez‐RamosL , RomeroR , SibaiB , GoodwinT , et al. Maternal side effects and safety of the oxytocin receptor antagonist antocin. American Journal of Obstetrics and Gynecology1997;176(1 Pt 2):S45. ">Romero 2000</a>). These latter two studies, both in the placebo comparison, included women of lower gestational age in the atosiban group compared with placebo group. One of these studies also recruited women from five different centres, and the inclusion criteria differed between the centres, which may have introduced bias. In the largest placebo‐controlled trial, while judged to be at low risk of bias for all other quality criteria, there were nearly twice as many atosiban‐treated patients enrolled at &lt; 26 weeks’ gestation. </p> </section> <section id="CD004452-sec-0104"> <h3 class="title" id="CD004452-sec-0104">Potential biases in the review process</h3> <p>We are aware that the review process itself is subject to bias, and we took steps to minimise bias. At least two review authors carried out data extraction and assessed risk of bias independently; however, a different review team may not have made identical decisions. </p> </section> <section id="CD004452-sec-0105"> <h3 class="title" id="CD004452-sec-0105">Agreements and disagreements with other studies or reviews</h3> <p>We found that although ORA (mainly atosiban) resulted in fewer maternal side effects than other tocolytics; there is no clear evidence of benefit in terms of prolongation of pregnancy or important infant outcomes when compared with other tocolytics or placebo. A recent network meta‐analysis (<a href="./references#CD004452-bbs2-0050" title="HaasDM , CaldwellDM , KirkpatrickP , McIntoshJJ , WeltonNJ . Tocolytic therapy for preterm delivery: systematic review and network meta‐analysis. BMJ2012;345:e6226. ">Haas 2012)</a> showed different results, reporting that atosiban was better than placebo in delaying delivery at 48 hours (odds ratio 2.02; 95% CI 1.1 to 3.8), although it also found that atosiban had a lower probability of being superior to other tocolytics. We did not show benefit for ORA in delaying birth for 48 hours when compared with placebo as in the Haas et al review (<a href="./references#CD004452-bbs2-0050" title="HaasDM , CaldwellDM , KirkpatrickP , McIntoshJJ , WeltonNJ . Tocolytic therapy for preterm delivery: systematic review and network meta‐analysis. BMJ2012;345:e6226. ">Haas 2012</a>). However, due to different methodological approaches, findings are difficult to compare. Further, the review reported that nifedipine (the most commonly used CCB) is the preferred first‐line tocolytic (<a href="./references#CD004452-bbs2-0050" title="HaasDM , CaldwellDM , KirkpatrickP , McIntoshJJ , WeltonNJ . Tocolytic therapy for preterm delivery: systematic review and network meta‐analysis. BMJ2012;345:e6226. ">Haas 2012)</a>. Another review, using indirect comparison of randomised trials, of the ORA atosiban with nifedipine concluded that nifedipine was more effective than atosiban and lowered the incidence of respiratory distress syndrome (<a href="./references#CD004452-bbs2-0035" title="CoomarasamyA , KnoxEM , GeeH , SongF , KhanKS . Effectiveness of nifedipine versus atosiban for tocolysis in preterm labour: a meta‐analysis with an indirect comparison of randomised trials. BJOG: an international journal of obstetrics and gynaecology2003;110:1045‐9. ">Coomarasamy 2003</a>). In the Cochrane review on CCB for inhibiting preterm labour, CCB (mainly nifedipine) was shown to prolong pregnancy and reduce neonatal morbidity (update of <a href="./references#CD004452-bbs2-0055" title="KingJF , FlenadyVJ , PapatsonisDNM , DekkerGA , CarbonneB . Calcium channel blockers for inhibiting preterm labour. Cochrane Database of Systematic Reviews2003, Issue 1. [DOI: 10.1002/14651858.CD002255] ">King 2003</a> in progress). Similar to our review, this review found limited trial outcome data comparing ORA with CCB (including the same two small studies included in this review (<a href="./references#CD004452-bbs2-0006" title="KashanianM , AkbarianAR , SoltanzadehM . Atosiban and nifedipin for the treatment of preterm labor. International Journal of Gynecology &amp; Obstetrics2005;91(1):10‐4. KashanianM , SoltanzadehM , Sheikh AnsariN . Atosiban and nifedipin for the treatment of preterm labor. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):69. ">Kashanian 2005</a>; <a href="./references#CD004452-bbs2-0012" title="GarmiG . Nifedipine compared to atosiban for treating preterm labor [ClinicalTrials.gov (http://clinicaltrials.gov/)]. accessed 9 April 2008. SalimR , GarmiG , NachumZ , ZafranN , BaramS , ShalevE . Nifedipine compared with atosiban for treating preterm labor: A randomized controlled trial. Obstetrics and Gynecology2012;120(6):1323‐31. ">Salim 2012</a>)). However, in our review, some indication for benefit of CCB (nifedipine) over the ORA atosiban was shown in the results of one small trial (145 women) (<a href="./references#CD004452-bbs2-0012" title="GarmiG . Nifedipine compared to atosiban for treating preterm labor [ClinicalTrials.gov (http://clinicaltrials.gov/)]. accessed 9 April 2008. SalimR , GarmiG , NachumZ , ZafranN , BaramS , ShalevE . Nifedipine compared with atosiban for treating preterm labor: A randomized controlled trial. Obstetrics and Gynecology2012;120(6):1323‐31. ">Salim 2012</a>). </p> <p>Consistent with our conclusions, Haas et al (<a href="./references#CD004452-bbs2-0050" title="HaasDM , CaldwellDM , KirkpatrickP , McIntoshJJ , WeltonNJ . Tocolytic therapy for preterm delivery: systematic review and network meta‐analysis. BMJ2012;345:e6226. ">Haas 2012</a>) supported further well‐designed, randomised, placebo‐controlled trials to evaluate ORA in prolonging pregnancy for women in preterm labour. The CCB, nifedipine has the advantage of ease of oral administration and is very inexpensive compared with atosiban (<a href="./references#CD004452-bbs2-0062" title="PapatsonisDNM , DeckerGA . Nifedipine in the management of preterm labour: evidence from the literature. In: CritchleyH , BennettP , ThorntonS editor(s). Preterm Birth. London: RCOG Press, 2004:296‐307. ">Papatsonis 2004</a>). However, more robust evidence from well‐designed, randomised trials with direct comparisons of nifedipine and ORA are required before strong recommendations for clinical practice can be made. One such study is ongoing (<a href="./references#CD004452-bbs2-0029" title="HeidaK . Nifedipine versus Atosiban in the treatment of threatened preterm labour: APOSTEL III. http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=2947 (accessed 6 January 2014). ">APOSTEL III</a>). </p> <p>Adequate comparison of ORAs with COX inhibitors (such as indomethacin) for preterm labour is also lacking. COX inhibitors have been the focus of a recent Cochrane review (<a href="./references#CD004452-bbs2-0053" title="KhanprakobT , LaopaiboonM , LumbiganonP , SangkomkamhangUS . Cyclo‐oxygenase (COX) inhibitors for preventing preterm labour. Cochrane Database of Systematic Reviews2012, Issue 10. [DOI: 10.1002/14651858.CD007748.pub2] ">Khanprakob 2012</a>), which concluded that, due to insufficient evidence, further well‐designed, placebo‐controlled trials are needed and should include comparisons with other agents and incorporate long‐term follow‐up of infants. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD004452-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD004452-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/full#CD004452-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD004452-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/full#CD004452-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 1 Birth less than 48 hours after trial entry." data-id="CD004452-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 1 Birth less than 48 hours after trial entry. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 2 Perinatal mortality (stillbirth and neonatal death up to 28 days)." data-id="CD004452-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 2 Perinatal mortality (stillbirth and neonatal death up to 28 days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 3 Stillbirth." data-id="CD004452-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 3 Stillbirth. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 4 Neonatal death." data-id="CD004452-fig-0006" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 4 Neonatal death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 5 Infant death (up to 12 months)." data-id="CD004452-fig-0007" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 5 Infant death (up to 12 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 6 Maternal death." data-id="CD004452-fig-0008" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 6 Maternal death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 7 Maternal adverse effects." data-id="CD004452-fig-0009" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 7 Maternal adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 8 Maternal adverse effects requiring cessation of treatment." data-id="CD004452-fig-0010" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 8 Maternal adverse effects requiring cessation of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 9 Caesarean section." data-id="CD004452-fig-0011" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 9 Caesarean section. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 10 Preterm birth (before completion of 37 weeks of gestation)." data-id="CD004452-fig-0012" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 10 Preterm birth (before completion of 37 weeks of gestation). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 11 Extremely preterm birth (before completion of 28 weeks of gestation)." data-id="CD004452-fig-0013" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 11 Extremely preterm birth (before completion of 28 weeks of gestation). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 12 Gestational age (weeks)." data-id="CD004452-fig-0014" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 12 Gestational age (weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 13 Birthweight (grams)." data-id="CD004452-fig-0015" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 13 Birthweight (grams). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 14 Respiratory distress syndrome." data-id="CD004452-fig-0016" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 14 Respiratory distress syndrome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 15 Intraventricular haemorrhage." data-id="CD004452-fig-0017" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 15 Intraventricular haemorrhage. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 16 Necrotising enterocolitis." data-id="CD004452-fig-0018" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 16 Necrotising enterocolitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 17 Neonatal jaundice." data-id="CD004452-fig-0019" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 17 Neonatal jaundice. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 18 Admission to neonatal intensive care unit." data-id="CD004452-fig-0020" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Oxytocin receptor antagonists versus placebo (by type of ORA), Outcome 18 Admission to neonatal intensive care unit. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 1 Birth less than 48 hours after trial entry." data-id="CD004452-fig-0021" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 1 Birth less than 48 hours after trial entry. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 2 Perinatal mortality." data-id="CD004452-fig-0022" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 2 Perinatal mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 3 Very preterm birth (before completion of 34 weeks of gestation)." data-id="CD004452-fig-0023" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 3 Very preterm birth (before completion of 34 weeks of gestation). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 4 Stillbirth." data-id="CD004452-fig-0024" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 4 Stillbirth. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 5 Neonatal death." data-id="CD004452-fig-0025" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 5 Neonatal death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 6 Maternal death." data-id="CD004452-fig-0026" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 6 Maternal death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 7 Maternal adverse effects." data-id="CD004452-fig-0027" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 7 Maternal adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 8 Maternal adverse effects requiring cessation of treatment." data-id="CD004452-fig-0028" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 8 Maternal adverse effects requiring cessation of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 9 Caesarean section." data-id="CD004452-fig-0029" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 9 Caesarean section. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 10 Interval between trial entry and birth (days)." data-id="CD004452-fig-0030" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 10 Interval between trial entry and birth (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 11 Preterm birth (before completion of 37 weeks of gestation)." data-id="CD004452-fig-0031" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 11 Preterm birth (before completion of 37 weeks of gestation). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 12 Extremely preterm birth (before completion of 28 weeks of gestation)." data-id="CD004452-fig-0032" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 12 Extremely preterm birth (before completion of 28 weeks of gestation). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 13 Gestational age (weeks)." data-id="CD004452-fig-0033" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 13 Gestational age (weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 14 Birthweight (grams)." data-id="CD004452-fig-0034" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 14 Birthweight (grams). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-CMP-002-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-CMP-002-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 15 Apgar score less than 7 at 5 minutes." data-id="CD004452-fig-0035" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 15 Apgar score less than 7 at 5 minutes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-CMP-002-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-CMP-002-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 16 Respiratory distress syndrome." data-id="CD004452-fig-0036" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 16 Respiratory distress syndrome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-CMP-002-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-CMP-002-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 17 Use of mechanical ventilation." data-id="CD004452-fig-0037" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 17 Use of mechanical ventilation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-CMP-002-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-CMP-002-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 18 Duration of mechanical ventilation (days)." data-id="CD004452-fig-0038" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 18 Duration of mechanical ventilation (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-CMP-002-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-CMP-002-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 19 Intraventricular haemorrhage." data-id="CD004452-fig-0039" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.19</div> <div class="figure-caption"> <p>Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 19 Intraventricular haemorrhage. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-CMP-002-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-CMP-002-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 20 Necrotising enterocolitis." data-id="CD004452-fig-0040" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.20</div> <div class="figure-caption"> <p>Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 20 Necrotising enterocolitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-CMP-002-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-CMP-002-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 21 Retinopathy of prematurity." data-id="CD004452-fig-0041" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.21</div> <div class="figure-caption"> <p>Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 21 Retinopathy of prematurity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-CMP-002-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-CMP-002-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 22 Neonatal sepsis." data-id="CD004452-fig-0042" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.22</div> <div class="figure-caption"> <p>Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 22 Neonatal sepsis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-CMP-002-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-CMP-002-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 23 Admission to neonatal intensive care unit." data-id="CD004452-fig-0043" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.23</div> <div class="figure-caption"> <p>Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 23 Admission to neonatal intensive care unit. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004452-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/urn:x-wiley:14651858:media:CD004452:CD004452-CMP-002-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_t/tCD004452-CMP-002-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 24 Neonatal length of hospital stay (days)." data-id="CD004452-fig-0044" src="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.24</div> <div class="figure-caption"> <p>Comparison 2 Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic), Outcome 24 Neonatal length of hospital stay (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/media/CDSR/CD004452/image_n/nCD004452-CMP-002-24.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="comparison" data-id="CD004452-tbl-0001"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Oxytocin receptor antagonists versus placebo (by type of ORA)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Birth less than 48 hours after trial entry <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.15, 7.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Atosiban versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.15, 7.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Perinatal mortality (stillbirth and neonatal death up to 28 days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.25 [0.79, 6.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Atosiban versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.25 [0.79, 6.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Barusiban versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Stillbirth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>883</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.04, 4.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Atosiban versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>720</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.04, 4.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Barusiban versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Neonatal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.09 [0.88, 19.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Atosiban versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.09 [0.88, 19.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Barusiban versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Infant death (up to 12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.13 [1.38, 27.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Atosiban versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.13 [1.38, 27.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Maternal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>501</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Atosiban versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>501</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Maternal adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>613</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [1.02, 2.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Atosiban versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>613</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [1.02, 2.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Maternal adverse effects requiring cessation of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>776</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.02 [2.05, 7.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Atosiban versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>613</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.02 [2.05, 7.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Barusiban versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Caesarean section <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [0.73, 3.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Atosiban versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [0.73, 3.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Preterm birth (before completion of 37 weeks of gestation) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>664</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.97, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Atosiban versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>501</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.99, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Barusiban versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.59, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Extremely preterm birth (before completion of 28 weeks of gestation) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>501</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.11 [1.02, 9.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Atosiban versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>501</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.11 [1.02, 9.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Gestational age (weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.5 [‐1.57, 0.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Atosiban versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.5 [‐1.57, 0.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Birthweight (grams) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>676</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐138.86 [‐250.53, ‐27.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Atosiban versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>676</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐138.86 [‐250.53, ‐27.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Respiratory distress syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>836</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.96, 1.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Atosiban versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>673</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.93, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Barusiban versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.69 [0.36, 20.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Intraventricular haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.45, 1.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Atosiban versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.45, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Necrotising enterocolitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>559</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.02, 1.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Atosiban versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>559</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.02, 1.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Neonatal jaundice <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.86, 1.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Barusiban versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.86, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Admission to neonatal intensive care unit <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.89, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 Atosiban versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.89, 1.34]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Oxytocin receptor antagonists versus placebo (by type of ORA)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004452-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Birth less than 48 hours after trial entry <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 ORA versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1389</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.66, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 ORA versus calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.44, 2.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Perinatal mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 ORA versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>816</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.21, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Very preterm birth (before completion of 34 weeks of gestation) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 ORA versus calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [0.89, 3.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Stillbirth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 ORA versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>861</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.05, 6.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Neonatal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 ORA versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.28, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 ORA versus calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Maternal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 ORA versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Maternal adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 ORA versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.35, 0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 ORA versus calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.21, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Maternal adverse effects requiring cessation of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 ORA versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.02, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 ORA versus calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.01, 8.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Caesarean section <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 ORA versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>247</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.50, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 ORA versus calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.37, 4.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Interval between trial entry and birth (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 ORA versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>22.9 [18.03, 27.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 ORA versus calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.70 [‐12.36, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Preterm birth (before completion of 37 weeks of gestation) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 ORA versus calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [1.13, 2.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Extremely preterm birth (before completion of 28 weeks of gestation) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 ORA versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.37, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 ORA versus calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.14 [0.20, 23.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Gestational age (weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 ORA versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [‐0.32, 0.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 ORA versus calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.20 [‐2.15, ‐0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Birthweight (grams) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 ORA versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>27.16 [‐55.46, 109.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 ORA versus calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐82.0 [‐270.78, 106.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Apgar score less than 7 at 5 minutes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 ORA versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.47, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 ORA versus calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.05, 5.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Respiratory distress syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 ORA versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1280</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.70, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 ORA versus calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.54, 3.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Use of mechanical ventilation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 ORA versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.63, 14.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 ORA versus calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.65, 3.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Duration of mechanical ventilation (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 ORA versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.30 [‐3.82, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Intraventricular haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 ORA versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>359</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.48, 2.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 ORA versus calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.16 [0.41, 11.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Necrotising enterocolitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 ORA versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.02, 3.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 ORA versus calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.72 [0.53, 178.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Retinopathy of prematurity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 ORA versus calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.16 [0.20, 23.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Neonatal sepsis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 ORA versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.56, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2 ORA versus calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.12, 4.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Admission to neonatal intensive care unit <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 ORA versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1062</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.78, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2 ORA versus calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [1.17, 2.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Neonatal length of hospital stay (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 ORA versus betamimetics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐5.13, 5.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.2 ORA versus calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.4 [‐0.04, 10.84]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Oxytocin receptor antagonists versus other classes of tocolytic agents (by type of other tocolytic)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004452.pub3/references#CD004452-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD004452.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD004452-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD004452-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD004452-note-0001">Français</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004452\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004452\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004452\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004452\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004452\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004452\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004452\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004452\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004452\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004452\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004452\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004452\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004452\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004452\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004452\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004452\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004452\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004452\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ZDBB8PHY&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004452.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004452.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD004452.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD004452.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004452.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714246481"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004452.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714246485"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004452.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d69fd7e4af3cd',t:'MTc0MDcxNDI0Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 